Uniprot_name	uniprot_id	Orig_AA	Position	Mut_AA	info	Pfam_AA	Pfam_Pos	Mutation	conc_scores	type	orth_25	orth_50	orth_75	orth_100	all_homs_25	all_homs_50	all_homs_75	all_homs_100	excl_para_25	excl_para_50	excl_para_75	excl_para_100	spec_para_25	spec_para_50	spec_para_75	spec_para_100	bpsh_25	bpsh_50	bpsh_75	bpsh_100	bpso_25	bpso_50	bpso_75	bpso_100
ABL1_HUMAN	P00519	A	337	T	 (in CHDSKM; increases kinase activity; no;effect on protein levels; dbSNP:rs1060499548)"";/evidence=""ECO:0000269|PubMed:28288113"";/id=""VAR_079483""	e	97	A337T	P00519/A337T	A	-3.25534	-3.41626	-4.29991	-2.97321	-1.44066	-0.8337	-0.20783	0.11381	0.44023	0.30873	0.7878	0.7678	-2.01812	-0.7404	-0.47875	-0.40458	-3.2981	-2.9794	-2.74447	-2.16396	-2.61513	-3.32194	-3.59032	-2.87245
AKT1_HUMAN	P31749	T	308	D	 5-fold activation and 18-fold activation; when;associated with D-473."";/evidence=""ECO:0000269|PubMed:12244301,;ECO:0000269|PubMed:8978681""	s	156	T308D	P31749/T308D	A	-4.15093	-4.44719	-4.82552	-3.86772	-4.15093	-4.44719	-4.82552	-3.86772	NA	NA	NA	-2.87509	-3.49464	-6.58599	-4.9435	-2.11839	-4.22587	-3.33221	-2.53988	-3.29655	-3.14577	-4.13369	-4.31067	-3.14909
AKT2_HUMAN	P31751	T	309	E	 Constitutively active; when associated with D-;474."";/evidence=""ECO:0000269|PubMed:15890450,;ECO:0000269|PubMed:20059950""	s	156	T309E	P31751/T309E	A	-3.49948	-4.4565	-4.89834	-3.49301	-3.49948	-4.4565	-4.89834	-3.49301	NA	NA	NA	-2.82697	-3.55442	-6.53117	-4.43656	-2.03403	-4.03591	-4.21468	-4.80299	-3.17513	-3.18673	-3.48879	-3.97504	-2.92007
ALK_HUMAN	Q9UM73	F	1174	L	 (in NBLST3; somatic mutation; constitutively;activated; retained in the endoplasmic reticulum and Golgi;compartments; dbSNP:rs863225281)"";/evidence=""ECO:0000269|PubMed:18923523,;ECO:0000269|PubMed:18923525, ECO:0000269|PubMed:21242967"";/id=""VAR_063857""	l	55	F1174L	Q9UM73/F1174L	A	-3.81827	-5.2478	-6.47368	-2.31841	-0.60269	0.94324	0.99964	1.10868	-0.25872	1.18764	1.16412	1.25703	-1.33672	-0.58613	-0.00266	-0.21463	-5.69483	-2.46391	-0.84444	-0.12169	-3.46176	-5.10815	-5.76626	-3.17882
ALK_HUMAN	Q9UM73	F	1174	V	 (in NBLST3; somatic mutation; constitutively;activated; retained in the endoplasmic reticulum and Golgi;compartments; dbSNP:rs281864719)"";/evidence=""ECO:0000269|PubMed:18923523,;ECO:0000269|PubMed:21242967"";/id=""VAR_063858""	l	55	F1174V	Q9UM73/F1174V	A	-4.54475	-6.10166	-7.42974	-5.00243	-3.26443	-2.40253	-2.05906	-1.75415	-2.97726	-2.15128	-1.89088	-1.60229	-2.61845	-2.78999	-4.00753	-1.88374	-6.56082	-6.12358	-4.63506	-5.17354	-4.15177	-5.95075	-6.669	-4.75915
ALK_HUMAN	Q9UM73	R	1275	Q	 (in NBLST3; constitutively activated;;retained in the endoplasmic reticulum and Golgi;compartments; dbSNP:rs113994087)"";/evidence=""ECO:0000269|PubMed:18724359,;ECO:0000269|PubMed:18923523, ECO:0000269|PubMed:18923525,;ECO:0000269|PubMed:21242967, ECO:0000269|PubMed:22932897"";/id=""VAR_063865""	k	146	R1275Q	Q9UM73/R1275Q	A	-3.55385	-5.17841	-6.25853	-2.72528	-5.96939	-4.9884	-5.03903	-4.67129	-5.44881	-4.93174	-5.10665	-4.7016	-4.07858	-4.3792	-5.1718	-2.92615	-5.60874	-6.54867	-5.39784	-3.07737	-3.2145	-5.03568	-5.67917	-5.57025
ANPRB_HUMAN	P20594	R	655	C	 (in ECDM; the mutation results in increased;guanylate cyclase activity; dbSNP:rs587777596)"";/evidence=""ECO:0000269|PubMed:24057292"";/id=""VAR_071876""	k	134	R655C	P20594/R655C	A	-3.56892	-4.84483	-5.66987	-4.99979	-6.12779	NA	NA	NA	-6.28096	NA	NA	NA	-5.50825	-6.6499	NA	NA	-7.42517	NA	NA	NA	-3.56892	-4.84483	-5.66987	-4.91904
AURKA_HUMAN	O14965	V	174	M	 (in a metastatic melanoma sample; somatic;mutation; constitutively enhanced kinase activity)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:19801554"";/id=""VAR_041129""	e	42	V174M	O14965/V174M	A	-2.37657	-2.40923	-1.67071	-0.99143	-2.37657	-2.40923	-1.67071	-0.99143	NA	NA	NA	-1.71848	0.93962	0.0626	0.43622	0.73391	-1.87863	-0.49552	-0.42758	-0.38425	-2.20007	-2.28951	-1.70751	-0.97766
AURKA_HUMAN	O14965	T	288	D	 Mimics phosphorylation state and increases;kinase activity."";/evidence=""ECO:0000269|PubMed:11039908""	s	156	T288D	O14965/T288D	A	-2.98062	-3.29061	-3.68424	-4.2565	-2.98062	-3.29061	-3.68424	-4.2565	NA	NA	NA	-2.77441	-7.15593	-9.09328	-3.35689	-2.11839	-4.03707	-2.53221	-2.22233	-2.64646	-3.36287	-3.5459	-3.91007	-4.12112
BRAF_HUMAN	P15056	G	464	V	 (in a colorectal cancer cell line; elevated;kinase activity; efficiently induces cell transformation;;dbSNP:rs121913348)"";/evidence=""ECO:0000269|PubMed:12068308"";/id=""VAR_018616""	G	8	G464V	P15056/G464V	A	-5.96008	-6.48539	-6.77158	-6.97791	-9.82259	-10.63952	-9.44574	-9.04811	-9.39175	-10.60902	-9.43187	-9.01854	-6.80608	-9.26335	-10.10032	-6.37288	-5.35051	-7.24206	-6.45666	-7.77503	-5.00116	-5.62015	-6.62878	-5.35214
BRAF_HUMAN	P15056	G	469	A	 (in NHL; also in a lung adenocarcinoma;sample; somatic mutation; elevated kinase activity;;efficiently induces cell transformation;;dbSNP:rs121913355)"";/evidence=""ECO:0000269|PubMed:12068308,;ECO:0000269|PubMed:14612909, ECO:0000269|PubMed:17344846"";/id=""VAR_018620""	G	13	G469A	P15056/G469A	A	-4.81638	-5.2907400000000004	-5.54906	-1.74663	-3.96012	-4.01347	-4.05465	-3.66913	-3.92598	-4.01817	-4.11584	-3.70449	-5.69824	-8.13383	-9.00922	-7.5473	-4.29319	-5.99086	-3.11257	-2.91936	-3.93268	-4.53616	-5.4291	-0.98949
BRAF_HUMAN	P15056	L	597	V	 (in NS7; also in a lung adenocarcinoma;sample; somatic mutation; elevated kinase activity;;efficiently induces cell transformation;;dbSNP:rs121913369)"";/evidence=""ECO:0000269|PubMed:12068308,;ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19206169"";/id=""VAR_018627""	l	144	L597V	P15056/L597V	A	-2.36305	-2.78727	-3.04962	-4.14273	-3.69517	-4.21503	-3.44708	-2.39386	-3.42825	-3.73339	-3.40978	-2.35562	-1.96967	-3.91575	-2.92928	-1.81337	-2.62801	-2.94932	-2.57854	-3.28753	-2.36306	-2.79226	-2.82433	-2.86571
BRAF_HUMAN	P15056	R	671	K	 Increased kinase activity and stability in;response to EGF treatment."";/evidence=""ECO:0000269|PubMed:21917714""	q	212	R671K	P15056/R671K	A	-3.39478	-3.76383	-3.3838	-2.62083	-1.36244	0.03133	0.45715	0.06204	0.09045	0.5468	0.91086	0.31773	-1.36275	-1.37327	-0.32715	0.33888	-3.02889	-2.2905	-1.1132	-1.6639	-2.64679	-3.16679	-3.25956	-2.00385
BRSK2_HUMAN	Q8IWQ3	T	174	E	 Constitutively activated."";/evidence=""ECO:0000269|PubMed:14976552,;ECO:0000269|PubMed:18339622, ECO:0000269|PubMed:22798068""	s	156	T174E	Q8IWQ3/T174E	A	-4.52578	-3.98484	-4.22867	-5.96779	-4.52578	-3.98484	-4.22867	-5.96779	NA	NA	NA	-2.80512	-3.8566	-2.90299	-1.98782	-2.03403	-7.6517	-6.18326	-4.18945	-3.71162	-4.30888	-4.8812	-5.21827	-5.25881
CDK19_HUMAN	Q9BWU1	Y	32	H	 (in DEE87; fails to rescue neurologic;phenotypes in a Drosophila model system; increased protein;kinase activity; dbSNP:rs1236246272)"";/evidence=""ECO:0000269|PubMed:32330417,;ECO:0000269|PubMed:33134521, ECO:0000269|PubMed:33495529"";/id=""VAR_084395""	f	12	Y32H	Q9BWU1/Y32H	A	-3.18791	-3.53706	-4.27084	-4.36325	-8.66901	-4.61818	-3.03276	-2.87291	-6.82591	-4.48486	-2.9722	-2.82862	-5.25864	-4.43157	-5.29107	-5.44742	-3.02536	-4.12041	-4.53218	-5.98086	-2.95519	-3.72605	-4.37947	-4.25991
CDK2_HUMAN	P24941	T	14	A	 2-fold increase in activity."";/evidence=""ECO:0000269|PubMed:1396589""	s	11	T14A	P24941/T14A	A	-2.74914	-3.22137	-2.9646	-3.65875	-1.54493	-0.91136	-0.64191	-0.85432	-1.54492	-0.8571	-0.66026	-0.83112	-1.67071	-2.64275	-1.02371	-1.27903	-3.18233	-3.00792	-3.15083	-2.4209	-2.67829	-3.07779	-2.83754	-3.45065
CDK2_HUMAN	P24941	Y	15	F	 2-fold increase in activity."";/evidence=""ECO:0000269|PubMed:1396589""	f	12	Y15F	P24941/Y15F	A	-2.55891	-2.90914	-3.08771	-2.80355	-3.1304	-3.04912	-2.66879	-1.92648	-3.11381	-2.99524	-2.66656	-1.90978	-1.96097	-2.63766	-3.28814	-1.42487	-2.88446	-3.06353	-3.11533	-2.8794400000000002	-2.51032	-2.81313	-2.98513	-2.76602
CDK7_HUMAN	P50613	S	164	A	 No mitotic repression of transcriptional;activity of the reconstituted TFIIH complex."";/evidence=""ECO:0000269|PubMed:9832506""	s	150	S164A	P50613/S164A	A	-2.16915	-2.78408	-2.67851	-2.40685	-1.28583	-1.08173	-1.07951	-1.11621	-0.94319	-0.98209	-1.01977	-1.05471	-1.17232	-1.44809	-1.42058	-1.54327	-2.16915	-2.79918	-2.15507	-2.13017	-2.07665	-2.73126	-2.56084	-2.30067
CDK9_HUMAN	P50750	K	48	R	 Decreased acetylation; leading to enhanced;protein kinase activity."";/evidence=""ECO:0000269|PubMed:28426094""	K	30	K48R	P50750/K48R	A	-1.50553	-1.66299	-1.94801	-3.12338	-9.27499	-4.9701	-7.23899	-6.90968	-10.43086	-5.08531	-7.25723	-6.90347	-3.52093	-4.7935	-5.48477	-6.29323	-1.62228	-2.38189	-6.37404	-5.9275	-1.49134	-1.60918	-1.69269	-3.20534
CDK9_HUMAN	P50750	S	175	A	 Constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:21533037""	e	149	S175A	P50750/S175A	A	-1.82812	-2.16544	-1.59782	-1.41309	-2.16636	-1.31017	-1.73971	-1.32395	-2.10261	-1.2359	-1.64943	-1.25525	-1.7313	-1.20243	-1.25657	-1.37569	-2.03072	-1.46966	-1.4799	-0.77348	-1.75588	-1.99003	-1.87462	-1.3031
CDK9_HUMAN	P50750	T	186	D	 Mimics autophosphorylation; constitutive;kinase activity, independently of calcium signaling."";/evidence=""ECO:0000269|PubMed:11145967,;ECO:0000269|PubMed:18566585, ECO:0000269|PubMed:21448926""	t	155	T186D	P50750/T186D	A	-3.0663	-3.44868	-3.88391	-4.81477	-5.63636	-2.95564	-3.37243	-3.67003	-5.15755	-2.95915	-3.34877	-3.64884	-5.18411	-6.32135	-3.26424	-3.38021	-3.27453	-4.39577	-8.97132	-6.60286	-2.97329	-3.24806	-3.43101	-4.39369
EGFR_HUMAN	P00533	G	719	S	 (found in a lung cancer sample; somatic;mutation; strongly increased kinase activity;;constitutively activated kinase with higher levels of basal;autophosphorylation; more sensitive to gefitinib than wild-;type; dbSNP:rs28929495)"";/evidence=""ECO:0000269|PubMed:15118125,;ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628,;ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580"";/id=""VAR_019297""	G	8	G719S	P00533/G719S	A	-4.9247	-5.49166	-5.85547	-8.32253	-6.1146	-7.11257	-8.56866	-11.23672	-6.1739	-6.98521	-8.5531	-10.12694	-2.77362	-3.99679	-4.74452	-5.28501	-4.99239	-5.67681	-7.66537	-9.77579	-4.8691700000000004	-5.26273	-5.5165	-8.10468
EGFR_HUMAN	P00533	S	768	I	 (found in a lung cancer sample;;constitutively activated kinase with higher levels of basal;autophosphorylation; more sensitive to gefitinib than wild-;type; dbSNP:rs121913465)"";/evidence=""ECO:0000269|PubMed:15623594,;ECO:0000269|PubMed:16205628"";/id=""VAR_069502""	k	54	S768I	P00533/S768I	A	-4.55193	-5.05133	-5.02305	-5.09737	-5.27234	-5.75696	-5.11977	-5.79911	-5.10033	-4.58363	-4.96574	-4.48195	-2.98343	-3.92416	-3.97809	-4.52264	-4.58557	-4.89342	-5.8196	-4.98695	-4.5112	-4.85212	-4.71693	-4.85796
EGFR_HUMAN	P00533	T	790	M	 (found in a lung cancer sample; increased;kinase activity; dbSNP:rs121434569)"";/evidence=""ECO:0000269|PubMed:16533793,;ECO:0000269|PubMed:18227510"";/id=""VAR_026098""	l	77	T790M	P00533/T790M	A	-4.2431	-4.3308	-4.70306	-0.42098	-5.02026	-5.99076	-6.98597	-1.92813	-5.61746	-6.53069	-6.99204	-6.79973	-2.47935	-3.44267	-4.1497	-4.75644	-4.28913	-4.55167	-6.50935	-1.1853	-4.19559	-4.54143	-4.36975	-0.24706
EGFR_HUMAN	P00533	L	858	R	 (found in a lung cancer sample; somatic;mutation; constitutively activated enzyme with strongly;increased kinase activity; more sensitive to gefitinib than;wild-type; dbSNP:rs121434568)"";/evidence=""ECO:0000269|PubMed:15118125,;ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628,;ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580"";/id=""VAR_019298""	l	144	L858R	P00533/L858R	A	-4.96286	-5.52208	-5.92939	-6.9958	-6.2477	-6.98319	-7.52602	-9.077	-6.33728	-6.74494	-7.49695	-8.98381	-3.0097	-4.13503	-4.83246	-4.83833	-5.02047	-5.73482	-7.69801	-8.32138	-4.91371	-5.2765	-5.55817	-6.73671
EGFR_HUMAN	P00533	L	861	Q	 (found in a lung cancer sample;;constitutively activated kinase with higher levels of basal;autophosphorylation; more sensitive to gefitinib than wild-;type; dbSNP:rs121913444)"";/evidence=""ECO:0000269|PubMed:15623594,;ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793"";/id=""VAR_026102""	e	147	L861Q	P00533/L861Q	A	-5.05825	-5.64597	-6.05984	-4.49773	-6.36485	-7.36319	-7.50481	-6.68047	-6.4587	-7.26434	-7.90354	-8.62313	-2.97989	-4.1502	-4.92061	-5.49016	-5.11756	-5.85864	-7.17765	-6.18883	-4.99883	-5.39418	-5.67361	-4.31378
EPHA2_HUMAN	P29317	R	721	Q	 (in CTRCT6; retained in the cytoplasm and;constitutively active it alters EPHA2 signaling;;dbSNP:rs116506614)"";/evidence=""ECO:0000269|PubMed:19649315"";/id=""VAR_062532""	k	105	R721Q	P29317/R721Q	A	-3.44937	-3.35115	-1.72946	-1.12553	-3.03334	-2.89708	-2.96611	-1.59016	-4.14177	-4.10447	-2.82578	-1.71027	-3.66245	-4.43418	-2.2363	-2.42408	-3.44937	-3.45099	-3.54903	-0.94563	-3.20394	-3.44937	-4.17086	-2.57806
EPHA3_HUMAN	P29320	Y	742	F	 Full kinase activity; when associated with F-;596 and F-602."";/evidence=""ECO:0000269|PubMed:18547520""	v	119	Y742F	P29320/Y742F	A	-2.29127	-2.45988	-2.89976	-1.62329	-3.77836	-2.87793	-2.81372	-0.76932	-3.88007	-3.12185	-2.73825	-0.76666	-2.70875	-3.22838	-3.4014	-2.31403	-2.38346	-3.09116	-2.66845	-0.89291	-2.28689	-2.38444	-2.8839	-1.60344
EPHA3_HUMAN	P29320	S	768	A	 Full kinase activity; when associated with F-;596 and F-602."";/evidence=""ECO:0000269|PubMed:18547520""	a	145	S768A	P29320/S768A	A	-2.09784	-2.33642	-2.88157	-3.60073	-3.90469	-3.20817	-3.94266	-2.34733	-4.0143	-3.44924	-3.96507	-2.32804	-2.58521	-3.282	-3.47876	-3.14546	-2.23795	-3.10917	-4.02297	-1.13227	-2.09634	-2.24006	-2.86127	-3.57035
FES_HUMAN	P07332	R	706	Q	 Negligible effect on autophosphorylation and;kinase activity."";/evidence=""ECO:0000269|PubMed:15867340,;ECO:0000269|PubMed:16455651""	k	146	R706Q	P07332/R706Q	A	-4.04202	-5.07343	-5.63578	-2.81525	-3.78488	-4.66875	-4.99681	-4.67131	-3.5455	-4.67204	-4.97793	-4.64975	-3.79179	-4.00797	-3.98371	-2.92615	-4.68362	-8.71452	-5.92477	-2.78858	-2.90765	-4.71053	-5.59864	-6.44505
FGFR2_HUMAN	P21802	K	526	E	 (in FSPC; constitutive kinase activity;;dbSNP:rs121918507)"";/evidence=""ECO:0000269|PubMed:16061565,;ECO:0000269|PubMed:17803937"";/id=""VAR_023788""	k	39	K526E	P21802/K526E	A	-3.04109	-2.1536	-2.76791	-2.27813	-1.1781	-1.24515	-0.1646	-0.17426	-0.90307	-0.66869	0.15118	0.22894	-3.38254	-2.29071	-1.27772	-1.05867	-3.17694	-2.48734	-1.00638	-1.23572	-3.02834	-1.82625	-2.59786	-2.77237
FGFR2_HUMAN	P21802	N	549	T	 Constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:17803937""	r	62	N549T	P21802/N549T	A	-3.85497	-4.25313	-4.59464	-3.13938	-3.81525	-6.10319	-4.3384	-4.38784	-3.90865	-6.12954	-4.0766	-4.33868	-4.19708	-4.51108	-5.32631	-4.99863	-3.98999	-4.62001	-3.80671	-2.66537	-3.84539	-4.18782	-4.44465	-3.06495
FGFR2_HUMAN	P21802	N	549	H	 (in CS; constitutive kinase activity;;dbSNP:rs1057519045)"";/evidence=""ECO:0000269|PubMed:11781872,;ECO:0000269|PubMed:17803937"";/id=""VAR_017276""	r	62	N549H	P21802/N549H	A	-3.59202	-4.05283	-4.45204	-1.91687	-3.2987	-5.64347	-3.43921	-3.53355	-3.40495	-5.46205	-3.3852	-3.51414	-4.11275	-4.00667	-4.83075	-4.39536	-3.73976	-4.49588	-3.98204	-1.97595	-3.56699	-3.97335	-4.2944	-1.77593
FGFR2_HUMAN	P21802	E	565	A	 Constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:17803937""	e	78	E565A	P21802/E565A	A	-3.51392	-3.80037	-4.1026300000000004	-5.41668	-4.58579	-6.64823	-4.76785	-5.44841	-4.8176	-6.62651	-4.77112	-5.42876	-3.83527	-5.50045	-6.33318	-6.87154	-3.59306	-4.12673	-3.86929	-5.82732	-3.50686	-3.74738	-3.982	-5.27335
FGFR2_HUMAN	P21802	E	565	G	 (in PS; constitutive kinase activity;;dbSNP:rs121918506)"";/evidence=""ECO:0000269|PubMed:11781872,;ECO:0000269|PubMed:17803937"";/id=""VAR_017277""	e	78	E565G	P21802/E565G	A	-3.32585	-3.55644	-3.84173	-5.13386	-4.53424	-6.62891	-7.21094	-8.29098	-4.75267	-6.63091	-7.22276	-8.24814	-3.63371	-5.05321	-5.7963	-6.27793	-3.38318	-3.86849	-4.08516	-5.63357	-3.32652	-3.51108	-3.73863	-4.98392
FGFR2_HUMAN	P21802	K	641	R	 (in PS; constitutive kinase activity;;dbSNP:rs1057519047)"";/evidence=""ECO:0000269|PubMed:11781872,;ECO:0000269|PubMed:17803937"";/id=""VAR_017278""	K	138	K641R	P21802/K641R	A	-1.97616	-2.17433	-2.40038	-4.92066	-4.25178	-4.52295	-4.76559	-4.41246	-4.24182	-4.52791	-4.63682	-4.29722	-2.27397	-3.54142	-4.26173	-4.74522	-2.00146	-2.42722	-3.20991	-3.43315	-1.97025	-2.12498	-2.30968	-4.76574
FLT3_HUMAN	P36888	D	835	E	 (in acute lymphoblastic leukemia patients and;acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121913487)"";/evidence=""ECO:0000269|PubMed:11290608,;ECO:0000269|PubMed:14504097"";/id=""VAR_065679""	e	147	D835E	P36888/D835E	A	-2.82239	-3.93432	-4.64152	-4.10206	-5.04893	-3.83672	-2.99379	-2.82581	-4.50467	-4.10011	-2.92961	-2.78922	-3.89872	-4.95912	-4.20543	-2.73595	-3.93432	-5.1161	-2.93143	-2.37906	-2.82239	-3.88669	-4.59924	-3.90438
FLT3_HUMAN	P36888	D	835	H	 (in acute lymphoblastic leukemia patients and;in acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121913488)"";/evidence=""ECO:0000269|PubMed:11290608,;ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097"";/id=""VAR_065680""	e	147	D835H	P36888/D835H	A	-3.55133	-4.72601	-5.49541	-5.16599	-6.09656	-3.05156	-3.10448	-2.87845	-2.38124	-3.29706	-3.07925	-2.8326	-4.78879	-5.86144	-5.22765	-4.78947	-4.72601	-5.98703	-0.51086	-1.79689	-3.55133	-4.68193	-5.4409	-4.9458
FLT3_HUMAN	P36888	D	835	N	 (in acute lymphoblastic leukemia patients and;in acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121913488)"";/evidence=""ECO:0000269|PubMed:11290608"";/id=""VAR_065681""	e	147	D835N	P36888/D835N	A	-3.04579	-4.1193	-4.86423	-4.42176	-5.24364	-4.01181	-3.34417	-3.21864	-4.81389	-3.96265	-3.30555	-3.17227	-4.16273	-5.11812	-4.38428	-2.79811	-4.1193	-5.35872	-2.00301	-1.37438	-3.04579	-4.07316	-4.8088	-4.21751
FLT3_HUMAN	P36888	D	835	V	 (in acute lymphoblastic leukemia patients and;in acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121909646)"";/evidence=""ECO:0000269|PubMed:11290608"";/id=""VAR_065682""	e	147	D835V	P36888/D835V	A	-4.96562	-6.21256	-7.04139	-7.03779	-7.64955	-5.40875	-3.16203	-2.56912	-7.66318	-5.73566	-3.14655	-2.54353	-6.37617	-7.44297	-6.90696	-6.78856	-6.21256	-7.55115	-4.32197	-1.06469	-4.96562	-6.15481	-6.99066	-6.7724
FLT3_HUMAN	P36888	D	835	Y	 (in acute lymphoblastic leukemia patients and;in acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121913488)"";/evidence=""ECO:0000269|PubMed:11290608,;ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097"";/id=""VAR_065683""	e	147	D835Y	P36888/D835Y	A	-4.81333	-5.99384	-6.76524	-6.67394	-7.35723	-2.72249	-3.55366	-3.42703	-6.96725	-3.15452	-3.53455	-3.3969	-5.94919	-6.88241	-6.56247	-6.24567	-5.99384	-7.20319	-4.30916	-3.71481	-4.81333	-5.94335	-6.71481	-6.44769
GWL_HUMAN	Q96GX5	K	72	M	 Hyperactive form."";/evidence=""ECO:0000269|PubMed:21164014""	k	40	K72M	Q96GX5/K72M	A	-4.41087	-5.05854	-5.02847	-6.51806	-4.41087	-5.05854	-5.02847	-6.51806	NA	NA	NA	-2.99457	-2.2676	-1.87293	-3.10082	-1.67855	-7.25424	-4.74899	-4.70461	-4.51036	-4.40168	-4.96702	-5.0064	-6.41806
IKKA_HUMAN	O15111	S	176	E	 Full activation."";/evidence=""ECO:0000269|PubMed:9346484,;ECO:0000269|PubMed:9520446""	s	152	S176E	O15111/S176E	A	-3.6112	-4.56626	-5.40826	-3.27974	-4.33941	-4.94029	-5.33739	-3.1598	-3.81452	-4.47485	-4.91509	-3.46544	NA	-2.34344	-2.34344	-3.30404	-3.53722	-4.49209	-5.61026	-2.62701	-3.53321	-4.44889	-5.44977	-3.13143
IKKB_HUMAN	O14920	K	171	E	 Increased activation of NF-kappa-B signaling."";/evidence=""ECO:0000269|PubMed:30337470""	k	146	K171E	O14920/K171E	A	-3.28537	-4.15513	-5.55495	-5.32298	-4.032	-4.69981	-5.01449	-5.46128	-3.83412	-3.96744	-4.17794	-4.78879	NA	-2.31158	-2.31158	-2.99621	-3.26942	-4.15059	-5.40149	-5.44268	-3.26942	-4.14362	-5.4333	-5.2892
IKKB_HUMAN	O14920	S	177	E	 Full activation. Interaction with TRIM21 is;enhanced; when associated with E-181. Monoubiquitinated;;when associated with R-163 and E-181. Strongly promoted NF-;kappa-B gene expression; when associated with E-181."";/evidence=""ECO:0000269|PubMed:19675099,;ECO:0000269|PubMed:9346484""	s	152	S177E	O14920/S177E	A	-3.70462	-4.71828	-5.53128	-3.28591	-4.57817	-5.28684	-5.60667	-3.1598	-4.35631	-4.50713	-4.74265	-3.40922	NA	-2.49408	-2.49408	-3.30404	-3.68664	-4.71248	-6.00273	-2.78519	-3.68664	-4.70524	-6.03976	-3.26158
IKKB_HUMAN	O14920	S	181	E	 Full activation. Interaction with TRIM21 is;enhanced; when associated with E-177. Monoubiquitinated;;when associated with R-163 and E-177. Strongly promoted NF-;kappa-B gene expression; when associated with E-177."";/evidence=""ECO:0000269|PubMed:19675099,;ECO:0000269|PubMed:9346484""	s	156	S181E	O14920/S181E	A	-3.70462	-4.71828	-5.73556	-6.62592	-4.57817	-5.28684	-5.60667	-6.72583	-4.35631	-4.50713	-4.74265	-4.76374	NA	-2.49408	-2.49408	-3.30404	-3.68664	-4.71248	-5.57447	-6.69532	-3.68664	-4.70524	-5.60949	-6.58649
IKKB_HUMAN	O14920	V	203	I	 (in IMD15A; gain-of-function mutation;resulting in increased activation of NF-kappa-B signaling;pathway; dbSNP:rs1563340753)"";/evidence=""ECO:0000269|PubMed:30337470"";/id=""VAR_081275""	v	178	V203I	O14920/V203I	A	-1.58165	-1.08056	-1.65029	-2.2826	-1.01332	-1.41801	-1.61056	-2.45174	-1.96378	-2.04617	-2.15133	-2.54163	NA	-1.06386	-1.06386	-1.50092	-1.57359	-1.07654	-1.5899	-2.31675	-1.57359	-1.06704	-1.6139	-2.25785
INSR_HUMAN	P06213	R	1201	Q	 (in HHF5 and IRAN type A; interferes with;kinase activation by insulin; dbSNP:rs121913156)"";/evidence=""ECO:0000269|PubMed:15161766,;ECO:0000269|PubMed:8082780, ECO:0000269|PubMed:8288049"";/id=""VAR_015929""	e	162	R1201Q	P06213/R1201Q	A	-4.63497	-5.17015	-5.39637	-6.21879	-5.60478	-6.13998	-8.85336	-10.52575	-5.52244	-6.57224	-9.18135	-10.47697	NA	-2.19437	-3.13559	-3.87509	-4.70086	-5.33277	-7.04615	-8.795	-4.0033	-4.913	-5.27933	-6.13012
JAK1_HUMAN	P23458	V	658	F	 Constitutively active. Increased receptor;signaling pathway via JAK-STAT."";/evidence=""ECO:0000269|PubMed:16239216""	e	68	V658F	P23458/V658F	A	-2.68534	-2.17024	-1.7076	-0.54547	-2.602	-2.57902	-1.81664	-0.62994000000000006	-2.63015	-2.76749	-1.79037	-1.74784	-2.43681	-1.89588	-1.87324	-1.98489	-3.00341	-2.86271	-2.0115	-0.2085	-3.00341	-2.74491	-2.25855	-0.15685
JAK1_HUMAN	P23458	S	703	I	 (in AIIDE; increased activation of protein;kinase activity; constitutive gain of function through the;transactivation of associated JAK kinases; increased;receptor signaling pathway via JAK-STAT)"";/evidence=""ECO:0000269|PubMed:32750333"";/id=""VAR_084992""	e	112	S703I	P23458/S703I	A	-0.47406	-0.66554	-0.51058	-0.4337	-0.63951	-0.93705	-0.56853	-0.49431	-1.95344	-1.29304	-1.13159	-1.32415	-3.07972	-1.71246	-1.77453	-1.96845	-3.80577	-0.49413	-0.71904	-0.82743	-3.80577	-0.4262	-0.59739	-0.64057
JAK2_HUMAN	O60674	V	617	F	 (in PV, THCYT3 and AML; associated with;susceptibility to Budd-Chiari syndrome; somatic mutation in;a high percentage of patients with essential;thrombocythemia or myelofibrosis; leads to constitutive;tyrosine phosphorylation activity that promotes cytokine;hypersensitivity; dbSNP:rs77375493)"";/evidence=""ECO:0000269|PubMed:15781101,;ECO:0000269|PubMed:15793561, ECO:0000269|PubMed:15858187,;ECO:0000269|PubMed:16247455, ECO:0000269|PubMed:16325696,;ECO:0000269|PubMed:16603627"";/id=""VAR_032697""	e	68	V617F	O60674/V617F	A	-2.80786	-2.43584	-2.74164	-3.06441	-2.57859	-2.4444	-2.69623	-3.14945	-1.67063	-1.61361	-1.68501	-1.51718	-2.55879	-2.32056	-1.54873	-1.45099	-2.59069	-3.19504	-2.24359	-2.24355	-2.59069	-3.19504	-2.24359	-2.24355
KAPCA_HUMAN	P17612	K	48	R	 Enhanced basal kinase activity; when;associated with Q-96, L-121, A-124, K-182 and A-184."";/evidence=""ECO:0000269|PubMed:21774789""	e	5	K48R	P17612/K48R	A	-1.43695	-1.52054	-1.06639	-1.21077	-1.43695	-1.52054	-1.06639	-1.21077	NA	NA	NA	-1.2881	-1.54186	-1.60974	-1.08248	-0.97315	-0.63413	0.68096	-0.21356	0.39091	-1.38754	-1.44285	-1.44637	-1.32293
KAPCA_HUMAN	P17612	L	96	Q	 Enhanced basal kinase activity; when;associated with R-48, L-121, A-124, K-182 and A-184."";/evidence=""ECO:0000269|PubMed:21774789""	l	52	L96Q	P17612/L96Q	A	-3.21831	-3.39676	-3.60952	-2.81815	-3.21831	-3.39676	-3.60952	-2.81815	NA	NA	NA	-2.98423	-6.8352	-5.06321	-4.04874	-3.81019	-5.67559	-7.8082	-5.19816	-3.06896	-3.12697	-3.23991	-3.25805	-3.79869
KAPCA_HUMAN	P17612	M	121	L	 Enhanced basal kinase activity; when;associated with R-48, Q-96, A-124, K-182 and A-184."";/evidence=""ECO:0000269|PubMed:21774789""	l	77	M121L	P17612/M121L	A	-2.3111	-2.38075	-1.60733	-1.28579	-2.3111	-2.38075	-1.60733	-1.28579	NA	NA	NA	-2.16709	-2.93409	-3.77578	-2.84037	-2.57818	-1.14868	-3.02366	-4.22495	-4.15551	-2.25499	-2.311	-1.21948	-0.24033
KAPCA_HUMAN	P17612	V	124	A	 Enhanced basal kinase activity; when;associated with R-48, Q-96, L-121, K-182 and A-184."";/evidence=""ECO:0000269|PubMed:21774789""	v	80	V124A	P17612/V124A	A	-2.51713	-2.64374	-2.71962	-3.24044	-2.51713	-2.64374	-2.71962	-3.24044	NA	NA	NA	-2.38371	-2.61922	-1.83715	-1.82986	-1.35632	-3.71651	-5.3679500000000004	-6.27871	-4.0424	-2.47249	-2.53924	-2.52796	-2.90704
KAPCA_HUMAN	P17612	Q	182	K	 Enhanced basal kinase activity; when;associated with R-48, Q-96, L-121, A-124 and A-184."";/evidence=""ECO:0000269|PubMed:21774789""	K	138	Q182K	P17612/Q182K	A	-2.06445	-2.23642	-1.08646	-0.48103	-2.06445	-2.23642	-1.08646	-0.48103	NA	NA	NA	-2.27662	2.84679	3.76232	3.90312	3.26296	0.97286	3.212	3.7806	3.99256	-1.87716	-2.04479	-0.83271	0.21667
KAPCA_HUMAN	P17612	T	184	A	 Enhanced basal kinase activity; when;associated with R-48, Q-96, L-121, A-124 and K-182."";/evidence=""ECO:0000269|PubMed:21774789""	t	140	T184A	P17612/T184A	A	-2.11057	-2.19771	-2.34908	-1.99892	-2.11057	-2.19771	-2.34908	-1.99892	NA	NA	NA	-2.0244	-1.43209	-0.23431	0.00769	-0.19246	-3.70707	-2.87903	-2.55902	-2.45575	-2.07807	-2.12531	-2.1258	-1.73893
KAPCA_HUMAN	P17612	L	206	R	 (in PPNAD4; somatic mutation; the mutation;results in cAMP-independent basal protein kinase activity;and constitutive activation of protein kinase A;;dbSNP:rs386352352)"";/evidence=""ECO:0000269|PubMed:24571724,;ECO:0000269|PubMed:24700472, ECO:0000269|PubMed:24747643,;ECO:0000269|PubMed:24855271"";/id=""VAR_071707""	l	164	L206R	P17612/L206R	A	-3.26	-3.43032	-2.84697	-3.42251	-3.26	-3.43032	-2.84697	-3.42251	NA	NA	NA	-2.99608	-4.82246	-5.25375	-5.25602	-2.94283	-5.52952	-8.27475	-6.61642	-4.79565	-3.167	-3.27117	-3.28179	-3.66107
KIT_HUMAN	P10721	D	816	F	 (in MASTC; sporadic case; somatic mutation;;requires 2 nucleotide substitutions; constitutively;activated and is much more rapidly autophosphorylated than;wild type)"";/evidence=""ECO:0000269|PubMed:9990072"";/id=""VAR_033133""	e	147	D816F	P10721/D816F	A	-5.20794	-6.23078	-6.70326	-6.56034	-7.84019	-5.92701	-5.19594	-5.98362	-8.11006	-5.89878	-5.163	-5.93136	-6.17911	-7.26762	-7.13768	-6.9929	-5.85283	-6.87323	-3.58885	-3.80961	-5.11353	-5.98355	-6.5395200000000004	-6.55687
KIT_HUMAN	P10721	D	816	H	 (in a testicular tumor; seminoma; somatic;mutation; constitutively activated; dbSNP:rs121913506)"";/evidence=""ECO:0000269|PubMed:10362788,;ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:20147452"";/id=""VAR_033134""	e	147	D816H	P10721/D816H	A	-3.70478	-4.74191	-5.18786	-4.56366	-5.72064	-3.24919	-3.17906	-2.87845	-6.11584	-3.16848	-3.14213	-2.82029	-4.74194	-5.86144	-5.28885	-4.78946	-4.36262	-5.38472	-0.4766	-1.79929	-3.59347	-4.48775	-5.00371	-4.5073
KIT_HUMAN	P10721	D	816	I	 (in MASTC; somatic mutation; constitutively;activated; requires 2 nucleotide substitutions;;dbSNP:rs1057519709)"";/evidence=""ECO:0000269|PubMed:19865100"";/id=""VAR_081064""	e	147	D816I	P10721/D816I	A	-5.30516	-6.46469	-6.95606	-6.50744	-7.92413	-6.09521	-5.46054	-4.75671	-8.34918	-6.05903	-4.74055	-4.71239	-6.5414	-7.66428	-7.29512	-7.04	-6.03179	-7.17	-4.45697	-4.42039	-5.21744	-6.17125	-6.78563	-6.60167
KIT_HUMAN	P10721	D	816	Y	 (in MASTSYS and MASTC; also found in acute;myeloid leukemia and a germ cell tumor of the testis;;somatic mutation; constitutively activated;;dbSNP:rs121913506)"";/evidence=""ECO:0000269|PubMed:16175573,;ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19865100,;ECO:0000269|PubMed:9657776, ECO:0000269|PubMed:9990072"";/id=""VAR_023828""	e	147	D816Y	P10721/D816Y	A	-4.8403	-5.84134	-6.35055	-5.91105	-7.14474	-3.17878	-3.57625	-3.42703	-7.46739	-3.13398	-3.55145	-3.38526	-5.88038	-6.88241	-6.5877	-6.24567	-5.46445	-6.54829	-4.15461	-3.71917	-4.74066	-5.58085	-6.15611	-5.87859
KIT_HUMAN	P10721	N	822	I	 (in MASTC; constitutively activated;;dbSNP:rs993022333)"";/evidence=""ECO:0000269|PubMed:21689725"";/id=""VAR_081065""	k	153	N822I	P10721/N822I	A	-4.61335	-5.75424	-6.27043	-6.00677	-6.65656	-4.0789	-2.86689	-2.3133	-6.71039	-3.9847	-2.74922	-2.16817	-5.95913	-5.82423	-4.46305	-3.43063	-5.33364	-5.60954	-3.39273	-2.14267	-4.54959	-5.45956	-6.10234	-5.86318
KPCD2_HUMAN	Q9BZL6	S	706	E	 Constitutive kinase activity; when associated;with E-710 or with E-244 and E-710. Increases Tyr-717;phosphorylation; when associated with E-710 or with E-710;and D-438."";/evidence=""ECO:0000269|PubMed:23503467,;ECO:0000269|PubMed:28428613""	s	152	S706E	Q9BZL6/S706E	A	-4.49375	-4.63558	-5.57893	-4.19476	-4.50353	-4.64065	-5.81142	-4.32909	-3.53216	-4.21381	-4.38996	-4.56101	NA	-2.21929	-2.93942	-3.44338	-4.1326599999999996	-4.5301	-5.49726	-4.35726	-4.1326599999999996	-4.5301	-5.49687	-4.34437
KPCD2_HUMAN	Q9BZL6	S	710	E	 Constitutive kinase activity; when associated;with E-706 or with E-244 and E-706. when associated with E-;710 or with E-244 and E-710. Increases Tyr-717;phosphorylation; when associated with E-710 or with E-710;and D-438."";/evidence=""ECO:0000269|PubMed:23503467,;ECO:0000269|PubMed:28428613""	s	156	S710E	Q9BZL6/S710E	A	-4.35511	-4.53538	-5.31752	-5.4299	-4.37263	-4.54277	-5.54328	-5.50517	-3.53216	-4.21381	-4.38996	-4.56101	NA	-2.21929	-2.93942	-3.44338	-3.89267	-4.3991	-5.23469	-4.9423	-3.89267	-4.3991	-5.23432	-4.93337
KPCD2_HUMAN	Q9BZL6	Y	717	F	 Abolishes phosphorylation. Decreases substrate;affinity and increases catalytic efficiency. Increases Ser-;706 or/and Ser-710 phosphorylation. Increases NF-kappa-B;activation in response to oxidative stress."";/evidence=""ECO:0000269|PubMed:28428613""	Y	163	Y717F	Q9BZL6/Y717F	A	-2.59378	-2.69531	-3.13695	-3.99181	-2.60365	-2.70064	-3.26578	-4.01795	-2.76371	-3.17049	-3.29895	-3.4062	NA	-2.01977	-2.46209	-2.74748	-2.41154	-2.62602	-3.01854	-3.73497	-2.41154	-2.62602	-3.01982	-3.73192
KPCL_HUMAN	P24723	V	374	I	 (associated with susceptibility to ischemic;stroke; increases autophosphorylation and kinase activity;;dbSNP:rs2230500)"";/evidence=""ECO:0000269|PubMed:17206144,;ECO:0000269|PubMed:17344846"";/id=""VAR_034604""	e	20	V374I	P24723/V374I	A	1.08633	0.94745	0.75003	1.53957	1.08633	0.94745	0.75003	1.53957	NA	NA	NA	-1.02994	-0.4235	-1.49985	-1.79134	-0.36206	1.16733	3.4006	3.25455	3.6842800000000002	1.14673	1.04528	0.96207	1.61471
KSYK_HUMAN	P43405	M	450	I	 (in IMD82; constitutively active protein;tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:33782605"";/id=""VAR_085997""	y	79	M450I	P43405/M450I	A	-2.29294	-2.45718	-2.41644	-2.92161	-5.08539	-2.08494	-2.02885	-1.86961	-1.8313	-0.92702	-0.63834	-0.54575	-1.89429	-1.65708	-1.43239	-1.67286	-2.23205	-2.98334	-4.5909	-3.12844	-3.03377	-2.17001	-2.19172	-1.8621
KSYK_HUMAN	P43405	S	550	F	 (in IMD82; constitutively active protein;tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:33782605"";/id=""VAR_085998""	s	175	S550F	P43405/S550F	A	-4.39729	-4.74311	-4.03948	-6.60313	-9.24986	-5.50947	-5.72503	-5.1082	-9.24577	-5.46103	-5.67262	-5.06385	-5.14829	-5.30711	-5.59806	-4.64621	-4.3986	-6.72212	-7.84727	-3.10996	-3.93453	-4.43822	-4.93342	-6.12427
KSYK_HUMAN	P43405	S	550	Y	 (in IMD82; constitutively active protein;tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:33782605"";/id=""VAR_085999""	s	175	S550Y	P43405/S550Y	A	-4.75725	-5.1088	-3.93526	-6.21943	-9.60679	-4.72293	-5.40093	-3.63265	-9.64498	-4.70373	-5.31512	-3.58396	-5.23838	-5.4007	-5.63629	-4.27343	-4.75629	-6.52205	-7.34306	-5.43591	-4.29409	-4.79966	-4.71647	-5.71339
LIMK1_HUMAN	P53667	T	508	E	 Phosphomimetic mutant; enhances kinase;activity."";/evidence=""ECO:0000269|PubMed:22328514""	s	156	T508E	P53667/T508E	A	-4.77699	-5.90943	-7.78606	-7.12827	-5.61161	-8.4191	-2.88987	-3.29269	-4.77671	-4.86653	-4.086	-1.49961	-2.68077	-3.55981	-3.20241	-3.3347	-4.64537	-5.60559	-6.28023	-5.02108	-4.45504	-5.41461	-8.29273	-6.79442
LIMK1_HUMAN	P53667	T	508	EE	: Enhances kinase activity."";/evidence=""ECO:0000269|PubMed:10196227,;ECO:0000269|PubMed:10652353""	s	156	T508EE	P53667/T508EE	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
LIMK2_HUMAN	P53671	T	505	E	 Phosphomimetic mutant; enhances kinase;activity."";/evidence=""ECO:0000269|PubMed:11018042,;ECO:0000269|PubMed:22328514""	s	156	T505E	P53671/T505E	A	-3.82453	-6.15471	-8.09923	-8.06689	-5.46717	-8.1918	-2.80884	-3.29269	-5.25539	-4.64134	-1.37945	-1.28482	-2.7346	-3.55981	-3.22445	-3.3347	-3.85704	-5.58937	-6.49887	-4.91485	-3.73053	-5.17802	-8.57764	-6.74418
LRRK2_HUMAN	Q5S007	I	2020	T	 (in PARK8; significant increase in;autophosphorylation of about 40% in comparison to wild-type;protein in vitro; shows a progressive reduction in neurite;length and branching; shows an increase in activity in;phosphorylation of RAB8A and RAB10; dbSNP:rs35870237)"";/evidence=""ECO:0000269|PubMed:15541309,;ECO:0000269|PubMed:15880653, ECO:0000269|PubMed:16172858,;ECO:0000269|PubMed:16251215, ECO:0000269|PubMed:16321986,;ECO:0000269|PubMed:17114044, ECO:0000269|PubMed:26824392,;ECO:0000269|PubMed:29212815"";/id=""VAR_024959""	l	144	I2020T	Q5S007/I2020T	A	-4.68923	-6.46962	-8.67552	-2.38365	-8.47351	-9.44424	-8.28036	-4.57971	-6.84769	-8.76385	-8.49932	-8.42205	NA	-2.66661	-2.66661	-3.72964	-4.90984	-7.25811	-9.33768	-3.66254	-4.22157	-5.2883	-7.18038	-2.74268
LRRK2_HUMAN	Q5S007	T	2031	S	 (in PARK8; shows an increase in activity in;phosphorylation of RAB8A and RAB10; dbSNP:rs78029637)"";/evidence=""ECO:0000269|PubMed:26824392,;ECO:0000269|PubMed:29212815"";/id=""VAR_082047""	s	156	T2031S	Q5S007/T2031S	A	-4.20602	-2.0549	-0.60475	-1.35894	-0.6994	-0.91439	-1.07034	-1.18466	-3.52154	-3.4101	-0.93279	-0.05016	NA	-2.216	-2.216	-2.00052	-4.43147	-1.06515	-0.8787	-1.20794	-3.7602	-4.83168	-1.03012	-1.22418
MAPK2_HUMAN	P49137	T	222	D	 Mimicks phosphorylation state, leading to;slight increase of basal kinase activity."";/evidence=""ECO:0000269|PubMed:14517288,;ECO:0000269|PubMed:15014438, ECO:0000269|PubMed:8846784""	s	156	T222D	P49137/T222D	A	-3.14235	-3.49951	-3.7754	-4.31757	-3.14235	-3.49951	-3.7754	-4.31757	NA	NA	NA	-2.74977	NA	-2.74977	-2.74977	-3.0223	-5.19432	-3.10621	-1.86258	-1.64521	-3.03021	-3.34738	-3.77134	-5.76381
MAPK2_HUMAN	P49137	T	222	E	 Mimicks phosphorylation state and constitutive;protein kinase activity; when associated with E-334."";/evidence=""ECO:0000269|PubMed:14517288,;ECO:0000269|PubMed:15014438, ECO:0000269|PubMed:8846784""	s	156	T222E	P49137/T222E	A	-3.23819	-3.64326	-3.95588	-4.10211	-3.23819	-3.64326	-3.95588	-4.10211	NA	NA	NA	-2.78593	NA	-2.78593	-2.78593	-3.02354	-5.52585	-3.51496	-3.31459	-2.42239	-3.07942	-3.4677	-3.94335	-5.87093
MAPK2_HUMAN	P49137	S	272	D	 Mimicks phosphorylation state, leading to;slight increase of basal kinase activity."";/evidence=""ECO:0000269|PubMed:8846784""	d	211	S272D	P49137/S272D	A	-1.92151	-1.44115	-1.33252	-1.07043	-1.92151	-1.44115	-1.33252	-1.07043	NA	NA	NA	-2.30338	NA	-2.30338	-2.30338	-1.31974	-1.52557	-0.27674	-0.20345	0.62172	-2.58126	-1.86832	-1.37255	-0.96448
MAPK5_HUMAN	Q8IW41	T	182	D	 Mimicks phosphorylation state and induces;constitutive protein kinase activity."";/evidence=""ECO:0000269|PubMed:12808055,;ECO:0000269|PubMed:21329882, ECO:0000269|PubMed:9628874""	s	156	T182D	Q8IW41/T182D	A	-3.05364	-3.17135	-4.39212	-4.61044	-3.05364	-3.17135	-4.39212	-4.61044	NA	NA	NA	-2.9336	-2.0777	-3.47431	-2.61034	-2.11839	-5.70126	-4.15188	-2.62688	-2.83316	-3.04607	-3.1249	-3.97885	-5.72352
MARK1_HUMAN	Q9P0L2	T	215	E	 Constitutively active."";/evidence=""ECO:0000269|PubMed:14976552""	s	156	T215E	Q9P0L2/T215E	A	-4.66782	-4.57962	-5.54683	-7.82638	-4.66782	-4.57962	-5.54683	-7.82638	NA	NA	NA	-2.73613	-6.4462	-3.27402	-3.17941	-2.03403	-7.77684	-4.64377	-4.35378	-3.65054	-3.87993	-4.76507	-6.15813	-7.39095
MELK_HUMAN	Q14680	T	167	D,	E: Phosphomimetic mutant that has similar;kinase activity as wild-type."";/evidence=""ECO:0000269|PubMed:14976552""	s	156	T167D	Q14680/T167D	A	-3.83748	-4.31803	-5.03323	-4.73004	-3.83748	-4.31803	-5.03323	-4.73004	NA	NA	NA	-2.83833	-5.50021	-4.54293	-2.49085	-2.11839	-7.16355	-7.95466	-3.19134	-3.46604	-3.82519	-4.15559	-5.04046	-4.61821
MK12_HUMAN	P53778	D	179	A	 Emulation of the active state."";/evidence=""ECO:0000269|PubMed:15284239""	e	149	D179A	P53778/D179A	A	-3.36797	-3.72845	-3.30199	-3.40978	-2.63615	-2.33022	-1.42611	-1.26698	-2.06962	-1.93808	-1.10088	-1.03458	-1.73484	-1.36974	-1.20853	-0.79238	-3.50572	-3.88453	-3.35829	-2.5556	-3.32172	-3.56005	-3.79661	-3.14175
MK14_HUMAN	Q16539	D	176	A	 Emulation of the active state. Increase in;activity; when associated with S-327 or L-327."";/evidence=""ECO:0000269|PubMed:15284239""	e	149	D176A	Q16539/D176A	A	-3.20581	-3.50575	-2.79228	-2.66388	-2.2094	-2.29302	-1.42567	-1.26698	-2.21276	-1.88682	-1.28228	-1.15215	-1.73484	-1.60886	-0.76784	-0.79238	-3.32974	-3.20275	-2.42349	-2.38316	-3.10727	-3.23729	-2.64945	-2.29763
MP2K2_HUMAN	P36507	P	128	Q	 (in CFC4; results in increased kinase;activity; dbSNP:rs267607230)"";/evidence=""ECO:0000269|PubMed:20358587"";/id=""VAR_069782""	p	58	P128Q	P36507/P128Q	A	-3.75648	-4.20447	-3.56629	-3.20209	-4.05382	-3.83786	-4.75759	-3.72024	-2.70221	-3.19294	-3.36145	-3.81886	-2.97226	-4.64186	-2.58435	-3.9653	-4.60136	-4.08392	-2.39044	-3.15601	-4.75856	-3.67167	-3.79164	-3.47375
MP2K3_HUMAN	P46734	S	218	E	 Constitutive activation."";/evidence=""ECO:0000269|PubMed:8622669""	s	151	S218E	P46734/S218E	A	-4.15995	-5.63589	-3.21417	-2.2108	-4.40531	-1.94275	-1.05455	-0.98673	-3.6478	-1.17585	-0.52374	-0.67797	-2.71336	-1.22814	-0.00887	-0.29488	-2.91075	-5.12084	-5.69151	-2.24545	-2.85883	-4.5731	-5.88119	-3.24367
MP2K3_HUMAN	P46734	T	222	E	 Constitutive activation."";/evidence=""ECO:0000269|PubMed:8622669""	t	155	T222E	P46734/T222E	A	-3.68581	-1.81733	-1.61905	-0.99884	-2.08672	-0.97887	-1.08968	-1.48743	-0.84039	-0.84986	-0.59569	-1.46698	-0.86617	-1.52278	-0.34194	0.22082	-3.33261	-2.54598	-1.55589	-1.32034	-3.27975	-4.71748	-2.19389	-1.11944
MP2K6_HUMAN	P52564	S	207	E	 Constitutive activation according to;PubMed:8622669, but not to PubMed:8621675.""	s	151	S207E	P52564/S207E	A	-4.16138	-5.04094	-2.41332	-2.2108	-4.25696	-2.08631	-0.97832	-0.98673	-1.6032	-1.05738	-0.98687	-0.67762	-2.97025	-1.18306	-0.50522	-0.29488	-2.85866	-5.81349	-5.02598	-2.1503	-2.74215	-4.50084	-5.98355	-3.62731
MP2K6_HUMAN	P52564	T	211	E	 Constitutive activation according to;PubMed:8622669, but not to PubMed:8621675.""	t	155	T211E	P52564/T211E	A	-3.69962	-1.82779	-0.83879	-0.99884	-3.3867	-1.02277	-1.00485	-1.48743	-1.18202	-0.82374	-1.08478	-1.46608	-0.82665	-1.51309	-0.62516	0.22082	-3.30467	-2.55744	-1.5998000000000001	-1.29259	-3.20579	-4.6519	-2.40119	-1.0341
MRCKA_HUMAN	Q5VT25	S	222	L	 Increase in autophosphorylation but not kinase;activity."";/evidence=""ECO:0000269|PubMed:11283256""	l	144	S222L	Q5VT25/S222L	A	-5.1543	-3.87612	-4.85881	-2.23925	-5.1543	-3.87612	-4.85881	-2.23925	NA	NA	NA	-3.15847	1.17763	1.33797	1.82439	0.84774	-1.32787	0.6213	0.70046	0.49369	-4.71341	-5.6063	-4.45585	-1.93529
NEK2_HUMAN	P51955	T	170	E	 Kinase activity increased by two fold."";/evidence=""ECO:0000269|PubMed:17197699""	s	152	T170E	P51955/T170E	A	-3.26334	-2.45535	-1.81612	-1.377	-3.26334	-2.45535	-1.81612	-1.377	NA	NA	NA	-3.08965	-0.61577	-0.52403	0.12692	0.36152	-0.96534	-1.23615	-2.01777	-0.9734	-3.22941	-2.36766	-1.79783	-1.34148
NEK2_HUMAN	P51955	S	171	D	 Kinase activity increased by two fold."";/evidence=""ECO:0000269|PubMed:17197699""	k	153	S171D	P51955/S171D	A	-3.02092	-2.40506	-1.3615	-1.4932	-3.02092	-2.40506	-1.3615	-1.4932	NA	NA	NA	-2.39294	0.38815	0.62046	-0.07715	0.21461	-1.20064	0.80296	0.57393	0.48407	-3.01908	-2.34063	-1.41354	-1.57175
NEK2_HUMAN	P51955	T	175	E	 Kinase activity increased by two fold."";/evidence=""ECO:0000269|PubMed:17197699""	s	156	T175E	P51955/T175E	A	-3.86795	-3.69116	-5.52522	-6.1211	-3.86795	-3.69116	-5.52522	-6.1211	NA	NA	NA	-3.08965	-8.71481	-9.20523	-2.68609	-2.03403	-6.63861	-3.71497	-4.11849	-3.69435	-3.86533	-3.61776	-5.44929	-6.07631
NEK6_HUMAN	Q9HC98	Y	108	A	 Increase in catalytic activity."";/evidence=""ECO:0000269|PubMed:19941817""	l	63	Y108A	Q9HC98/Y108A	A	-4.32211	-4.68756	-4.9493	-6.24593	-4.32211	-4.68756	-4.9493	-6.24593	NA	NA	NA	-3.98	-3.03257	-3.04351	-2.83704	-2.17345	-7.75018	-5.26013	-4.86103	-3.1424	-4.22569	-4.6387	-4.89911	-6.19963
NEK7_HUMAN	Q8TDX7	Y	97	A	 5-fold increase in catalytic activity."";/evidence=""ECO:0000269|PubMed:19941817""	l	63	Y97A	Q8TDX7/Y97A	A	-3.6068	-4.1938	-4.89645	-6.32516	-3.6068	-4.1938	-4.89645	-6.32516	NA	NA	NA	NA	-6.50791	-2.73017	-4.87854	-2.17345	-8.55877	-5.35636	-5.4817	-3.27245	-3.17838	-3.89548	-4.11706	-6.18228
NEK7_HUMAN	Q8TDX7	Y	97	F,	L: Moderate increase in catalytic activity."";/evidence=""ECO:0000269|PubMed:19941817""	l	63	Y97F	Q8TDX7/Y97F	A	-1.78437	-2.0194	-2.51006	-4.22166	-1.78437	-2.0194	-2.51006	-4.22166	NA	NA	NA	NA	-1.684	-0.31621	-0.77728	-0.18012	-3.02572	-1.81013	-1.7108	-1.22401	-1.65003	-1.91142	-2.13052	-4.17969
PAK1_HUMAN	Q13153	T	423	E	 Constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:10551809""	s	156	T423E	Q13153/T423E	A	-4.03387	-4.21067	-4.31171	-4.39833	-5.97653	-2.98655	-3.2088	-2.9175	-6.1941	-3.49305	-3.18933	-2.88659	-3.90275	-6.58285	-5.73431	-3.7635	-4.05647	-5.88893	-7.59257	-2.31453	-3.42414	-4.01862	-4.40186	-3.74085
PAK1_HUMAN	Q13153	Y	429	C	 (in IDDMSSD; gain-of-function; enhanced PAK1;kinase activity and significantly reduced homodimerization;;dbSNP:rs1565583382)"";/evidence=""ECO:0000269|PubMed:30290153"";/id=""VAR_081555""	e	162	Y429C	Q13153/Y429C	A	-5.18666	-5.26261	-5.28209	-6.62089	-5.67631	-3.13533	-2.55078	-2.41518	-5.23402	-3.15593	-2.50862	-2.37758	-5.26473	-3.20258	-3.10997	-3.19546	-5.19765	-6.53483	-7.57493	-2.97418	-4.76827	-5.17241	-5.37529	-5.79004
PAK4_HUMAN	O96013	S	445	N	 Approximately 30-fold increased;autophosphorylation (constitutively active mutant)."";/evidence=""ECO:0000269|PubMed:11313478""	N	128	S445N	O96013/S445N	A	-3.24165	-3.52325	-3.6999	-0.13916	4.87323	5.69797	6.02664	5.94089	5.8571	6.74476	7.00739	6.71644	1.83488	2.40956	3.91468	4.60527	-3.45823	-0.38682	2.02239	3.19057	-2.99679	-3.41643	-3.69128	-0.13644
PDPK1_HUMAN	O15530	A	277	V	 3-fold increase in kinase activity."";/evidence=""ECO:0000269|PubMed:10364160""	t	192	A277V	O15530/A277V	A	-2.6614	-3.31808	-1.13174	-0.28058	-2.6614	-3.31808	-1.13174	-0.28058	NA	NA	NA	-2.1099	1.09384	1.89869	2.07849	1.45928	-2.21919	0.42277	0.3666	0.64888	-2.62031	-3.48128	-1.36256	-0.27431
PGFRA_HUMAN	P16234	H	650	Q	 (in a hypereosinophilic syndrome sample;;constitutively activated kinase)"";/evidence=""ECO:0000269|PubMed:21224473"";/id=""VAR_066465""	k	54	H650Q	P16234/H650Q	A	-3.5973	-4.58179	-5.30828	-6.78307	-6.03617	-2.8836	-3.08934	-2.8733	-6.10136	-2.84769	-2.95448	-2.79764	-4.78707	-3.08913	-2.07736	-1.84711	-4.47338	-5.73115	-6.45841	-3.81573	-3.56789	-4.54505	-5.2203	-6.58961
PGFRA_HUMAN	P16234	N	659	K	 (in GIST sample; constitutively activated;kinase; dbSNP:rs1057519700)"";/evidence=""ECO:0000269|PubMed:15928335"";/id=""VAR_066466""	r	62	N659K	P16234/N659K	A	-2.79479	-3.65253	-4.23907	-5.51918	-6.79698	-3.29751	-2.22908	-2.0932	-7.12202	-3.33569	-2.19533	-2.06636	-4.70887	-6.01435	-2.94683	-2.50446	-3.55851	-4.60518	-5.26556	-0.69762	-2.77342	-3.61008	-4.16688	-5.35774
PGFRA_HUMAN	P16234	N	659	S	 (in a hypereosinophilic syndrome sample;;constitutively activated kinase)"";/evidence=""ECO:0000269|PubMed:21224473"";/id=""VAR_066467""	r	62	N659S	P16234/N659S	A	-2.89414	-3.6335	-4.18107	-5.33643	-5.72474	-4.85537	-3.5279	-3.31657	-5.99472	-4.41481	-3.51498	-3.28637	-4.67405	-5.77756	-4.90799	-4.92406	-3.55712	-4.52099	-6.09709	-2.34363	-2.87109	-3.59793	-4.1153	-5.18981
PGFRA_HUMAN	P16234	D	842	V	 (in a GIST sample; imatinib resistant,;constitutively activated kinase; dbSNP:rs121908585)"";/evidence=""ECO:0000269|PubMed:12522257,;ECO:0000269|PubMed:15928335, ECO:0000269|PubMed:20972453"";/id=""VAR_066471""	e	147	D842V	P16234/D842V	A	-4.31564	-5.1395	-5.72083	-6.23429	-7.50222	-5.58834	-3.17398	-2.56912	-7.12687	-5.66214	-2.91303	-2.5456	-6.35691	-7.44297	-7.97849	-6.78856	-5.04194	-6.07278	-4.61315	-1.093	-4.28226	-5.10224	-5.65105	-5.81161
PGFRA_HUMAN	P16234	D	842	Y	 (in a GIST sample; imatinib sensitive,;constitutively activated kinase; dbSNP:rs121913265)"";/evidence=""ECO:0000269|PubMed:15928335"";/id=""VAR_066472""	e	147	D842Y	P16234/D842Y	A	-4.02804	-4.81645	-5.36178	-5.76746	-6.47712	-3.12615	-3.57816	-3.42703	-6.26308	-3.1789	-3.61832	-3.39868	-5.88038	-6.88241	-7.37058	-6.24567	-4.72195	-5.70843	-4.56284	-3.78778	-4.00343	-4.7711	-5.30088	-5.38495
PGFRB_HUMAN	P09619	V	665	A	 (in PENTT; gain of function in protein;tyrosine kinase activity; shows ligand-independent;constitutive signaling; dbSNP:rs1554108211)"";/evidence=""ECO:0000269|PubMed:26279204"";/id=""VAR_075866""	v	61	V665A	P09619/V665A	A	-2.98827	-3.54078	-4.09349	-5.28955	-6.04176	-6.35778	-4.63142	-4.76232	-6.4016	-6.31094	-4.53272	-4.75366	-3.86516	-4.78749	-4.69194	-5.04105	-3.16622	-4.2110900000000004	-6.06912	-6.06396	-2.86054	-3.24562	-3.96864	-4.73865
PIM1_HUMAN	P11309	H	68	Y	 Increased kinase activity."";/evidence=""ECO:0000269|PubMed:15808862""	k	31	H68Y	P11309/H68Y	A	-3.277	-3.71048	-2.05025	-1.51459	-3.277	-3.71048	-2.05025	-1.51459	NA	NA	NA	-2.71907	0.03208	0.2955	0.68919	0.90059	-2.0662	-1.93254	-2.16691	-1.94114	-3.139	-3.62148	-1.68859	-1.5213
PLK1_HUMAN	P53350	S	137	D	 Increases activity. Results in a block in;G1/S."";/evidence=""ECO:0000269|PubMed:12207013,;ECO:0000269|PubMed:18615013""	e	84	S137D	P53350/S137D	A	-3.37478	-4.14718	-5.27951	-6.17179	-3.37478	-4.14718	-5.27951	-6.17179	NA	NA	NA	-2.30576	0.95779	3.36317	4.18148	2.31315	-4.16127	-1.96992	-0.80704	-1.59978	-3.20805	-3.87894	-4.40369	-5.5788
PLK1_HUMAN	P53350	T	210	D	 Increases activity and restores recovery after;DNA damage checkpoint."";/evidence=""ECO:0000269|PubMed:12207013,;ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:17461553,;ECO:0000269|PubMed:18615013, ECO:0000269|PubMed:19160488""	s	156	T210D	P53350/T210D	A	-3.8692	-4.99966	-6.2334	-6.26513	-3.8692	-4.99966	-6.2334	-6.26513	NA	NA	NA	-2.83874	-4.9768	-5.06423	-3.30285	-2.11839	-5.69044	-2.37113	-2.75409	-2.64903	-3.7296	-4.72937	-5.87373	-6.10598
PLK4_HUMAN	O00444	T	170	D	 Activating mutant."";/evidence=""ECO:0000269|PubMed:18239451,;ECO:0000269|PubMed:19164942""	s	156	T170D	O00444/T170D	A	-4.54909	-5.55043	-6.45695	-7.57655	-4.54909	-5.55043	-6.45695	-7.57655	NA	NA	NA	-2.76061	-5.71189	-5.02638	-2.99772	-2.11839	-8.12461	-4.30368	-2.21731	-1.96237	-4.49033	-5.29641	-6.28831	-8.17333
PRKX_HUMAN	P51817	H	93	Q	 Constitutive kinase activity; when associated;with R-202."";/evidence=""ECO:0000269|PubMed:16236808""	k	44	H93Q	P51817/H93Q	A	-3.84333	-4.42312	-7.02528	-5.09291	-3.84333	-4.42312	-7.02528	-5.09291	NA	NA	NA	-3.08851	-1.27689	-1.2834700000000001	-1.10097	-0.45275	-6.71769	-5.50981	-5.07971	-4.78733	-3.79384	-4.34482	-6.89811	-7.66556
PRKX_HUMAN	P51817	W	202	R	 Constitutive kinase activity; when associated;with Q-93."";/evidence=""ECO:0000269|PubMed:16236808""	t	155	W202R	P51817/W202R	A	-6.25676	-5.55669	-8.42325	-7.51764	-6.25676	-5.55669	-8.42325	-7.51764	NA	NA	NA	-5.39235	-2.90277	-2.34961	-1.67738	-0.27502	-8.43815	-6.43462	-6.30982	-5.40699	-6.23434	-5.829	-8.52043	-8.79477
RAF1_HUMAN	P04049	T	491	D	 Increased kinase activity but can still be;inhibited by PPP5C; when associated with D-494."";/evidence=""ECO:0000269|PubMed:16892053""	k	146	T491D	P04049/T491D	A	-4.06297	-4.49157	-4.53406	-4.00008	-3.60123	-4.85637	-2.92005	-2.66201	-3.05024	-2.9664	-2.4586	-2.36915	-2.75152	-3.70679	-4.09113	-0.63759	-3.7303	-4.81334	-5.88925	-3.70471	-3.10018	-3.96831	-4.75649	-2.47353
ROR2_HUMAN	Q01974	D	482	G	 Slight increase in kinase activity."";/evidence=""ECO:0000269|PubMed:25029443""	G	10	D482G	Q01974/D482G	A	-2.59944	-2.62039	-0.08042	1.70297	-2.73082	0.08971	2.12411	2.5159	1.66412	2.22012	2.41218	3.29272	NA	-3.21222	-3.21222	-2.25173	-2.33403	-3.09966	0.45523	1.60442	-2.33403	-3.13848	0.34967	1.50584
RYK_HUMAN	P34925	N	484	F	 Gain of an autophosphorylation activity. Gain;of an autophosphorylation activity; when associated with A-;359. Gain of an autophosphorylation activity; when;associated with G-334 and G-482."";/evidence=""ECO:0000269|PubMed:10454588""	F	142	N484F	P34925/N484F	A	-4.49376	-4.0089	-4.06325	-4.03879	-4.55766	-4.30404	-3.98429	-0.46589	-4.27838	-0.41563	-0.32641	1.12698	NA	NA	NA	-3.58404	-4.47915	-4.78372	-4.02904	0.11253	-4.46848	-4.77271	-4.43525	-3.69382
RYK_HUMAN	P34925	A	485	G	 Gain of an autophosphorylation activity. Gain;of an autophosphorylation activity; when associated with G-;334 and F-481."";/evidence=""ECO:0000269|PubMed:10454588""	G	143	A485G	P34925/A485G	A	-2.05613	-2.54185	-2.39057	-2.07952	-2.12324	-2.82449	-2.04744	-0.73814	-2.45691	0.08645	-1.15027	-0.13983	NA	NA	NA	-1.99166	-2.55598	-2.83559	-2.32261	-0.4059	-2.53646	-2.82781	-2.2716	-2.48525
SIK2_HUMAN	Q9H0K1	T	175	E	 Constitutively active."";/evidence=""ECO:0000269|PubMed:14976552""	s	156	T175E	Q9H0K1/T175E	A	-4.56081	-5.60305	-5.80997	-7.80515	-4.56081	-5.60305	-5.80997	-7.80515	NA	NA	NA	-2.8915	-3.62297	-3.01186	-2.81969	-2.03403	-7.70694	-5.66392	-3.2532	-3.40121	-3.657	-5.1985	-5.87064	-6.95652
SRC_HUMAN	P12931	P	302	E	 Kinase active. Interacts with PDLIM4; when;associated with E-307 and F-419."";/evidence=""ECO:0000269|PubMed:19307596""	k	34	P302E	P12931/P302E	A	-4.15489	-3.87853	-3.66648	-1.98177	1.24829	2.05208	1.70404	1.25626	1.83022	2.22745	1.88133	1.42659	-1.76055	1.27327	1.83681	1.81759	-5.05884	-2.20173	-1.089	-1.60677	-4.11887	-4.15602	-5.22135	-1.71249
SRC_HUMAN	P12931	P	307	E	 Kinase active. Interacts with PDLIM4; when;associated with E-302 and F-419."";/evidence=""ECO:0000269|PubMed:19307596""	k	39	P307E	P12931/P307E	A	-4.15489	-4.45801	-5.70947	-3.35711	-0.59443	1.04101	1.4084	1.35071	-0.10927	1.04041	1.53423	1.455	-2.74057	0.53344	-0.07478	0.01953	-3.9435	-2.94866	-1.46487	-0.70832	-4.11887	-4.15602	-4.15688	-2.95014
TIE2_HUMAN	Q02763	Y	897	C	 (in VMCM; increased ligand-independent;autophosphorylation and kinase activation;;dbSNP:rs80338909)"";/evidence=""ECO:0000269|PubMed:19888299"";/id=""VAR_066606""	e	72	Y897C	Q02763/Y897C	A	-5.29945	-6.31541	-4.71232	-3.25612	-3.71425	-3.63045	-0.93162	-0.98513	-4.23146	-2.80849	-0.10235	-0.22545	-4.65469	-4.59561	-4.85771	-4.8549	-5.83794	-6.14585	-3.95353	-0.72053	-5.23003	-5.63759	-6.52803	-3.112
TIE2_HUMAN	Q02763	Y	897	S	 (in VMCM; also found in a patient with;solitary sporadic venous malformations; increased ligand-;independent autophosphorylation and kinase activation;;dbSNP:rs80338909)"";/evidence=""ECO:0000269|PubMed:10369874,;ECO:0000269|PubMed:19079259, ECO:0000269|PubMed:19888299"";/id=""VAR_008716""	e	72	Y897S	Q02763/Y897S	A	-5.29619	-6.52059	-5.32869	-2.34441	-3.51383	-1.8011	-2.01102	-2.25902	-2.85752	-1.01746	-1.29977	-1.52255	-4.17653	-4.44036	-4.77264	-4.82887	-5.99342	-6.33173	-4.40009	-3.70186	-5.2179	-5.76268	-6.78335	-2.48339
TIE2_HUMAN	Q02763	R	915	H	 (in VMCM; strongly increased ligand-;independent autophosphorylation and kinase activation;;dbSNP:rs387906745)"";/evidence=""ECO:0000269|PubMed:19888299"";/id=""VAR_066607""	e	90	R915H	Q02763/R915H	A	-3.38368	-4.51187	-5.51826	-1.77676	-5.00303	-2.80953	-2.35618	-2.13932	-5.32886	-2.75445	-2.26383	-2.10831	-4.42367	-3.83697	-4.23975	-1.40886	-3.99999	-5.3904	-5.32219	-2.57505	-3.32505	-3.77975	-4.74985	-3.6031
TSSK1_HUMAN	Q9BXA7	T	174	E	 Constitutively active."";/evidence=""ECO:0000269|PubMed:15733851""	s	156	T174E	Q9BXA7/T174E	A	-3.53705	-3.64408	-4.47229	-3.63629	-3.53705	-3.64408	-4.47229	-3.63629	NA	NA	NA	-2.93581	-7.32119	-3.36607	-2.07714	-2.03403	-7.24854	-5.63626	-5.59825	-3.74489	-3.32022	-3.57375	-4.30584	-3.08564
VGFR1_HUMAN	P17948	N	1050	D	 Strongly increases kinase activity. Increases;activity in promoting proliferation of endothelial cells."";/evidence=""ECO:0000269|PubMed:16286478""	s	151	N1050D	P17948/N1050D	A	0.83302	1.7122	2.08286	1.82125	2.84395	1.99511	1.31491	1.46865	3.47313	1.76389	1.2662	1.47822	1.29368	1.8062	1.72272	1.53412	-3.1304	0.82146	0.56439	0.23777	-2.56016	0.34382	0.87334	0.99208
VGFR2_HUMAN	P35968	C	1045	A	 Significantly higher kinase activity."";/evidence=""ECO:0000269|PubMed:23199280""	t	140	C1045A	P35968/C1045A	A	-7.43156	-8.12959	-5.42152	-3.68514	-4.44105	-2.63343	-1.85385	-1.63075	-2.8161	-1.47484	-1.33632	-1.23147	-6.71832	-3.06041	-3.10089	-2.3951	-5.31841	-7.3427	-3.75783	-2.03777	-5.20741	-6.82369	-7.92742	-5.32177
ZAP70_HUMAN	P43403	K	362	E	 Increases constitutive kinase activity on LAT;phosphorylation, strongly increases subcellular;localization of CD69 at the cell surface and decreases;autoinhibition conformation."";/evidence=""ECO:0000269|PubMed:26783323""	t	23	K362E	P43403/K362E	A	-2.20017	-0.8461	-0.874	-0.88136	-0.50222	-0.80314	-1.08065	-1.1597	-0.22678	-0.93557	-1.04861	-1.12892	-1.1892	-0.52954	-0.80813	-0.42786	-1.33208	-0.71175	-0.56557	-1.58814	-3.15119	-1.30615	-0.72094	-0.63002
AKT1_HUMAN	P31749	K	179	M	 Abolished serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:33594058""	K	30	K179M	P31749/K179M	D	-4.01119	-4.30466	-4.63773	-5.40957	-4.01119	-4.30466	-4.63773	-5.40957	NA	NA	NA	-2.94981	-6.44239	-10.59222	-10.58969	-6.03829	-4.62776	-6.38193	-7.67298	-9.05386	-3.19117	-3.99184	-4.12259	-4.67679
AURKA_HUMAN	O14965	G	198	N	 Reduces interaction with TPX2. Reduces kinase;activity tenfold. Promotes interaction with the AURKB;binding partners INCENP and BIRC5 that are normally not;bound by AURKA."";/evidence=""ECO:0000269|PubMed:19357306""	e	65	G198N	O14965/G198N	D	-4.34366	-4.76162	-4.36124	-2.46458	-4.34366	-4.76162	-4.36124	-2.46458	NA	NA	NA	-3.37099	1.15205	1.05751	0.77758	0.73621	-3.30627	-2.4123	-2.22851	-2.0036	-4.04943	-4.55428	-4.95106	-2.51316
AURKA_HUMAN	O14965	D	274	N	 Abolishes cilia disassembly and kinase;activity."";/evidence=""ECO:0000269|PubMed:14580337,;ECO:0000269|PubMed:17604723""	D	141	D274N	O14965/D274N	D	-3.08995	-3.39319	-3.70514	-3.69282	-3.08995	-3.39319	-3.70514	-3.69282	NA	NA	NA	-2.52881	-6.93265	-9.88151	-7.16441	-4.2271	-3.62326	-5.98787	-7.00383	-6.11527	-2.88542	-3.26746	-3.54532	-3.64559
AURKA_HUMAN	O14965	T	288	A	 Reduces cilia disassembly and kinase;activity."";/evidence=""ECO:0000269|PubMed:17604723""	s	156	T288A	O14965/T288A	D	-2.00256	-2.2579	-2.57561	-2.88093	-2.00256	-2.2579	-2.57561	-2.88093	NA	NA	NA	-2.04437	-4.71245	-5.07633	-2.99775	-2.53045	-2.98442	-2.40389	-2.39688	-2.49146	-2.45499	-2.58515	-2.8826	-2.7855
AURKB_HUMAN	Q96GD4	K	106	R	 Leads to loss of kinase activity and severely;impairs mitotic progression."";/evidence=""ECO:0000269|PubMed:12686604,;ECO:0000269|PubMed:12925766, ECO:0000269|PubMed:14722118,;ECO:0000269|PubMed:16179162""	K	30	K106R	Q96GD4/K106R	D	-1.81865	-1.32769	-1.83611	-2.40271	-1.81865	-1.32769	-1.83611	-2.40271	NA	NA	NA	-1.63962	-6.01784	-6.99372	-5.42843	-3.99689	-2.0826	-3.77049	-5.08765	-4.0173	-1.76794	-1.85659	-2.12698	-2.7171
AURKC_HUMAN	Q9UQB9	K	72	R	 Impairs kinase activity."";/evidence=""ECO:0000269|PubMed:15316025,;ECO:0000269|PubMed:15499654""	K	30	K72R	Q9UQB9/K72R	D	-1.86334	-2.36735	-1.82977	-2.40271	-1.86334	-2.36735	-1.82977	-2.40271	NA	NA	NA	-1.68983	-6.06017	-6.97559	-5.52688	-3.99689	-1.78816	-2.30923	-2.4169	-3.12699	-1.78816	-2.30923	-2.4169	-3.12699
AURKC_HUMAN	Q9UQB9	D	166	Y	 Impairs kinase activity, and keeps AURKC with;the chromosomes until the end of mitosis."";/evidence=""ECO:0000269|PubMed:15938719""	D	123	D166Y	Q9UQB9/D166Y	D	-4.49101	-5.41447	-5.67421	-5.74705	-4.49101	-5.41447	-5.67421	-5.74705	NA	NA	NA	-4.02591	-9.13621	-8.47665	-7.54354	-7.10065	-4.31639	-5.32583	-5.54159	-5.66025	-4.31639	-5.32583	-5.54159	-5.66025
AURKC_HUMAN	Q9UQB9	T	198	A	 Impairs kinase activity."";/evidence=""ECO:0000269|PubMed:15316025,;ECO:0000269|PubMed:15670791""	s	156	T198A	Q9UQB9/T198A	D	-2.37124	-3.03141	-3.23583	-4.74451	-2.37124	-3.03141	-3.23583	-4.74451	NA	NA	NA	-2.07054	-4.90778	-4.65011	-2.9917	-2.53045	-2.26551	-2.9536	-3.12114	-4.65999	-2.26551	-2.9536	-3.12114	-4.65999
BRAF_HUMAN	P15056	K	483	S	 Reduces kinase activity with MAP2K1."";/evidence=""ECO:0000269|PubMed:21441910""	K	30	K483S	P15056/K483S	D	-4.31959	-4.74026	-4.31456	-7.64677	-11.9056	-9.95299	-9.56084	-10.05969	-12.9697	-9.7393	-9.68792	-10.02563	-5.28069	-7.97591	-9.00607	-7.42558	-3.84885	-5.55715	-7.21673	-6.6963	-3.58967	-4.04047	-4.85908	-6.29699
BRSK1_HUMAN	Q8TDC3	T	189	A	 Prevents phosphorylation and activation by;STK11/LKB1 complex."";/evidence=""ECO:0000269|PubMed:14976552""	s	156	T189A	Q8TDC3/T189A	D	-3.25104	-3.02445	-3.0394	-4.60808	-3.25104	-3.02445	-3.0394	-4.60808	NA	NA	NA	-2.0391	-3.10104	-4.28396	-2.53296	-2.53045	-5.46777	-6.81105	-4.05612	-2.79763	-3.14429	-3.4802399999999998	-3.88492	-4.65241
BRSK2_HUMAN	Q8IWQ3	T	174	A	 Prevents phosphorylation and activation by;STK11/LKB1 complex."";/evidence=""ECO:0000269|PubMed:14976552,;ECO:0000269|PubMed:18339622, ECO:0000269|PubMed:22798068""	s	156	T174A	Q8IWQ3/T174A	D	-3.11873	-3.02547	-3.01848	-4.60808	-3.11873	-3.02547	-3.01848	-4.60808	NA	NA	NA	-2.00162	-3.57071	-3.50161	-2.57726	-2.53045	-5.45951	-6.86661	-4.43774	-2.49806	-2.98405	-3.37694	-3.60819	-4.23901
BTK_HUMAN	Q06187	R	520	 Q	 (in XLA; severe; prevents activation due to;absence of contact between the catalytic loop and the;regulatory phosphorylated residue; dbSNP:rs128621202)"";/evidence=""ECO:0000269|PubMed:7633429,;ECO:0000269|PubMed:7809124, ECO:0000269|PubMed:7849697,;ECO:0000269|PubMed:7880320"";/id=""VAR_006251""	r	122	R520Q	Q06187/R520Q	D	-4.07884	-4.58787	-5.06689	-7.55555	-9.19767	-9.16729	-8.70427	-8.50118	-8.82451	-9.18207	-8.68915	-8.44561	-3.96535	-5.8895	-6.4778	-4.2239	-3.82061	-4.5873	-7.64595	-8.96288	-2.90243	-3.8947	-4.80178	-5.5204
CDK12_HUMAN	Q9NYV4	D	877	N	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:24662513""	D	141	D877N	Q9NYV4/D877N	D	-3.36291	-3.78934	-5.33422	-6.15204	-9.31104	-9.85637	-8.49047	-6.92723	-8.99864	-9.55735	-8.45574	-6.91895	-4.90819	-6.2279	-7.034	-7.87181	-3.38143	-5.0299	-5.97987	-7.88004	-2.91421	-4.27102	-5.46288	-5.87037
CDK14_HUMAN	O94921	K	164	R	 Abolishes protein kinase activity."";/evidence=""ECO:0000269|PubMed:17517622,;ECO:0000269|PubMed:19524571""	K	30	K164R	O94921/K164R	D	-1.54905	-1.51202	-1.79069	-3.10717	-9.30347	-6.01675	-6.78643	-6.90968	-10.85315	-6.38172	-6.84038	-6.90036	-2.68695	-4.62065	-5.52193	-6.29323	-1.34457	-2.77024	-2.99496	-4.42012	-1.49306	-1.34175	-1.69066	-2.98565
CDK16_HUMAN	Q00536	K	194	A	 Loss of kinase activity. Abolishes effect on;insulin secretion."";/evidence=""ECO:0000269|PubMed:22184064,;ECO:0000269|PubMed:22798068""	K	30	K194A	Q00536/K194A	D	-2.99003	-3.41458	-3.85559	-6.05208	-10.6276	-11.75104	-9.66043	-10.1119	-10.83291	-11.75981	-9.65864	-10.11102	-4.14575	-6.58674	-7.46076	-8.27455	-3.14589	-5.64952	-5.86122	-6.93537	-2.95715	-3.15945	-3.68608	-5.78308
CDK19_HUMAN	Q9BWU1	G	28	 R	 (in DEE87; decreased protein kinase;activity)"";/evidence=""ECO:0000269|PubMed:33495529"";/id=""VAR_084393""	G	8	G28R	Q9BWU1/G28R	D	-3.96301	-4.37157	-5.42397	-4.16515	-9.91078	-11.08122	-10.12674	-9.62084	-10.35511	-10.91245	-10.14901	-9.62692	-5.29939	-6.2743	-7.80951	-8.62006	-3.71596	-5.24056	-3.76038	-6.25994	-3.65461	-4.72102	-3.96601	-3.94285
CDK20_HUMAN	Q8IZL9	T	161	A	 Impairs CDK2 T-160 phosphorylation and;activity."";/evidence=""ECO:0000269|PubMed:14597612""	t	155	T161A	Q8IZL9/T161A	D	-2.08293	-1.29232	-2.0187	-2.29899	-4.16075	-3.85542	-5.01678	-3.44949	-8.78776	-5.37124	-6.16828	-3.99179	-3.59865	-4.3366	-4.57115	-2.10283	-1.35961	-2.03631	-3.23106	-4.61409	-2.00441	-1.28675	-1.903	-2.26737
CDK2_HUMAN	P24941	T	160	A	 Abolishes activity."";/evidence=""ECO:0000269|PubMed:1396589""	t	155	T160A	P24941/T160A	D	-2.74914	-2.86283	-3.06698	-3.15276	-2.75644	-3.45084	-4.94188	-3.44947	-2.87385	-3.40137	-5.08403	-3.43827	-2.16967	-4.10882	-4.7218	-2.10283	-2.8311	-2.89063	-2.95676	-3.83067	-2.67829	-2.72891	-2.97831	-2.76122
CDK2_HUMAN	P24941	L	166	R	 Reduced phosphorylation by CAK and reduced;kinase activity."";/evidence=""ECO:0000269|PubMed:17373709""	s	161	L166R	P24941/L166R	D	-3.92954	-3.43385	-2.70396	-3.56024	-0.65699	0.40321	1.12974	1.53256	-0.67985	0.43874	1.16792	1.55441	-2.2439	-0.82296	-0.11042	0.48515	-3.37882	-3.79308	-3.91298	-2.66697	-3.8308	-3.22995	-3.60314	-4.25751
CDK8_HUMAN	P49336	V	27	 L	 (in IDDHBA; decreased protein kinase;activity)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083786""	l	7	V27L	P49336/V27L	D	-2.0867	-2.04627	-2.13696	-2.10501	-0.05122	-0.37509	-0.67737	-0.93222	0.67144	-0.28124	-0.51688	-0.83931	-1.43478	-0.69189	-0.74163	-0.6302	-2.08988	-2.1972	-2.06453	0.02821	-1.98469	-2.0883	-2.20051	-2.12103
CDK8_HUMAN	P49336	R	29	 G	 (in IDDHBA; decreased protein kinase;activity; dbSNP:rs1593218885)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083787""	e	9	R29G	P49336/R29G	D	-3.44118	-3.63105	-2.93248	-2.32541	-3.94496	-2.80114	-2.53004	-3.07118	-2.15649	-1.53869	-1.75827	-2.79202	-2.36201	-1.88624	-1.21515	-1.6543	-3.45699	-3.08922	-2.42703	-3.92713	-3.40796	-3.78556	-2.64943	-2.31192
CDK8_HUMAN	P49336	G	30	 S	 (in IDDHBA; decreased protein kinase;activity; dbSNP:rs1593218890)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083788""	G	10	G30S	P49336/G30S	D	-3.29181	-3.73258	-4.42098	-5.02068	-12.43417	-12.10478	-8.81935	-8.70604	-12.44532	-12.15405	-8.79902	-8.69335	-6.67477	-7.40245	-8.78596	-9.52618	-3.32474	-4.44044	-5.0728	-9.30001	-3.15145	-3.91682	-4.79256	-5.13819
CDK8_HUMAN	P49336	S	62	 L	 (in IDDHBA; decreased protein kinase;activity; dbSNP:rs1565977796)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083789""	k	44	S62L	P49336/S62L	D	-3.44144	-3.8196	-3.60715	-3.84303	-2.16841	0.33449	0.00463	-0.13054	-1.06069	1.18354	0.56787	0.30034	-3.41007	-1.35634	-0.86053	-1.05447	-3.48306	-3.59363	-3.76801	-4.47221	-3.25846	-3.64795	-3.76888	-3.71875
CDK8_HUMAN	P49336	R	178	 Q	 (in IDDHBA; decreased protein kinase;activity; dbSNP:rs1418353379)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083791""	k	146	R178Q	P49336/R178Q	D	-2.27563	-2.58091	-3.31654	-3.53323	-7.44995	-7.15371	-6.9913	-3.46475	-7.44826	-7.06883	-6.91969	-3.40119	-3.59935	-3.21718	-4.12651	-1.92516	-2.27245	-3.15758	-3.83369	-5.13443	-2.64814	-2.6455	-3.43315	-3.49965
CDK8_HUMAN	P49336	V	193	 G	 (in IDDHBA; decreased protein kinase;activity)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083792""	f	157	V193G	P49336/V193G	D	-3.37575	-3.67557	-4.33319	-3.92716	-4.79262	-4.54862	-2.24328	-1.92243	-2.83866	-2.8669	-0.76065	-0.73398	-2.37972	-2.2972	-1.61814	-1.08055	-3.3673	-4.17497	-3.98954	-5.29294	-3.5854	-3.72134	-4.42373	-3.94504
CDK8_HUMAN	P49336	I	223	 M	 (in IDDHBA; decreased protein kinase;activity; dbSNP:rs1593310364)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083793""	i	186	I223M	P49336/I223M	D	-1.92197	-2.23043	-2.75839	-3.08874	-6.75956	-4.89163	-4.27075	-3.19181	-5.48216	-4.67872	-4.15454	-3.08795	-4.25271	-4.2718	-4.99617	-2.952	-1.93284	-2.61463	-3.04701	-4.70901	-2.03578	-2.2883	-2.74704	-3.07412
CDK9_HUMAN	P50750	K	44	R	 Impaired kinase and transcriptional elongation;activities, but normal cyclin T1 and HEXIM1 binding."";/evidence=""ECO:0000269|PubMed:17452463""	i	26	K44R	P50750/K44R	D	-1.50553	-0.94013	-0.7779	-1.09554	0.41704	-0.4195	-0.63708	-0.56631	0.70333	-0.34035	-0.54612	-0.51034	-1.16322	-1.0157	-0.15251	-0.92731	-0.94547	-0.82771	-2.24469	-0.28517	-1.49134	-1.10607	-0.90201	-1.03133
CDK9_HUMAN	P50750	K	48	Q	 Mimics acetylation; leading to impaired;protein kinase activity."";/evidence=""ECO:0000269|PubMed:28426094""	K	30	K48Q	P50750/K48Q	D	-1.86769	-2.12966	-2.51675	-4.02934	-9.9725	-5.99781	-8.16263	-8.08899	-11.03744	-6.11248	-8.17715	-8.08213	-4.29752	-5.67735	-6.40965	-7.31506	-2.02867	-3.07075	-7.35111	-6.70057	-1.83447	-1.99907	-2.1341	-4.1257
CHK1_HUMAN	O14757	K	38	R	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:12446774,;ECO:0000269|PubMed:14681223""	K	30	K38R	O14757/K38R	D	-1.88324	-2.59748	-3.6145	-5.87811	-1.88324	-2.59748	-3.6145	-5.87811	NA	NA	NA	-1.39701	-5.15077	-7.18735	-6.04336	-3.99689	-3.05581	-7.31086	-8.83916	-6.47092	-1.84901	-2.30337	-3.35878	-4.69354
CHK1_HUMAN	O14757	D	130	A	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:10673501,;ECO:0000269|PubMed:11390642, ECO:0000269|PubMed:11535615,;ECO:0000269|PubMed:11821419, ECO:0000269|PubMed:12588868,;ECO:0000269|PubMed:14681206, ECO:0000269|PubMed:15311285,;ECO:0000269|PubMed:9278511""	D	123	D130A	O14757/D130A	D	-4.15802	-4.3951	-5.34892	-3.96675	-4.15802	-4.3951	-5.34892	-3.96675	NA	NA	NA	-2.9971	-6.51372	-7.91051	-7.2424	-6.76782	-5.87936	-11.74195	-13.14473	-6.19604	-3.98642	-4.83333	-6.10747	-3.6415
CHK2_HUMAN	O96017	D	368	N	 Loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:15342622""	D	141	D368N	O96017/D368N	D	-3.21089	-3.69261	-4.03298	-4.64808	-3.21089	-3.69261	-4.03298	-4.64808	NA	NA	NA	-2.29008	-7.80828	-6.10537	-6.32035	-4.2271	-4.12175	-4.16286	-4.56336	-4.23455	-3.17592	-4.11741	-4.02316	-4.59225
CHK2_HUMAN	O96017	H	371	 Y	 (confers a moderate risk of breast cancer;;partially reduces kinase activity; dbSNP:rs531398630)"";/evidence=""ECO:0000269|PubMed:21618645"";/id=""VAR_066012""	l	144	H371Y	O96017/H371Y	D	-2.04702	-0.82017	-0.37413	0.48468	-2.04702	-0.82017	-0.37413	0.48468	NA	NA	NA	-3.12247	-0.51455	0.47023	0.76141	0.55203	-0.18722	0.5464	0.61323	0.70433	-2.07897	-1.33643	-0.40205	0.4858
CILK1_HUMAN	Q9UPZ9	T	157	A	 Reduction of activity and loss of;autophosphorylation. Loss of activity and;autophosphorylation; when associated with F-159."";/evidence=""ECO:0000269|PubMed:10699974""	t	155	T157A	Q9UPZ9/T157A	D	-3.0645	-3.7024	-3.65852	-5.39656	-8.45743	-8.85026	-5.29003	-3.44947	-9.59489	-9.22667	-5.28404	-3.40681	-2.8192	-3.27841	-4.54548	-2.10283	-3.02484	-4.1952	-5.11887	-7.0903	-2.97208	-4.01809	-3.81072	-5.55204
CILK1_HUMAN	Q9UPZ9	Y	159	F	 Reduction of activity and loss of;autophosphorylation. Loss of activity and;autophosphorylation; when associated with A-157."";/evidence=""ECO:0000269|PubMed:10699974""	f	157	Y159F	Q9UPZ9/Y159F	D	-2.6253	-3.69555	-3.28903	-4.69233	-3.17349	-3.70035	-4.31842	-4.76014	-2.9163	-3.85453	-4.24216	-4.66686	-3.69996	-3.9573	-4.92122	-5.09481	-2.57679	-3.66961	-5.29857	-4.32165	-2.53722	-3.52471	-3.9078	-5.84639
CILK1_HUMAN	Q9UPZ9	R	272	 Q	 (in ECO; significantly impairs kinase;activity; decreased localization at the ciliary tips;;impaired ciliogenesis; results in abnormally elongated;cilia; impairs mitosis, cell-cycle exit and radial;neuroblast migration, while promoting apoptosis, when;tested in a heterologous system; loss of nuclear;localization; dbSNP:rs118203918)"";/evidence=""ECO:0000269|PubMed:19185282,;ECO:0000269|PubMed:24797473, ECO:0000269|PubMed:24853502,;ECO:0000269|PubMed:29539279"";/id=""VAR_057994""	R	252	R272Q	Q9UPZ9/R272Q	D	-3.76848	-3.97813	-4.78143	-6.65837	-10.06936	-10.79486	-10.39893	-8.35945	-14.05745	-14.86257	-12.21546	-8.35686	-4.77962	-5.34599	-7.34841	-8.31405	-3.6937	-4.91763	-7.55621	-9.89674	-3.60325	-4.7021	-5.53889	-8.32168
CSK_HUMAN	P41240	Y	304	F	 Decreases activity by two-thirds and alters;conformation."";/evidence=""ECO:0000269|PubMed:9148770""	y	113	Y304F	P41240/Y304F	D	-2.08388	-2.74395	-3.25208	-3.57636	-3.05434	-3.49185	-3.34088	-3.05829	-3.1283	-3.39045	-3.285	-3.02996	-2.39182	-2.43195	-3.16404	-2.88018	-2.0873	-2.72408	-2.86081	-3.22047	-2.03845	-2.04755	-2.95101	-3.21199
CTRO_HUMAN	O14578	G	106	 V	 (in MCPH17; impairs kinase activity; exhibits;abnormal mitotic cytokinesis; exhibits multipolar spindles;;increases the neurons apoptotic process;;dbSNP:rs886037892)"";/evidence=""ECO:0000269|PubMed:27453578"";/id=""VAR_077442""	G	10	G106V	O14578/G106V	D	-6.30493	-8.5047	-9.3425	-11.86825	-6.30493	-8.5047	-9.3425	-11.86825	-11.02077	-11.25329	-10.31771	-10.39986	-10.83207	-11.76857	-11.5365	-8.7973	-11.27687	-13.3062	-10.67108	-9.27138	-6.2265	-7.5262	-9.23849	-11.72705
CTRO_HUMAN	O14578	K	126	 Q	 (in MCPH17; impairs kinase activity; exhibits;abnormal mitotic cytokinesis; exhibits multipolar spindles;;increases the neurons apoptotic process;;dbSNP:rs886037893)"";/evidence=""ECO:0000269|PubMed:27453578"";/id=""VAR_077443""	K	30	K126Q	O14578/K126Q	D	-3.4842	-5.66425	-6.85784	-10.15902	-3.4842	-5.66425	-6.85784	-10.15902	-7.88441	-8.23143	-7.8202	-8.06905	-8.42545	-9.76782	-9.45039	-4.94897	-9.00858	-10.70001	-7.32021	-6.98584	-3.41891	-4.62163	-6.53572	-9.78326
CTRO_HUMAN	O14578	D	230	 V	 (in MCPH17; impairs kinase activity; exhibits;abnormal mitotic cytokinesis; exhibits multipolar spindles;;increases the neurons apoptotic process;;dbSNP:rs886037894)"";/evidence=""ECO:0000269|PubMed:27453578"";/id=""VAR_077444""	d	132	D230V	O14578/D230V	D	-5.89755	-8.17209	-9.21294	-9.34997	-5.89755	-8.17209	-9.21294	-9.34997	-3.46704	-3.63413	-3.65878	-3.79685	-3.37855	-3.17372	-1.57574	-1.87711	-8.21676	-6.9623	-4.55749	-3.8515	-5.83781	-7.17377	-8.97424	-9.15432
DAPK3_HUMAN	O43293	K	42	A	 Loss of kinase activity at low concentrations;of ATP."";/evidence=""ECO:0000269|PubMed:17158456""	K	30	K42A	O43293/K42A	D	-2.95811	-3.52244	-8.34937	-8.37988	-2.95811	-3.52244	-8.34937	-8.37988	NA	NA	NA	-2.66258	-6.28381	-6.66465	-6.18192	-6.35451	-5.73766	-10.6163	-11.24312	-9.86131	-2.92075	-3.19037	-8.06455	-8.24281
DAPK3_HUMAN	O43293	T	112	 M	 (in a colorectal adenocarcinoma sample;;somatic mutation; greatly reduces kinase activity,;increases cell proliferation and cell survival)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:21487036"";/id=""VAR_040438""	s	96	T112M	O43293/T112M	D	-3.06471	-2.66321	-1.95849	-2.31634	-3.06471	-2.66321	-1.95849	-2.31634	NA	NA	NA	-2.59114	-2.84925	-1.77787	-1.71969	-1.56274	-2.54056	-4.56655	-4.18993	-4.91986	-3.04074	-3.01399	-3.19772	-2.20013
DAPK3_HUMAN	O43293	D	161	 N	 (in an ovarian mucinous carcinoma sample;;somatic mutation; greatly reduces kinase activity,;increases cell proliferation and cell survival)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:21487036"";/id=""VAR_040439""	D	141	D161N	O43293/D161N	D	-2.77768	-3.38508	-7.79556	-8.18546	-2.77768	-3.38508	-7.79556	-8.18546	NA	NA	NA	-2.28895	-5.39402	-5.76332	-4.20911	-4.2271	-5.41572	-10.30646	-10.81591	-5.86108	-2.74586	-3.03386	-7.52875	-8.02067
DAPK3_HUMAN	O43293	T	180	A	 Greatly reduced kinase activity."";/evidence=""ECO:0000269|PubMed:21487036""	t	160	T180A	O43293/T180A	D	-2.42994	-2.9228	-5.15767	-5.61954	-2.42994	-2.9228	-5.15767	-5.61954	NA	NA	NA	-2.08973	-3.80333	-3.84734	-4.32793	-4.47205	-3.71377	-6.16826	-6.56327	-5.3863	-2.39901	-2.61794	-5.16741	-5.60005
DAPK3_HUMAN	O43293	P	216	 S	 (in a lung neuroendocrine carcinoma sample;;somatic mutation; greatly reduces kinase activity,;increases cell proliferation, cell adhesion and cell;survival)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:21487036"";/id=""VAR_040440""	p	196	P216S	O43293/P216S	D	-4.4217	-5.23567	-10.30364	-12.0776	-4.4217	-5.23567	-10.30364	-12.0776	NA	NA	NA	-3.79951	-7.35656	-7.75528	-5.91132	-5.08309	-7.70817	-12.37711	-9.30493	-8.27714	-4.34422	-4.75983	-10.03293	-12.02072
DAPK3_HUMAN	O43293	T	265	A	 Loss of phosphorylation by ROCK1,;catalytically inactive."";/evidence=""ECO:0000269|PubMed:17158456""	t	254	T265A	O43293/T265A	D	-2.42994	-2.34055	-4.9571	-4.57106	-2.42994	-2.34055	-4.9571	-4.57106	NA	NA	NA	-2.08973	-3.16034	-2.1064	-1.9853	-1.85909	-3.42664	-4.64526	-3.69285	-3.79166	-2.39901	-2.37088	-4.63611	-4.52914
DDR2_HUMAN	Q16832	K	608	A	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:16186108""	K	30	K608A	Q16832/K608A	D	-3.51168	-4.56996	-4.8769	-4.98304	-5.18033	-5.10818	-4.13868	NA	-4.61593	-3.11726	-3.89465	NA	NA	-2.85607	-2.85607	-3.65015	-3.53657	-4.64321	-6.86643	-2.99359	-3.43106	-4.31717	-4.62701	-5.91073
DYR1A_HUMAN	Q13627	K	188	R	 Abolished protein kinase activity."";/evidence=""ECO:0000269|PubMed:23665168,;ECO:0000269|PubMed:25620562""	K	30	K188R	Q13627/K188R	D	-1.92613	-2.31285	-3.33091	-5.39357	-3.69334	-6.51621	-4.30433	-4.08717	-5.50926	-6.26622	-4.24723	-4.0292	-2.06959	-2.85001	-3.84642	-4.44371	-1.91513	-4.39586	-5.21336	-5.54103	-1.74433	-2.13571	-3.18014	-5.36541
DYR1A_HUMAN	Q13627	Y	321	F	 Mildly reduces kinase activity. Does not;abolish autophosphorylation on tyrosine residues."";/evidence=""ECO:0000269|PubMed:23665168""	f	157	Y321F	Q13627/Y321F	D	-2.3674	-2.69694	-3.45921	-4.80842	-4.34432	-7.1621	-4.14223	-3.80303	-5.40784	-6.59502	-3.95717	-3.62661	-2.53574	-3.26922	-4.06653	-3.49549	-2.24162	-4.12569	-6.12658	-5.97231	-2.06353	-2.57928	-3.35435	-4.77392
DYR1B_HUMAN	Q9Y463	K	140	R	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:10910078""	K	30	K140R	Q9Y463/K140R	D	-2.1725	-2.4711	-3.38542	-5.39357	-4.57484	-6.62116	-4.29532	-4.08717	-6.15532	-6.27223	-4.24509	-4.0301	-2.06959	-2.83349	-3.84642	-4.44371	-2.48438	-4.46794	-6.84718	-5.04067	-2.21426	-2.52649	-3.26336	-5.39586
DYR1B_HUMAN	Q9Y463	D	239	A	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:32611815""	D	123	D239A	Q9Y463/D239A	D	-4.46999	-4.92584	-6.19001	-8.22191	-7.48032	-9.41693	-7.05629	-6.76422	-8.738	-9.02673	-6.98714	-6.6597	-4.2024	-5.4610900000000004	-6.84001	-7.37427	-4.97848	-7.30682	-9.55814	-10.87203	-4.54368	-5.01877	-6.00611	-8.31108
DYR1B_HUMAN	Q9Y463	Y	271	F	 Abolishes kinase activity; when associated;with F-273."";/evidence=""ECO:0000269|PubMed:10910078""	t	155	Y271F	Q9Y463/Y271F	D	-2.10745	-2.41197	-2.83348	-2.91802	-3.40269	-5.14574	-3.86627	-3.74794	-4.27634	-4.82179	-3.73634	-3.69692	-2.53574	-2.73831	-3.78922	-3.52298	-2.41049	-3.36001	-4.18612	-5.54724	-2.07718	-2.45588	-2.68188	-2.67448
DYRK2_HUMAN	Q92630	K	251	R	 Abolishes protein serine/threonine kinase;activity."";/evidence=""ECO:0000269|PubMed:23362280""	K	30	K251R	Q92630/K251R	D	-1.8339	-2.65425	-3.33104	-3.70108	-3.886	-6.94561	-6.55703	-4.08717	-7.00618	-7.72648	-3.96074	-4.00342	-1.8823	-2.6136	-3.37829	-4.44371	-1.84366	-2.35742	-3.04873	-5.07002	-1.68807	-1.85183	-2.75852	-3.2952
DYRK4_HUMAN	Q9NR20	Y	264	F	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:21127067""	f	157	Y264F	Q9NR20/Y264F	D	-2.76653	-4.94909	-7.02682	-6.86146	-3.879	-7.68864	-6.42335	-3.80303	-3.76139	-7.04368	-5.97835	-3.57815	-2.44157	-3.26922	-3.03168	-3.49549	-2.8049	-4.10102	-4.14055	-5.17579	-2.64501	-3.73601	-6.0323	-6.92864
E2AK2_HUMAN	P19525	T	446	A	 Significant loss of activity and impairs;autophosphorylation of T-451."";/evidence=""ECO:0000269|PubMed:11337501""	t	155	T446A	P19525/T446A	D	-2.99843	-3.37894	-2.48313	-2.64959	-2.99843	-3.37894	-2.48313	-2.64959	NA	NA	NA	-1.91333	-1.79344	-0.71284	-1.05371	-0.91814	-3.48705	-2.74503	-2.57843	-2.24926	-2.57189	-3.43252	-2.30006	-2.92092
EGFR_HUMAN	P00533	K	745	A,	M: Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:19560417""	K	30	K745A	P00533/K745A	D	-4.03481	-4.4905	-4.85278	-8.33248	-5.13695	-6.23498	-6.86079	-8.30985	-5.24945	-6.12728	-6.7747	-7.35117	-2.77939	-3.56516	-4.19226	-4.64516	-4.06535	-4.6834	-6.7818	-9.49143	-4.01621	-4.28687	-4.5167	-8.08072
ERBB4_HUMAN	Q15303	K	751	R	 Abolishes kinase activity. Abolishes;phosphorylation, proteolytic processing and nuclear;localization."";/evidence=""ECO:0000269|PubMed:11390655,;ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867""	K	30	K751R	Q15303/K751R	D	-2.25891	-2.94224	-3.1884	-6.04962	-3.61469	-4.57673	-4.03543	-5.08896	-3.61082	-3.09895	-3.93034	-4.41769	-1.52446	-2.03355	-2.54107	-2.8747	-2.47952	-3.02289	-4.78732	-7.65266	-2.15116	-2.74529	-2.99893	-5.919
ERN1_HUMAN	O75460	K	599	A	 Loss of autophosphorylation and of;endoribonuclease activity. Inhibition of growth arrest."";/evidence=""ECO:0000269|PubMed:11175748,;ECO:0000269|PubMed:9637683""	K	30	K599A	O75460/K599A	D	-4.16226	-5.20312	-5.97809	-7.45723	-5.61438	-8.71466	-12.51538	-14.78131	-8.87781	-11.93305	-14.22018	-15.33323	NA	-2.7649	-3.52458	-4.3651	-4.20794	-6.81992	-8.2315	-10.07414	-3.66957	-4.28349	-5.86051	-6.77095
FAK2_HUMAN	Q14289	K	457	A	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:15166227""	K	30	K457A	Q14289/K457A	D	-3.63124	-4.63636	-5.39443	-6.31763	-3.63407	-4.63808	-5.38691	-6.32313	NA	-2.63146	-3.48275	-3.52047	NA	-2.63146	-2.63146	-3.45815	-3.67526	-3.66205	-4.8326	-5.99877	-3.67526	-3.66205	-4.8326	-5.99877
FER_HUMAN	P16591	K	591	R	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:9722593""	K	30	K591R	P16591/K591R	D	-2.02488	-2.8233	-3.4623	-7.55503	-8.98085	-7.597	-7.23411	-7.54899	-6.07143	-7.73599	-7.23327	-7.53834	-3.59002	-3.96179	-6.26034	-5.13188	-2.14131	-6.24841	-6.64414	-6.47947	-1.94491	-2.14131	-3.21321	-6.39046
FES_HUMAN	P07332	K	590	E	 Abolishes kinase activity. Fails to inhibit;proliferation of melanoma cells."";/evidence=""ECO:0000269|PubMed:15485904,;ECO:0000269|PubMed:28463229""	K	30	K590E	P07332/K590E	D	-3.60704	-4.4728	-5.24979	-9.50204	-9.41823	-10.03548	-11.2184	-10.21252	-9.21969	-10.0335	-11.2021	-10.1786	-5.30014	-5.69762	-6.48616	-6.98142	-4.24967	-8.45397	-7.41133	-10.17256	-2.64617	-4.27273	-5.1164	-8.45439
FES_HUMAN	P07332	M	704	V	 Reduced autophosphorylation and strongly;reduced kinase activity."";/evidence=""ECO:0000269|PubMed:15867340,;ECO:0000269|PubMed:16455651""	l	144	M704V	P07332/M704V	D	-4.0359	-4.90943	-5.63066	-5.29209	-7.86801	-4.25202	-2.91081	-1.72484	-7.41282	-4.01026	-2.70186	-1.53954	-3.83282	-3.7346	-3.76813	-2.71029	-4.61905	-6.14671	-4.92806	-3.42739	-3.05187	-4.64098	-5.53158	-5.71746
FES_HUMAN	P07332	Y	713	F	 Reduces kinase activity by over 90%."";/evidence=""ECO:0000269|PubMed:7687763""	k	153	Y713F	P07332/Y713F	D	-2.80205	-3.25091	-2.78892	-4.18242	NA	-4.9367	-3.3949	-2.77782	NA	-4.69391	-3.25695	-2.63128	NA	NA	-3.87255	-3.39431	-3.04046	-3.26036	-3.83391	-2.03125	-2.18984	-3.04718	-2.82888	-3.55457
FES_HUMAN	P07332	V	743	M	 Strongly reduced autophosphorylation and;kinase activity."";/evidence=""ECO:0000269|PubMed:15867340,;ECO:0000269|PubMed:16455651""	v	180	V743M	P07332/V743M	D	-2.99588	-3.61071	-4.12876	-6.11407	-4.43277	-3.63958	-2.75952	-2.75163	-3.99634	-3.46938	-2.70244	-2.705	-3.66485	-3.9211	-3.39889	-2.6121	-3.47133	-7.09855	-4.52269	-5.08337	-2.1143	-3.56949	-4.38958	-5.34196
FES_HUMAN	P07332	S	759	F	 Reduced autophosphorylation and strongly;reduced kinase activity."";/evidence=""ECO:0000269|PubMed:15867340,;ECO:0000269|PubMed:16455651""	p	195	S759F	P07332/S759F	D	-1.84791	-1.12568	-0.607	-0.55765	-3.98134	-1.75656	-1.24864	0.42453	-4.16338	-1.67122	-1.1652	0.498	-1.2759	-0.95822	-0.09789	-0.01711	-1.86229	-1.85153	-2.96597	-3.83223	-3.1026	-1.85854	-0.89257	-0.43927
FGFR1_HUMAN	P11362	K	618	 N	 (in HH2; some patients also carry GNRHR;mutations; impairs tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:19820032,;ECO:0000269|PubMed:23643382"";/id=""VAR_069293""	g	118	K618N	P11362/K618N	D	-2.6369	-3.19199	-4.02275	-2.91187	-3.32812	-1.17713	-1.20109	-1.27059	-2.88874	-1.12277	-1.1721	-1.22746	-3.29188	-4.93419	-1.25335	-0.60416	-2.8367	-3.58081	-2.67713	-2.03475	-2.65048	-2.90684	-3.68874	-4.93512
FGFR1_HUMAN	P11362	P	722	 H	 (in HH2; associated with K-724; also found in;a family member with isolated anosmia; reduced tyrosine;kinase activity; dbSNP:rs267606805)"";/evidence=""ECO:0000269|PubMed:16606836,;ECO:0000269|PubMed:23643382"";/id=""VAR_031005""	a	230	P722H	P11362/P722H	D	-4.3298	-5.36661	-6.62863	-8.95094	-8.0262	-9.33909	-8.38573	-8.01401	-8.31086	-9.35045	-8.40614	-7.971	-5.48803	-7.54938	-8.34433	-8.75118	-4.73053	-5.9679	-7.4034	-7.55871	-4.34787	-4.87779	-6.30205	-8.83184
FGFR1_HUMAN	P11362	N	724	 K	 (in HH2; associated with H-722; also found in;a family member with isolated anosmia; reduced tyrosine;kinase activity; dbSNP:rs267606806)"";/evidence=""ECO:0000269|PubMed:16606836,;ECO:0000269|PubMed:23643382"";/id=""VAR_031007""	e	232	N724K	P11362/N724K	D	-3.13103	-3.95788	-2.12957	-3.29708	-1.33018	-2.46679	-3.15915	-4.09365	-1.25494	-2.37234	-3.09751	-4.02102	-2.28425	-2.6774	-4.11977	-2.98665	-3.44124	-2.59703	-0.36222	-1.4127	-3.14929	-3.56415	-2.91827	-3.73894
FGFR2_HUMAN	P21802	A	628	 T	 (in LADDS; strongly reduced kinase activity;;dbSNP:rs121918509)"";/evidence=""ECO:0000269|PubMed:16501574"";/id=""VAR_029884""	K	125	A628T	P21802/A628T	D	-2.73457	-2.65456	-2.9934	-4.73916	-4.48123	-6.10044	-6.2871	-6.07359	-4.62274	-6.14435	-6.27142	-6.04394	-2.89781	-4.38946	-5.01564	-5.48005	-2.39656	-3.02456	-3.62957	-3.16709	-2.71872	-2.59645	-2.88395	-4.62236
FGFR3_HUMAN	P22607	K	508	A	 Loss of kinase activity. Abolishes;ubiquitination."";/evidence=""ECO:0000269|PubMed:12297284,;ECO:0000269|PubMed:16410555""	K	30	K508A	P22607/K508A	D	-3.6921	-3.78752	-4.16827	-7.16941	-7.04109	-8.80185	-8.66191	-10.7594	-7.00587	-8.79418	-8.6709	-10.75197	-3.8894	-5.48613	-6.32919	-6.88832	-3.7739	-4.25473	-4.92631	-6.79316	-3.65944	-3.78276	-4.14819	-6.91264
FGFR3_HUMAN	P22607	Y	724	F	 Strongly reduced kinase activity. Strongly;reduced mitogen activity."";/evidence=""ECO:0000269|PubMed:11294897""	k	238	Y724F	P22607/Y724F	D	-2.52487	-2.60079	-2.93082	-4.91318	-4.08025	-4.83365	-3.83319	-3.85234	-4.22942	-4.67376	-3.66831	-3.79988	-2.59406	-3.46222	-3.9288	-4.25381	-2.59301	-2.62908	-3.09042	-3.46254	-2.4947	-2.59793	-2.83693	-4.74145
FLT3_HUMAN	P36888	K	644	A	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:15831474""	K	30	K644A	P36888/K644A	D	-3.29149	-3.80782	-4.54764	-5.61857	-6.2496	-7.32552	-9.43046	-10.75939	-6.89441	-7.70771	-9.43917	-10.76182	-4.39242	-5.40043	-5.96092	-6.88832	-3.80782	-5.16752	-7.92374	-7.37468	-3.29149	-3.76593	-4.48521	-5.531
HCK_HUMAN	P08631	Y	411	A	 Reduced catalytic activity and higher affinity;for target peptides."";/evidence=""ECO:0000269|PubMed:10644735""	l	154	Y411A	P08631/Y411A	D	-4.42939	-2.46926	-2.78667	-2.64697	-6.10084	-3.8491	-3.25379	-2.76574	-6.54962	-3.46264	-3.21433	-2.69022	-2.1736	-3.75265	-4.11683	-2.95201	-5.34253	-4.4833	-4.01503	-1.98438	-5.00737	-4.37141	-3.57832	-2.75992
HIPK1_HUMAN	Q86Z02	D	315	N	 Loss of kinase activity and impaired MAP3K5-;JNK inactivation."";/evidence=""ECO:0000269|PubMed:15701637""	D	123	D315N	Q86Z02/D315N	D	-4.12897	-3.89857	-4.37822	-6.22977	-7.73022	-9.84609	-5.59388	-5.5215	-10.05409	-7.06877	-6.06882	-5.57473	-3.63789	-4.90905	-5.57928	-6.1055	-4.14733	-6.57223	-7.83186	-10.99666	-3.3495	-4.14733	-5.10666	-7.14785
HIPK3_HUMAN	Q9H422	K	226	R	 Loss of kinase activity and impaired;activation of SF1."";/evidence=""ECO:0000269|PubMed:17210646""	K	30	K226R	Q9H422/K226R	D	-3.04179	-3.31708	-3.69963	-5.89074	-7.78878	-7.8258	-4.3061	-4.08717	-6.50908	-6.69184	-4.09846	-4.11477	-2.20938	-3.2914	-3.84642	-4.44371	-2.88994	-4.72489	-5.89684	-5.59035	-2.20553	-2.88994	-3.41461	-5.42004
IGF1R_HUMAN	P08069	K	1033	A	 Kinase inactive. Abolishes tyrosine;phosphorylation and abolishes interaction with IRS1, SHC1;and PIK3R1."";/evidence=""ECO:0000269|PubMed:7541045""	K	30	K1033A	P08069/K1033A	D	-4.58715	-5.21504	-5.83783	-6.69116	-5.48697	-6.18326	-8.7512	-10.54248	-5.33308	-7.51637	-9.59502	-11.11611	NA	-2.75149	-3.56463	-4.22796	-4.42701	-5.14118	-7.14122	-8.79207	-3.39836	-4.58715	-5.07977	-5.86418
IKKA_HUMAN	O15111	T	23	A	 Loss of phosphorylation and decrease of kinase;activity."";/evidence=""ECO:0000269|PubMed:10485710""	e	9	T23A	O15111/T23A	D	-2.52615	-2.13155	-1.39695	-1.0619	-2.69685	-2.21235	-2.63652	-1.79265	-2.97135	-3.3862	-3.59756	-3.08464	NA	-1.96638	-1.96638	-2.62771	-2.42604	-2.19811	-1.43524	-1.00877	-2.79235	-2.28887	-1.2558	-0.85346
IKKB_HUMAN	O14920	S	177	A	 Decrease of activity."";/evidence=""ECO:0000269|PubMed:19675099,;ECO:0000269|PubMed:9346484""	s	152	S177A	O14920/S177A	D	-2.45841	-3.14184	-3.52035	-3.32515	-3.05907	-3.47212	-3.68648	-3.43048	-2.90076	-2.99627	-3.14569	-3.01425	NA	-1.61564	-1.61564	-2.1834	-2.44445	-3.13805	-3.94857	-3.17592	-2.44445	-3.13609	-3.96656	-3.29792
IKKB_HUMAN	O14920	S	181	A	 Decrease of activity."";/evidence=""ECO:0000269|PubMed:19675099,;ECO:0000269|PubMed:9346484""	s	156	S181A	O14920/S181A	D	-2.45841	-3.14184	-3.39337	-3.8191	-3.05907	-3.47212	-3.68648	-3.89108	-2.90076	-2.99627	-3.14569	-2.83552	NA	-1.61564	-1.61564	-2.1834	-2.44445	-3.13805	-3.30994	-3.84249	-2.44445	-3.13609	-3.32104	-3.79974
IKKE_HUMAN	Q14164	E	168	A	 Slight decrease of kinase activity."";/evidence=""ECO:0000269|PubMed:10421793""	s	152	E168A	Q14164/E168A	D	-3.82753	-3.98094	-3.12081	-2.94891	-3.8638	-4.0365	-2.9155	-3.00906	-3.24316	-3.50579	-2.57648	-2.00204	NA	-2.82417	-2.82417	-3.36856	-4.39084	-3.94112	-3.07049	-2.66208	-4.39084	-3.94112	-3.07049	-2.61897
IKKE_HUMAN	Q14164	S	172	A	 Loss of autophosphorylation and of kinase;activity."";/evidence=""ECO:0000269|PubMed:10421793""	s	156	S172A	Q14164/S172A	D	-3.11649	-3.24348	-3.40825	-3.61803	-3.14678	-3.27437	-3.50428	-3.82161	-2.13525	-3.29141	-3.64811	-3.96563	NA	-1.74866	-1.74866	-2.34857	-3.199	-3.20277	-3.52144	-3.60296	-3.199	-3.20277	-3.52144	-3.60114
IKKE_HUMAN	Q14164	S	172	E	 Decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:10421793""	s	156	S172E	Q14164/S172E	D	-4.94067	-5.22547	-5.60092	-3.21749	-5.01422	-5.28818	-5.78932	-3.42783	-2.89724	-4.86373	-5.4365	-5.95233	NA	-2.40038	-2.40038	-3.36844	-4.61974	-5.11661	-5.7756	-2.9615	-4.61974	-5.11661	-5.7756	-2.94676
ILK_HUMAN	Q13418	E	359	K	 Inactivation of ILK."";/evidence=""ECO:0000269|PubMed:9736715""	E	167	E359K	Q13418/E359K	D	-3.67932	-4.82339	-7.84927	-8.78516	-8.20123	-9.57577	-10.515	-8.71466	-7.40374	-9.42219	-10.36895	-8.67768	-6.82624	-8.35283	-6.47102	-5.19849	-3.05835	-3.7886	-7.31837	-7.94926	-3.00933	-3.40403	-4.45077	-7.87651
INSR_HUMAN	P06213	K	1057	A	 Abolishes the kinase activity and abolishes;interaction with IRS1, SHC1, GRB7 and PIK3R1."";/evidence=""ECO:0000269|PubMed:10803466,;ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849""	K	30	K1057A	P06213/K1057A	D	-4.72848	-5.06702	-5.29185	-5.83478	-5.6437	-6.17612	-8.94855	-10.54248	-5.67126	-6.71046	-9.27642	-10.5735	NA	-2.74085	-3.56463	-4.22796	-4.7889	-5.24737	-7.04413	-8.85707	-4.17459	-4.81185	-5.17707	-5.73978
INSR_HUMAN	P06213	K	1057	M,	R: Abolishes the kinase activity."";/evidence=""ECO:0000269|PubMed:10803466,;ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849""	K	30	K1057M	P06213/K1057M	D	-5.24141	-5.59847	-5.82907	-6.34067	-6.18959	-6.66216	-9.35293	-10.9951	-6.19533	-7.14663	-9.66528	-11.01434	NA	-2.99282	-3.93945	-4.61727	-5.30182	-5.77612	-7.49526	-9.27219	-4.64397	-5.32464	-5.70813	-6.26445
INSR_HUMAN	P06213	E	1206	 D	 (in IRAN type A; accelerates degradation of;the protein and impairs kinase activity)"";/evidence=""ECO:0000269|PubMed:7983039"";/id=""VAR_015931""	E	167	E1206D	P06213/E1206D	D	-3.0588	-3.47906	-3.67252	-4.51076	-3.86022	-4.38282	-7.36155	-7.55284	-3.79596	-4.85537	-7.74062	-7.49342	NA	-1.52749	-2.10172	-2.56326	-3.11512	-3.62483	-5.41487	-7.36301	-2.59405	-3.26381	-3.57364	-4.41663
INSR_HUMAN	P06213	W	1220	 L	 (in IRAN type A; accelerates degradation of;the protein and impairs kinase activity; dbSNP:rs52800171)"";/evidence=""ECO:0000269|PubMed:7983039,;ECO:0000269|PubMed:8390949"";/id=""VAR_004100""	W	181	W1220L	P06213/W1220L	D	-8.29115	-8.85883	-9.08158	-10.01057	-9.33049	-9.90871	-9.35649	-10.58951	-9.21953	-10.42951	-9.57706	-10.54672	NA	-5.18563	-6.59707	-7.49095	-8.40149	-9.05747	-8.02534	-9.27922	-7.55121	-8.58989	-8.96837	-9.94361
KAPCG_HUMAN	P22612	I	74	 M	 (in BDPLT19; patient platelets show impaired;activation; dbSNP:rs724159972)"";/evidence=""ECO:0000269|PubMed:25061177"";/id=""VAR_072672""	k	31	I74M	P22612/I74M	D	-1.70072	-1.81622	-1.89438	-2.36872	-1.70072	-1.81622	-1.89438	-2.36872	NA	NA	NA	-1.71737	-2.63119	-2.43768	-1.90368	-1.68713	-1.82222	-1.85399	-1.09023	-0.4875	-1.82442	-1.75144	-1.78858	-2.07318
KC1D_HUMAN	P48730	K	38	M	 Impaired kinase activity and abnormal;subcellular localization with exclusive accumulation to the;nucleus."";/evidence=""ECO:0000269|PubMed:11161704""	K	30	K38M	P48730/K38M	D	-3.50368	-4.43408	-5.16419	-6.60229	-5.46532	-5.63714	-6.90507	-4.94222	-4.98033	-7.1226	-6.93561	-4.88469	-3.31376	-3.6138	-3.88682	-5.08962	-3.51013	-4.95687	-5.13618	-5.68142	-3.50501	-4.38436	-5.14446	-5.30805
KC1D_HUMAN	P48730	T	44	 A	 (in FASPS2; strongly reduces kinase activity;;dbSNP:rs104894561)"";/evidence=""ECO:0000269|PubMed:15800623,;ECO:0000269|PubMed:23636092"";/id=""VAR_029075""	k	36	T44A	P48730/T44A	D	-2.11004	-3.01485	-1.28097	-0.94997	-1.15833	-0.3158	0.14578	0.05461	-0.5372	-0.14856	0.20121	0.05176	-2.34915	-0.82319	-0.54714	-0.597	-2.11602	-1.8254	-1.33034	-1.09544	-2.09913	-2.97002	-1.38186	-1.05544
KC1D_HUMAN	P48730	H	46	 R	 (in FASPS2; strongly reduces kinase activity;;dbSNP:rs397514693)"";/evidence=""ECO:0000269|PubMed:23636092"";/id=""VAR_069801""	k	38	H46R	P48730/H46R	D	-3.22835	-4.44223	-4.38986	-4.87326	-4.31706	-3.76961	-3.91801	-3.32019	-3.65617	-4.25577	-3.70669	-3.0871	-4.08175	-4.42871	-2.96654	-2.02133	-3.23562	-4.26524	-4.40266	-4.52827	-3.21062	-4.35867	-4.31448	-4.52643
KC1D_HUMAN	P48730	T	176	I	 Impaired kinase activity and abnormal;subcellular localization with exclusive accumulation to the;nucleus."";/evidence=""ECO:0000269|PubMed:11161704""	t	160	T176I	P48730/T176I	D	-3.03687	-4.20925	-5.02263	-6.09322	-5.34235	-7.3831	-8.50648	-8.1752300000000009	-5.25194	-7.51871	-8.25171	-8.04024	-2.8854	-3.2062	-3.49327	-4.74623	-3.07612	-4.80533	-5.01793	-5.72914	-3.02352	-4.16066	-4.97809	-5.30176
KCC1A_HUMAN	Q14012	K	49	A	 Catalytically inactive form; prevents CDK4;activation."";/evidence=""ECO:0000269|PubMed:14754892,;ECO:0000269|PubMed:7641687""	K	30	K49A	Q14012/K49A	D	-3.01855	-2.79838	-3.26592	-4.33841	-3.01855	-2.79838	-3.26592	-4.33841	NA	NA	NA	-2.768	-6.15774	-6.6651	-7.20691	-6.35451	-3.2044	-7.01211	-6.71866	-7.70583	-2.99965	-2.97709	-2.71842	-3.64898
KCC1D_HUMAN	Q8IU85	K	52	A	 Catalytically inactive form."";/evidence=""ECO:0000269|PubMed:16324104""	K	30	K52A	Q8IU85/K52A	D	-2.97328	-3.21883	-3.81146	-4.33841	-2.97328	-3.21883	-3.81146	-4.33841	NA	NA	NA	-2.76874	-6.11283	-6.62853	-7.16158	-6.35451	-3.67404	-8.49334	-8.15417	-6.48983	-2.94504	-2.8883	-3.12184	-4.3562
KPCA_HUMAN	P17252	T	497	A	 Abolishes phosphorylation and catalytic;activity; when associated with A-494 and A-495."";/evidence=""ECO:0000269|PubMed:8349635""	s	156	T497A	P17252/T497A	D	-3.03803	-3.36489	-3.69696	-3.46582	-3.03803	-3.36489	-3.69696	-3.46582	NA	NA	NA	-1.91801	-4.23586	-3.91207	-3.98332	-2.53045	-4.11471	-4.7263	-3.46677	-2.4114	-2.83142	-3.48157	-3.67518	-3.17481
KPCE_HUMAN	Q02156	K	437	W	 Abolishes activity and S-729 phosphorylation."";/evidence=""ECO:0000269|PubMed:11964154""	K	30	K437W	Q02156/K437W	D	-4.27587	-4.57287	-4.67835	-7.04238	-4.27587	-4.57287	-4.67835	-7.04238	NA	NA	NA	-3.16577	-7.30106	-8.97691	-9.62735	-6.09421	-5.12756	-9.3435	-12.44561	-10.78224	-3.89545	-4.35121	-4.60777	-6.92949
KPCI_HUMAN	P41743	K	274	W	 Abolishes activity."";/evidence=""ECO:0000269|PubMed:10906326""	k	21	K274W	P41743/K274W	D	-3.80378	-4.07048	-4.10988	-4.02006	-3.80378	-4.07048	-4.10988	-4.02006	NA	NA	NA	-3.26574	-3.68021	-4.6621	-5.24621	-3.51589	-4.54456	-5.60104	-5.18549	-6.38131	-3.47127	-3.87127	-3.85121	-3.78617
KS6A5_HUMAN	O75582	S	212	A	 Inactivates the N-terminal kinase domain."";/evidence=""ECO:0000269|PubMed:15568999""	s	156	S212A	O75582/S212A	D	-1.07632	-0.50457	-0.6163	-0.52008	-1.07632	-0.50457	-0.6163	-0.52008	NA	NA	NA	-1.64901	-0.00447	-1.84206	-1.74372	-0.65701	-0.82587	0.22481	0.31366	0.0675	-1.89333	-0.68427	-0.77135	-0.55478
KS6B1_HUMAN	P23443	K	167	N	 Greatly reduces activity. Greatly reduces;phosphorylation at T-412 and moderately reduces;phosphorylation at T-252."";/evidence=""ECO:0000269|PubMed:17446865""	e	72	K167N	P23443/K167N	D	-2.71715	-2.94622	-3.0937	-3.27248	-2.71715	-2.94622	-3.0937	-3.27248	NA	NA	NA	-2.15998	0.3737	1.09935	2.1631	0.8077	-3.51931	-2.6391	-2.11828	-2.4998	-2.57484	-3.05313	-3.2048	-4.03001
LATS2_HUMAN	Q9NRM7	K	697	A	 Loss of kinase activity, autophosphorylation;and tumor suppressor activity."";/evidence=""ECO:0000269|PubMed:10871863,;ECO:0000269|PubMed:12853976""	K	30	K697A	Q9NRM7/K697A	D	-4.10296	-4.39703	-5.58783	-7.64994	-4.10296	-4.39703	-5.58783	-7.64994	NA	NA	NA	-2.86436	-9.37306	-10.59176	-10.54287	-6.35451	-6.29822	-9.83231	-12.98301	-10.98365	-3.47357	-4.17441	-4.95371	-7.6584
LATS2_HUMAN	Q9NRM7	S	872	A	 Loss of tumor suppressor activity."";/evidence=""ECO:0000269|PubMed:12853976""	s	156	S872A	Q9NRM7/S872A	D	-2.99272	-3.17586	-3.9742	-4.23944	-2.99272	-3.17586	-3.9742	-4.23944	NA	NA	NA	-1.72304	-2.21078	-1.28041	-1.31317	-0.64995	-4.48599	-3.53672	-3.09855	-2.32263	-2.46063	-3.0781	-3.59154	-4.93041
LIMK1_HUMAN	P53667	T	508	A	 Abolishes activation by ROCK1."";/evidence=""ECO:0000269|PubMed:10196227,;ECO:0000269|PubMed:10652353""	s	156	T508A	P53667/T508A	D	-3.77117	-4.51643	-6.06612	-5.68209	-4.34756	-2.547	-2.03486	-2.37303	-0.98693	-0.51215	-0.48577	-0.51397	-1.84334	-2.53919	-0.55211	-0.22057	-3.68356	-4.31867	-4.83814	-4.74673	-3.54189	-4.19361	-5.94023	-5.59531
LIMK1_HUMAN	P53667	T	508	V	 Reduces kinase activity."";/evidence=""ECO:0000269|PubMed:10196227,;ECO:0000269|PubMed:10652353""	s	156	T508V	P53667/T508V	D	-4.27759	-5.16547	-7.37161	-6.64793	-4.96987	-6.35914	-4.59009	-5.60824	-3.84374	-3.98418	-3.15615	-3.66434	-2.31983	-3.11814	-2.68864	-2.74731	-4.17895	-4.9281	-6.12441	-5.44234	-4.01136	-4.77557	-7.06948	-6.3548
LRRK2_HUMAN	Q5S007	K	1906	A	 Loss of kinase activity. Decreases proteosomal;degradation of MAPT; when associated with N-1994 and A-;2017."";/evidence=""ECO:0000269|PubMed:26014385""	K	30	K1906A	Q5S007/K1906A	D	-4.63975	-6.50802	-8.91897	-12.08851	-8.77612	-11.83727	-12.78331	NA	-7.16595	-8.94102	NA	NA	NA	-2.6722	-2.6722	-3.73817	-4.89624	-7.32808	-10.33715	-11.96594	-4.13734	-5.11133	-7.23571	-10.62886
LRRK2_HUMAN	Q5S007	D	1994	N	 Loss of kinase activity. No loss of;interaction with SEC16A and no loss of ability to recruit;SEC16A to endoplasmic reticulum exit sites. Decreases;proteosomal degradation of MAPT; when associated with A-;1906 and A-2017."";/evidence=""ECO:0000269|PubMed:25201882,;ECO:0000269|PubMed:26014385, ECO:0000269|PubMed:26824392""	D	123	D1994N	Q5S007/D1994N	D	-4.54344	-6.51058	-8.79086	-12.580260000000001	-8.58008	-11.90221	-9.89597	-6.40344	-6.65403	-7.55035	-9.14068	-5.73644	NA	-2.37361	-2.37361	-3.40758	-4.78029	-7.28231	-11.87082	-13.75525	-4.02603	-5.20702	-7.18724	-10.73714
LRRK2_HUMAN	Q5S007	D	2017	A	 Loss of kinase activity. Decreases proteosomal;degradation of MAPT; when associated with A-1906 and N-;1994. Loss of phosphorylation of RAB10; when associated;with G-1441, C-1699, or S-2019."";/evidence=""ECO:0000269|PubMed:26014385,;ECO:0000269|PubMed:29125462, ECO:0000269|PubMed:29212815,;ECO:0000269|PubMed:30635421""	D	141	D2017A	Q5S007/D2017A	D	-5.55846	-7.59564	-9.67731	-12.63403	-9.48674	-12.42494	-13.15525	-12.17802	-7.83294	-11.33914	-12.18282	-11.11888	NA	-3.17332	-3.17332	-4.41873	-5.81213	-8.29441	-12.32181	-13.95956	-4.99471	-6.25359	-8.21284	-11.1899
LTK_HUMAN	P29376	Y	753	F	 Abolishes interaction with PI3-kinase subunit;p85, impairs PI3 kinase activity and leads to apoptosis;(demonstrated with chimeric EGFR-LTK)."";/evidence=""ECO:0000269|PubMed:9223670""	k	238	Y753F	P29376/Y753F	D	-3.02028	-3.6867	-4.33094	-3.28308	-3.45479	-3.20098	-2.94547	-2.63108	-3.45044	-3.1492	-2.8886	-2.5779	-2.19307	-2.66769	-3.3213	-2.98305	-3.89413	-5.85101	-6.255	-6.90812	-2.99096	-3.95155	-3.99811	-3.7065
LYN_HUMAN	P07948	Y	397	F	 Strongly reduced kinase activity."";/evidence=""ECO:0000269|PubMed:16920712""	l	154	Y397F	P07948/Y397F	D	-1.98733	-2.32046	-3.13893	-5.6106	-7.59841	-4.3969	-2.3013	-2.19409	-7.74846	-4.15004	-2.1433	-2.06302	-2.77307	-3.51602	-3.35401	-3.18962	-1.77261	-3.35006	-4.07543	-6.14627	-1.43875	-1.78987	-3.09921	-4.19017
M3K11_HUMAN	Q16584	K	144	A	 Greatly reduced autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:11053428,;ECO:0000269|PubMed:8195146""	K	30	K144A	Q16584/K144A	D	-4.98896	-5.51216	-6.14984	-8.77429	-12.77493	-12.58561	-9.45888	-9.44788	-12.1706	-9.60047	-9.27018	-9.40457	-6.56543	-8.35505	-8.75028	-7.31299	-4.44163	-7.28411	-9.93147	-5.49055	-3.41015	-4.93703	-6.06875	-8.06559
M3K11_HUMAN	Q16584	K	144	R	 Loss of kinase activity. Prevents activation;of SAPK and MAPK14."";/evidence=""ECO:0000269|PubMed:11053428,;ECO:0000269|PubMed:8195146""	K	30	K144R	Q16584/K144R	D	-3.25901	-3.68055	-4.19802	-6.66332	-10.51042	-10.23495	-9.58614	-7.54898	-9.76003	-10.39496	-8.77386	-7.45361	-4.54687	-6.27356	-6.71558	-5.13188	-2.83152	-5.20297	-8.00305	-8.25809	-2.17399	-3.20747	-4.12052	-5.88535
M3K11_HUMAN	Q16584	E	164	A	 Greatly reduced autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:8195146""	E	48	E164A	Q16584/E164A	D	-4.92943	-5.43192	-6.11982	-7.23599	-12.40806	-11.08253	-10.62305	-9.86977	-11.91962	-11.00415	-10.40244	-9.71332	-6.16029	-8.11679	-8.54721	-7.17657	-4.35978	-7.29723	-8.09991	-9.20328	-3.22308	-4.87299	-6.05609	-8.18528
M3K11_HUMAN	Q16584	T	277	A	 Severely reduced autophosphorylation activity.;Prevents phosphorylation of SAPK and MAPK14."";/evidence=""ECO:0000269|PubMed:11053428""	s	151	T277A	Q16584/T277A	D	-4.20091	-3.99155	-4.51956	-2.50433	-2.23963	-2.35735	-2.33438	-2.12658	-1.70729	-1.91702	-2.02	-1.75724	-2.36378	-2.63671	-2.69416	-0.29004	-3.71397	-3.6976	-3.31107	-1.02114	-2.64185	-4.15433	-4.98919	-2.3822
M3K11_HUMAN	Q16584	S	281	A	 Reduced autophosphorylation activity. Reduced;activation of SAPK and MAPK14."";/evidence=""ECO:0000269|PubMed:11053428""	s	156	S281A	Q16584/S281A	D	-3.53412	-3.56907	-4.02708	-2.09796	-0.87094	-0.1927	-0.24421	-0.27404	-0.12479	0.3166	-0.16903	0.05443	-1.4213	-0.97127	-0.88541	-0.89469	-3.10722	-3.73482	-1.86901	-1.81587	-2.15843	-3.48264	-4.1634	-2.8786
M3K13_HUMAN	O43283	K	195	A	 Kinase inactive. Fails to activate NF-kappa-;B."";/evidence=""ECO:0000269|PubMed:12492477""	K	30	K195A	O43283/K195A	D	-3.73994	-4.15549	-5.14283	-8.20967	-11.51076	-8.52027	-9.03119	-9.44788	-11.50713	-8.50908	-9.06111	-9.41623	-6.50145	-8.09992	-8.60311	-7.31299	-3.7891	-5.95729	-8.44923	-5.51388	-3.55273	-3.79758	-5.13348	-7.41504
M3K20_HUMAN	Q9NYL2	T	161	A	 Loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:15342622""	s	151	T161A	Q9NYL2/T161A	D	-2.69479	-3.41666	-3.55463	-2.93389	-2.79534	-2.28715	-2.21892	-2.12658	-2.68145	-2.20268	-2.13378	-2.05034	-2.66531	-2.72556	-2.64423	-0.29004	-3.35481	-4.58815	-3.72856	-1.76048	-2.44015	-3.33704	-4.02069	-2.55442
M3K20_HUMAN	Q9NYL2	T	162	A	 Slight loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:15342622""	s	152	T162A	Q9NYL2/T162A	D	-2.69479	-3.41666	-3.39988	-3.70031	-2.50925	-2.6424	-2.61093	-2.08942	-2.20629	-2.48041	-2.46952	-1.96775	-3.70497	-3.21495	-2.91834	-1.91515	-3.35481	-3.96502	-3.84174	-2.02117	-2.44015	-3.33704	-3.29255	-3.36395
M3K20_HUMAN	Q9NYL2	S	165	A	 Loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:15342622""	s	156	S165A	Q9NYL2/S165A	D	-2.17684	-2.81399	-2.56437	-2.34343	-1.47622	-0.38017	-0.16925	-0.27403	-1.34049	-0.25442	-0.08505	-0.21539	-0.99598	-0.88512	-0.96756	-0.89469	-2.77759	-4.08672	-4.18406	-0.9238	-1.95407	-2.75857	-2.78202	-2.52529
M3K5_HUMAN	Q99683	K	709	R	 Loss of kinase activity. Abolishes DAXX-;mediated apoptosis. Loss of RC3H2-mediated ubiquitination."";/evidence=""ECO:0000269|PubMed:17210579,;ECO:0000269|PubMed:24448648, ECO:0000269|PubMed:9743501""	K	30	K709R	Q99683/K709R	D	-2.99867	-3.60725	-4.70715	-7.90445	-7.68188	-6.70944	-5.62627	-4.48433	-6.17448	-6.61692	-5.64346	-4.48457	-4.9527	-6.07497	-6.81571	-3.77497	-3.06903	-6.56625	-10.9261	-7.34442	-2.37011	-2.92416	-4.30228	-7.34729
M3K9_HUMAN	P80192	T	304	A	 Reduces threonine phosphorylation. Impairs JNK;activation."";/evidence=""ECO:0000269|PubMed:15610029""	s	151	T304A	P80192/T304A	D	-4.22558	-4.42649	-4.38133	-2.50433	-2.72243	-2.58909	-2.45325	-2.12658	-2.18188	-2.20956	-2.08155	-1.75993	-2.70187	-2.54818	-2.6971	-0.29004	-3.97402	-3.43423	-3.05861	-0.96555	-3.14741	-4.04396	-4.91874	-2.36312
M3K9_HUMAN	P80192	T	305	A	 Little effect on threonine phosphorylation.;Mildly impairs JNK activation."";/evidence=""ECO:0000269|PubMed:15610029""	s	152	T305A	P80192/T305A	D	-4.22558	-4.42649	-4.1682	-2.58158	-2.31177	-2.81877	-2.78589	-2.08942	-1.45674	-2.19732	-2.29836	-1.61595	-2.61775	-2.92053	-2.97051	-1.91515	-3.97402	-3.77377	-1.94895	-2.0529	-3.14741	-4.04396	-4.91874	-2.466
M3K9_HUMAN	P80192	S	308	A	 Impairs JNK activation."";/evidence=""ECO:0000269|PubMed:15610029""	s	156	S308A	P80192/S308A	D	-3.54946	-3.72211	-3.89945	-2.09796	-0.99157	-0.53291	-0.64473	-0.27404	-0.12201	-0.09941	-0.23923	0.05213	-3.82021	-0.97969	-0.93214	-0.89469	-3.34867	-3.62699	-1.80445	-1.85291	-2.63112	-3.40676	-4.12295	-2.86266
M3K9_HUMAN	P80192	T	312	A	 Loss of threonine phosphorylation. Strongly;impairs JNK activation."";/evidence=""ECO:0000269|PubMed:15610029""	t	160	T312A	P80192/T312A	D	-4.22558	-4.42649	-4.03789	-4.52937	-4.87888	-3.3434	-3.40068	-3.39354	-3.83985	-3.04924	-3.14539	-3.17876	-3.85866	-1.22277	-1.01439	-1.25511	-3.97402	-5.27607	-5.66324	-4.13794	-3.14741	-4.04396	-4.91874	-4.06234
MAK_HUMAN	P20794	T	157	A	 Abolishes autophosphorylation and impairs;kinase activity."";/evidence=""ECO:0000269|PubMed:21986944""	t	155	T157A	P20794/T157A	D	-3.07556	-3.6605	-3.65849	-5.39656	-8.51596	-8.70335	-5.05586	-3.44947	-9.28898	-8.96072	-5.03431	-3.40678	-2.3404	-3.07431	-4.54548	-2.10283	-3.01697	-4.13302	-5.16101	-7.1827	-2.95898	-4.0038	-3.82078	-5.54481
MAPK2_HUMAN	P49137	K	93	R	 Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:14517288""	K	30	K93R	P49137/K93R	D	-1.5671	-1.79812	-1.62801	-3.4516	-1.5671	-1.79812	-1.62801	-3.4516	NA	NA	NA	-1.45853	NA	-1.45853	-1.45853	-1.57449	-3.09832	-7.4746	-7.941	-7.26765	-1.54792	-1.70441	-1.95648	-3.83927
MAPK2_HUMAN	P49137	D	207	A	 Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:8846784""	D	141	D207A	P49137/D207A	D	-3.60478	-3.46045	-3.70032	-5.84605	-3.60478	-3.46045	-3.70032	-5.84605	NA	NA	NA	-3.31671	NA	-3.31671	-3.31671	-3.47181	-5.45724	-8.75602	-9.36408	-9.10091	-3.47502	-3.32492	-3.63622	-5.63748
MAPK2_HUMAN	P49137	T	222	A	 Strong decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:14517288,;ECO:0000269|PubMed:15014438, ECO:0000269|PubMed:8846784""	s	156	T222A	P49137/T222A	D	-2.22079	-2.51671	-2.74667	-1.06461	-2.22079	-2.51671	-2.74667	-1.06461	NA	NA	NA	-1.98933	NA	-1.98933	-1.98933	-2.15369	-3.60447	-3.51281	-1.55729	-1.36844	-2.13915	-2.41182	-2.73462	-1.51602
MAPK2_HUMAN	P49137	S	272	A	 Strong decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:8846784""	d	211	S272A	P49137/S272A	D	-1.61162	-1.45405	-1.38098	-1.21011	-1.61162	-1.45405	-1.38098	-1.21011	NA	NA	NA	-1.72526	NA	-1.72526	-1.72526	-1.10905	-1.49909	-0.59834	-0.32492	-0.27924	-1.86988	-1.66748	-1.45573	-1.05645
MAPK5_HUMAN	Q8IW41	K	51	M	 Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:12808055""	K	30	K51M	Q8IW41/K51M	D	-3.08778	-3.21001	-4.62473	-7.51644	-3.08778	-3.21001	-4.62473	-7.51644	NA	NA	NA	-2.96445	-5.94229	-7.02517	-6.88924	-6.03829	-5.88799	-9.53769	-8.28052	-8.89495	-3.08182	-3.16013	-4.3039	-6.72648
MARK1_HUMAN	Q9P0L2	T	215	A	 Prevents phosphorylation and activation by;STK11/LKB1 complex."";/evidence=""ECO:0000269|PubMed:14976552""	s	156	T215A	Q9P0L2/T215A	D	-3.24411	-2.91784	-3.5693	-4.95179	-3.24411	-2.91784	-3.5693	-4.95179	NA	NA	NA	-1.93191	-5.00775	-3.6888	-3.72072	-2.53045	-5.60385	-5.63271	-4.06318	-2.41557	-2.70321	-3.29909	-4.37157	-4.70752
MARK2_HUMAN	Q7KZI7	T	208	A	 Prevents phosphorylation and activation by;STK11/LKB1 complex."";/evidence=""ECO:0000269|PubMed:14976552""	s	156	T208A	Q7KZI7/T208A	D	-3.10461	-3.41089	-4.45577	-4.95179	-3.10461	-3.41089	-4.45577	-4.95179	NA	NA	NA	-2.02674	-4.42193	-3.57072	-3.75915	-2.53045	-4.82437	-5.55453	-3.934	-2.84632	-2.63154	-2.99682	-4.39296	-4.69382
MARK3_HUMAN	P27448	T	211	A	 Prevents phosphorylation and activation by;STK11/LKB1 complex."";/evidence=""ECO:0000269|PubMed:14976552""	s	156	T211A	P27448/T211A	D	-3.22206	-3.34903	-3.57154	-4.95179	-3.22206	-3.34903	-3.57154	-4.95179	NA	NA	NA	-1.96776	-5.02048	-3.62697	-4.01046	-2.53045	-4.77652	-5.10164	-3.37726	-2.37289	-2.62467	-3.22295	-4.39266	-4.7092
MARK4_HUMAN	Q96L34	T	214	A	 Prevents phosphorylation and activation by;STK11/LKB1 complex."";/evidence=""ECO:0000269|PubMed:14976552""	s	156	T214A	Q96L34/T214A	D	-3.21708	-3.45975	-4.22519	-4.95179	-3.21708	-3.45975	-4.22519	-4.95179	NA	NA	NA	-1.98253	-5.05554	-3.57108	-3.62613	-2.53045	-5.87975	-4.95337	-4.03397	-2.26431	-2.8192	-3.17506	-4.62939	-4.73079
MARK4_HUMAN	Q96L34	T	214	E	 Mimicks phosphorylation state, leading to;increased activity. Decreases mTORC1 activity."";/evidence=""ECO:0000269|PubMed:14976552,;ECO:0000269|PubMed:23184942""	s	156	T214E	Q96L34/T214E	D	-4.59706	-4.9869	-5.94452	-7.82638	-4.59706	-4.9869	-5.94452	-7.82638	NA	NA	NA	-2.69564	-6.49939	-3.07855	-3.16894	-2.03403	-8.07874	-4.47766	-4.20711	-2.23178	-3.94838	-4.54812	-6.35536	-7.42769
MELK_HUMAN	Q14680	D	150	A	 Abolishes enzymatic activity."";/evidence=""ECO:0000269|PubMed:14699119,;ECO:0000269|PubMed:16216881, ECO:0000269|PubMed:17280616""	D	141	D150A	Q14680/D150A	D	-4.26331	-4.70601	-5.64365	-7.26157	-4.26331	-4.70601	-5.64365	-7.26157	NA	NA	NA	-3.05633	-7.74863	-10.01475	-7.85771	-6.30247	-7.47493	-10.83842	-13.14989	-11.25364	-4.26107	-4.56509	-5.35749	-7.2017
MELK_HUMAN	Q14680	T	167	A	 Abolishes activation of serine/threonine-;protein kinase activity and has only weak activity."";/evidence=""ECO:0000269|PubMed:14976552""	s	156	T167A	Q14680/T167A	D	-2.70036	-3.1232	-3.87345	-3.86074	-2.70036	-3.1232	-3.87345	-3.86074	NA	NA	NA	-1.84549	-4.63903	-4.26229	-2.7403	-2.53045	-5.46826	-5.67023	-4.73407	-2.46263	-2.69351	-2.99491	-3.70142	-3.78768
MELK_HUMAN	Q14680	S	171	A	 Abolishes activation of serine/threonine-;protein kinase activity and has only weak activity."";/evidence=""ECO:0000269|PubMed:16216881""	t	160	S171A	Q14680/S171A	D	-2.36587	-2.73671	-3.37072	-4.10692	-2.36587	-2.73671	-3.37072	-4.10692	NA	NA	NA	-1.62039	-3.15615	-3.87413	-2.15474	-1.82287	-3.87307	-5.59762	-6.59321	-4.44799	-2.35251	-2.6144	-3.23563	-4.10376
MELK_HUMAN	Q14680	S	171	D	 Inactive."";/evidence=""ECO:0000269|PubMed:16216881""	t	160	S171D	Q14680/S171D	D	-3.33177	-3.76649	-4.3796	-6.16612	-3.33177	-3.76649	-4.3796	-6.16612	NA	NA	NA	-2.43066	-5.23218	-6.58839	-4.09643	-2.55974	-5.90722	-8.60118	-9.85916	-5.1177	-3.31287	-3.60794	-4.42141	-6.13477
MK08_HUMAN	P45983	K	55	D	 Abolished protein kinase activity."";/evidence=""ECO:0000269|PubMed:22966201""	K	30	K55D	P45983/K55D	D	-2.76599	-2.95547	-3.02041	-4.79194	-12.02053	-8.20776	-10.53968	-10.46316	-12.03411	-8.22045	-10.57879	-10.43273	-4.30995	-6.13287	-7.10298	-8.229	-2.86604	-5.52214	-6.40043	-8.33921	-2.58989	-2.82725	-3.09802	-4.58028
MK11_HUMAN	Q15759	T	180	A	 Inactivation."";/evidence=""ECO:0000269|PubMed:15356147""	t	155	T180A	Q15759/T180A	D	-2.42664	-2.43103	-2.5677	-2.34363	-6.68479	-6.02054	-4.45893	-3.44947	-7.27812	-5.99192	-4.37113	-3.42209	-3.88875	-3.78617	-3.97095	-2.10283	-2.49688	-4.16263	-3.75334	-5.59891	-2.34108	-2.44569	-2.5767	-2.5675
MK11_HUMAN	Q15759	Y	182	F	 Inactivation."";/evidence=""ECO:0000269|PubMed:15356147""	f	157	Y182F	Q15759/Y182F	D	-2.02245	-2.05093	-2.1637	-2.1983	-8.56757	-9.07757	-4.6563	-4.76014	-8.75475	-9.03624	-4.64332	-4.71692	-3.19793	-4.9314	-3.98231	-5.09481	-2.08112	-3.39825	-3.61949	-4.06087	-1.95478	-2.03528	-2.14645	-2.58695
MK14_HUMAN	Q16539	A	34	V	 Lowered kinase activity."";/evidence=""ECO:0000269|PubMed:7493921""	s	11	A34V	Q16539/A34V	D	-2.30753	-2.54852	-2.66852	-1.52649	-6.25824	-4.40528	-4.90936	-3.92449	-6.65908	-4.55573	-5.01583	-3.91951	-3.94559	-1.87724	-2.47571	-2.18354	-2.388	-4.02777	-4.34615	-5.28766	-2.2942	-2.31313	-2.43478	-1.29041
MK14_HUMAN	Q16539	Y	69	H	 Lowered kinase activity."";/evidence=""ECO:0000269|PubMed:15284239""	l	46	Y69H	Q16539/Y69H	D	-3.39257	-3.58811	-3.5378	-3.77634	-6.12609	-5.44231	-4.63769	-3.48839	-5.67595	-5.12745	-4.28497	-3.23547	-3.51227	-3.72895	-4.27842	-3.00501	-3.44025	-3.59753	-3.59037	-4.84115	-3.2484	-3.40036	-3.35365	-3.63495
MK15_HUMAN	Q8TD08	K	42	R	 Loss of autophosphorylation and activity. Does;not increase dopamine transporter activity. Impairs kinase;activity. Does not rescue cilium assembly in MAPK15-;depleted cells."";/evidence=""ECO:0000269|PubMed:11875070,;ECO:0000269|PubMed:28842414, ECO:0000269|PubMed:29021280""	K	30	K42R	Q8TD08/K42R	D	-2.5818	-3.27202	-3.49265	-3.91787	-10.36292	-12.46137	-6.86994	-6.90968	-10.41297	-12.35437	-6.85593	-6.89809	-3.06231	-4.11689	-4.76878	-6.29323	-2.68685	-3.60487	-5.11543	-5.64118	-2.53434	-2.68914	-3.29228	-3.83771
MK15_HUMAN	Q8TD08	R	59	Q	 Does not increase dopamine transporter;activity. Impairs kinase activity."";/evidence=""ECO:0000269|PubMed:28842414""	r	47	R59Q	Q8TD08/R59Q	D	-3.86312	-4.24736	-4.72621	-5.30094	-6.17786	-6.13023	-6.41147	-5.74257	-6.07259	-6.11808	-6.31312	-5.71724	-4.43818	-6.07731	-6.52538	-6.20615	-4.03659	-4.81658	-6.55244	-2.03725	-3.65394	-4.1262	-4.38404	-5.10331
MK15_HUMAN	Q8TD08	T	175	A	 Loss of autophosphorylation and activity.;Still heavily phosphorylated at Tyr-177. Does not rescues;inhibition of O-glycosylation in MAPK15-depleted cells;;when associated with F-177."";/evidence=""ECO:0000269|PubMed:11875070,;ECO:0000269|PubMed:16336213, ECO:0000269|PubMed:24618899""	t	155	T175A	Q8TD08/T175A	D	-3.05593	-3.48403	-3.74813	-3.87535	-4.8343	-5.61444	-5.61934	-3.44949	-4.804	-5.57642	-5.59317	-3.40377	-4.00496	-3.83088	-4.19203	-2.10283	-3.19765	-3.68729	-4.56761	-5.53772	-2.94876	-3.22522	-3.51588	-3.77253
MK15_HUMAN	Q8TD08	Y	177	A	 Loss of autophosphorylation and activity.;Heavily phosphorylated at Thr-175."";/evidence=""ECO:0000269|PubMed:11875070,;ECO:0000269|PubMed:16336213""	f	157	Y177A	Q8TD08/Y177A	D	-4.97229	-6.49648	-6.94608	-6.73238	-9.31578	-9.14673	-7.21265	-7.36963	-9.24721	-9.024	-7.14266	-7.30532	-4.68028	-4.03507	-3.57452	-4.13622	-5.30689	-6.35125	-8.11833	-6.06366	-4.69564	-5.37921	-6.54159	-6.76051
MP2K1_HUMAN	Q02750	K	97	A	 Loss of catalytic activity. Strongly reduces;phosphorylation upon UV irradiation."";/evidence=""ECO:0000269|PubMed:20956560""	K	30	K97A	Q02750/K97A	D	-3.36398	-5.38573	-7.63827	-6.75333	-10.81351	-10.12559	-12.09531	-8.42019	-6.26978	-6.89939	-7.24144	-9.00626	-4.06249	-7.55369	-7.4222	-7.61408	-3.10536	-4.99756	-5.67116	-7.82465	-2.87808	-3.33575	-4.68435	-4.80189
MP2K3_HUMAN	P46734	S	218	A	 Inactivation."";/evidence=""ECO:0000269|PubMed:8622669""	s	151	S218A	P46734/S218A	D	-2.80326	-3.48557	-2.98396	-1.35467	-1.58825	-0.83533	-0.95731	-1.33586	-1.04048	-0.59183	-0.67541	-1.11633	-1.73641	-2.25589	-1.16574	-0.55529	-2.00073	-3.54468	-3.5445	-1.7949	-1.95265	-3.19221	-3.74981	-2.3109
MP2K3_HUMAN	P46734	T	222	A	 Inactivation."";/evidence=""ECO:0000269|PubMed:8622669""	t	155	T222A	P46734/T222A	D	-2.69207	-2.11156	-1.31589	-0.94397	-2.96504	-1.34579	-0.93253	-1.92037	-1.48816	-1.38141	-0.49381	-1.92081	-1.34011	-1.81318	-0.71546	-1.24457	-2.33763	-2.41719	-1.9646	-1.44475	-2.28793	-2.92848	-2.42035	-1.19832
MP2K5_HUMAN	Q13163	K	195	M	 Inactivation."";/evidence=""ECO:0000269|PubMed:7759517""	K	30	K195M	Q13163/K195M	D	-5.40949	-5.75667	-6.27858	-6.87054	-14.9784	-10.60284	-10.11362	-6.83022	-14.81333	-10.69901	-10.07151	-7.02159	-4.44568	-7.98055	-9.36351	-7.31918	-4.14771	-5.39113	-6.28016	-7.95968	-3.77777	-4.24485	-5.45172	-4.94178
MP2K5_HUMAN	Q13163	S	311	A	 Inactivation."";/evidence=""ECO:0000269|PubMed:7759517""	s	151	S311A	Q13163/S311A	D	-2.45857	-0.48416	-0.42529	-0.78276	-2.49537	-1.28516	-1.21393	-1.33586	-3.83044	-1.39983	-1.23554	-1.27236	-1.91221	-2.51134	-2.31559	-0.55529	-2.16952	-2.85856	-2.90818	-2.15141	-2.14344	-2.22641	-2.4424	-1.65335
MP2K5_HUMAN	Q13163	T	315	A	 Inactivation."";/evidence=""ECO:0000269|PubMed:7759517""	s	156	T315A	Q13163/T315A	D	-2.60323	-2.74704	-2.66372	-2.54206	-5.98736	-5.4011	-5.44633	-4.09146	-6.19235	-5.41034	-5.4121	-4.36406	-1.34149	-3.32196	-3.88319	-3.38565	-3.01107	-2.96179	-3.64551	-2.6799	-2.57319	-3.0865	-3.14312	-2.36504
MP2K6_HUMAN	P52564	S	207	A	 Inactivation.""	s	151	S207A	P52564/S207A	D	-2.80004	-3.48342	-1.20723	-1.35467	-3.70953	-0.87009	-0.83403	-1.33586	-2.06224	-1.56862	-1.5105	-1.11597	-1.62341	-2.63598	-0.35052	-0.55529	-1.97983	-4.00795	-3.57607	-1.80366	-1.88471	-3.13243	-3.70918	-2.50035
MP2K6_HUMAN	P52564	T	211	A	 Inactivation.""	t	155	T211A	P52564/T211A	D	-2.69775	-2.10356	-1.02637	-0.94397	-1.36229	-1.26288	-0.90871	-1.92037	-1.49495	-1.56986	-1.60002	-1.91993	-1.21768	-1.66835	-0.91082	-1.24457	-2.34088	-2.55018	-1.74528	-1.20103	-2.26223	-2.86717	-2.4856	-0.999
MRCKA_HUMAN	Q5VT25	S	234	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:11283256""	l	154	S234A	Q5VT25/S234A	D	-3.23524	-3.47398	-4.03817	-4.29387	-3.23524	-3.47398	-4.03817	-4.29387	NA	NA	NA	-1.58826	0.73417	1.14695	1.47354	0.83274	-1.2563	0.33288	0.31918	0.20346	-2.86893	-3.11161	-3.98654	-4.17057
MRCKA_HUMAN	Q5VT25	T	240	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:11283256""	t	160	T240A	Q5VT25/T240A	D	-3.82377	-3.76224	-4.391	-5.45997	-3.82377	-3.76224	-4.391	-5.45997	NA	NA	NA	-1.98669	-7.93276	-6.55757	-6.9076	-4.47205	-5.25613	-4.77219	-4.86023	-4.30638	-3.37	-3.38946	-4.30295	-5.37763
MUSK_HUMAN	O15146	G	584	C,	D: Mild decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:25029443""	G	10	G584C	O15146/G584C	D	-5.75879	-8.17239	-8.73333	-8.81549	-9.4265	-9.96498	-10.6453	-10.53634	-7.29855	-8.98617	-9.77619	-9.68288	-5.41054	-6.33026	-7.11629	-7.38833	-7.45704	-8.88136	-9.203	-9.7959	-4.84978	-6.61728	-8.1803	-9.22437
MYLK_HUMAN	Q15746	A	1491	 S	 (in AAT7; decreases kinase activity;;dbSNP:rs1576422965)"";/evidence=""ECO:0000269|PubMed:29544503"";/id=""VAR_083425""	A	28	A1491S	Q15746/A1491S	D	-3.6685	-5.13657	-4.2411	-3.90767	-3.6685	-5.13657	-4.2411	-3.90767	NA	NA	NA	-1.85645	-3.55778	-3.85216	-4.10519	-4.46194	-4.8834	-5.0815	-5.14221	-5.09002	-3.47023	-5.01199	-4.18961	-3.91339
NEK10_HUMAN	Q6ZWH5	K	548	R	 Catalytically inactive. Impaired mucociliary;transport."";/evidence=""ECO:0000269|PubMed:20956560,;ECO:0000269|PubMed:31959991""	K	30	K548R	Q6ZWH5/K548R	D	-1.86314	-2.49781	-3.62303	-5.03949	-1.86314	-2.49781	-3.62303	-5.03949	NA	NA	NA	-1.51501	-3.8754	-4.5572	-5.12405	-3.99689	-8.07069	-3.87089	-5.41827	-4.44485	-1.82447	-2.37244	-3.40743	-4.93911
NEK2_HUMAN	P51955	T	175	A	 Kinase activity decreased by two fold."";/evidence=""ECO:0000269|PubMed:17197699""	s	156	T175A	P51955/T175A	D	-2.54394	-2.41478	-3.73915	-4.36333	-2.54394	-2.41478	-3.73915	-4.36333	NA	NA	NA	-2.0113	-5.219	-4.93155	-2.80918	-2.53045	-4.22444	-4.16131	-3.27035	-2.07035	-2.53882	-2.36644	-3.71164	-4.33518
NEK6_HUMAN	Q9HC98	K	74	M	 Loss of autophosphorylation and of kinase;activity and induction of apoptosis; when associated with;M-75."";/evidence=""ECO:0000269|PubMed:14563848,;ECO:0000269|PubMed:19001501""	K	30	K74M	Q9HC98/K74M	D	-3.21295	-3.44265	-4.3969	-7.62376	-3.21295	-3.44265	-4.3969	-7.62376	NA	NA	NA	-3.07686	-6.19467	-7.09385	-6.11091	-6.03829	-7.28927	-9.66973	-11.58284	-8.6497	-3.1666	-3.41181	-4.11071	-7.55815
NEK6_HUMAN	Q9HC98	K	75	M	 Loss of autophosphorylation and of kinase;activity and induction of apoptosis; when associated with;M-74."";/evidence=""ECO:0000269|PubMed:14563848,;ECO:0000269|PubMed:19001501""	k	31	K75M	Q9HC98/K75M	D	-3.21295	-3.44265	-3.49952	-3.93421	-3.21295	-3.44265	-3.49952	-3.93421	NA	NA	NA	-3.07686	1.61808	2.09406	1.01375	1.17539	-3.54298	-1.81123	-0.99911	-0.51756	-3.1666	-3.41181	-3.30184	-3.83697
NIM1_HUMAN	Q8IY84	T	229	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:15733851""	s	156	T229A	Q8IY84/T229A	D	-2.00777	-2.65838	-3.94238	-4.1609	-2.00777	-2.65838	-3.94238	-4.1609	NA	NA	NA	-1.80873	-5.90758	-3.84474	-3.56115	-2.53045	-6.39261	-5.85366	-2.62262	-1.76281	-1.96138	-2.37695	-3.59513	-4.05628
NUAK1_HUMAN	O60285	K	84	A	 Abolishes kinase activity and ability to;induce senescence."";/evidence=""ECO:0000269|PubMed:19927127,;ECO:0000269|PubMed:21317932""	K	30	K84A	O60285/K84A	D	-3.10743	-3.76542	-4.49148	-7.98326	-3.10743	-3.76542	-4.49148	-7.98326	NA	NA	NA	-2.67813	-7.79066	-7.97993	-8.42901	-6.35451	-7.39868	-6.6303	-7.52755	-8.41922	-3.0165	-3.40212	-6.30315	-7.72495
NUAK1_HUMAN	O60285	T	211	A	 Prevents phosphorylation and activation by;STK11/LKB1 complex. Abolishes ability to induce;senescence."";/evidence=""ECO:0000269|PubMed:14976552,;ECO:0000269|PubMed:19927127, ECO:0000269|PubMed:21317932""	s	156	T211A	O60285/T211A	D	-2.78238	-3.32332	-4.63199	-6.20132	-2.78238	-3.32332	-4.63199	-6.20132	NA	NA	NA	-2.05144	-5.0212	-3.25341	-3.33431	-2.53045	-8.27573	-6.12437	-3.92391	-3.44473	-2.57367	-3.02661	-7.12579	-6.03323
NUAK2_HUMAN	Q9H093	K	81	R	 Loss of autophosphorylation, kinase activity;and of anti-apoptotic activity."";/evidence=""ECO:0000269|PubMed:15345718""	K	30	K81R	Q9H093/K81R	D	-2.34761	-2.46392	-2.45546	-6.18815	-2.34761	-2.46392	-2.45546	-6.18815	NA	NA	NA	-1.57555	-5.50188	-7.61657	-6.42405	-3.99689	-8.16306	-10.26825	-10.98259	-6.2657	-2.0917	-2.40509	-6.65623	-8.45098
OXSR1_HUMAN	O95747	K	46	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:14707132,;ECO:0000269|PubMed:16389068""	K	30	K46A	O95747/K46A	D	-3.12939	-3.30553	-3.83526	-5.45669	-9.81871	-15.37999	-8.12502	-8.42019	-9.9784	-15.33745	-8.1221	-8.41136	-4.81373	-7.75552	-6.93328	-7.61408	-3.36438	-4.467	-6.80041	-6.43074	-3.08173	-3.19975	-3.72273	-5.21722
PAK1_HUMAN	Q13153	K	299	R	 Strongly decreases activity. Abolishes kinase;activity; when associated with N-389."";/evidence=""ECO:0000269|PubMed:22153498""	K	30	K299R	Q13153/K299R	D	-1.87738	-1.95792	-2.01182	-3.19466	-6.78813	-5.4193	-5.5947	-4.48433	-7.64485	-6.39495	-5.46903	-4.47809	-2.78967	-5.46917	-6.87611	-3.77497	-1.88512	-3.11413	-5.34915	-6.45649	-1.60592	-1.86929	-2.04421	-2.95074
PAK1_HUMAN	Q13153	D	389	N	 Abolishes kinase activity; when associated;with R-299."";/evidence=""ECO:0000269|PubMed:22153498""	D	123	D389N	Q13153/D389N	D	-2.80779	-2.96791	-3.0554	-4.79352	-10.94228	-7.98358	-7.3758	-5.75869	-13.67386	-10.58334	-7.38467	-5.74937	-4.2515	-7.13541	-8.41733	-4.74747	-2.81558	-4.20367	-5.97777	-5.74833	-2.83498	-2.79357	-3.06012	-4.02769
PAK1_HUMAN	Q13153	T	423	A	 Decreases CDC42-stimulated activity and;autophosphorylation."";/evidence=""ECO:0000269|PubMed:10551809""	s	156	T423A	Q13153/T423A	D	-2.77593	-2.8691	-2.94285	-3.8081	-6.4944	-4.16487	-5.03085	-4.09146	-6.79387	-4.88528	-4.99882	-4.06103	-2.42805	-3.54235	-4.10882	-3.38565	-2.79162	-4.14153	-4.74394	-3.73524	-2.34644	-2.77147	-3.0113	-3.38582
PAK1_HUMAN	Q13153	Y	429	 C	 (in IDDMSSD; gain-of-function; enhanced PAK1;kinase activity and significantly reduced homodimerization;;dbSNP:rs1565583382)"";/evidence=""ECO:0000269|PubMed:30290153"";/id=""VAR_081555""	e	162	Y429C	Q13153/Y429C	D	-5.18666	-5.26261	-5.28209	-6.62089	-5.67631	-3.13533	-2.55078	-2.41518	-5.23402	-3.15593	-2.50862	-2.37758	-5.26473	-3.20258	-3.10997	-3.19546	-5.19765	-6.53483	-7.57493	-2.97418	-4.76827	-5.17241	-5.37529	-5.79004
PAK2_HUMAN	Q13177	K	278	R	 Abolishes kinase activity and;autophosphorylation."";/evidence=""ECO:0000269|PubMed:9786869""	K	30	K278R	Q13177/K278R	D	-1.37873	-1.54434	-1.81491	-3.19466	-7.28707	-5.49563	-5.6006	-4.48433	-8.40993	-5.36041	-5.56023	-4.47807	-2.78967	-5.46917	-6.87611	-3.77497	-1.46034	-2.58336	-4.60067	-7.3569	-1.57851	-1.43479	-1.62045	-2.50119
PAK2_HUMAN	Q13177	T	402	A	 Abolishes kinase activity and greatly inhibits;autophosphorylation of PAK-2p27 and PAK-2p34."";/evidence=""ECO:0000269|PubMed:9786869""	s	156	T402A	Q13177/T402A	D	-2.77123	-2.8429	-2.53703	-3.8081	-6.11925	-4.2343	-5.04807	-4.09146	-6.30786	-4.13241	-5.0076599999999996	-4.06101	-2.42805	-3.54235	-4.10882	-3.38565	-2.74685	-4.07257	-4.76182	-3.07009	-2.44191	-2.68197	-2.99598	-3.38015
PASK_HUMAN	Q96RG2	R	1058	A	 Induces lower protein kinase activity."";/evidence=""ECO:0000269|PubMed:20943661""	k	54	R1058A	Q96RG2/R1058A	D	-2.61163	-3.8108	-3.00089	-1.77227	-2.61163	-3.8108	-3.00089	-1.77227	NA	NA	NA	-3.33105	-1.54217	-1.48786	-1.49423	-0.95311	-1.90032	-2.31482	-2.41371	-2.26266	-2.58697	-3.7429	-3.2359	-1.72922
PASK_HUMAN	Q96RG2	A	1151	K	 Induces lower protein kinase activity and;ability to autophosphorylate."";/evidence=""ECO:0000269|PubMed:20943661""	k	146	A1151K	Q96RG2/A1151K	D	-6.08969	-6.2346	-6.80139	-2.22429	-6.08969	-6.2346	-6.80139	-2.22429	NA	NA	NA	-2.36971	0.25951	0.68749	0.75297	1.34257	-1.40097	-0.75271	-0.17269	0.17506	-5.92615	-6.17508	-7.12517	-2.18702
PASK_HUMAN	Q96RG2	Y	1152	F	 Induces lower protein kinase activity."";/evidence=""ECO:0000269|PubMed:20943661""	e	147	Y1152F	Q96RG2/Y1152F	D	-4.03259	-3.47057	-1.12977	-0.46214	-4.03259	-3.47057	-1.12977	-0.46214	NA	NA	NA	-2.05367	-1.24866	-1.85205	-1.2495	-1.09305	-1.00932	-1.75262	-1.80961	0.10513	-3.9217	-3.45947	-1.54038	-0.52168
PIM1_HUMAN	P11309	L	193	F	 Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:15808862""	l	148	L193F	P11309/L193F	D	-2.43414	-2.70773	-2.45483	0.49537	-2.43414	-2.70773	-2.45483	0.49537	NA	NA	NA	-1.7125	0.21649	-0.367	0.0744	-0.11925	0.11937	0.37852	0.32735	0.18719	-2.34044	-2.64689	-1.79311	-0.5219
PINK1_HUMAN	Q9BXM7	D	362	A	 Abolishes MFN2 phosphorylation and interaction;with PRKN; when associated with A-219 and A-384. Loss of;enzyme activity and impaired localization of PRKN to;mitochondria; when associated with M-219 and A-384."";/evidence=""ECO:0000269|PubMed:18957282,;ECO:0000269|PubMed:23620051, ECO:0000269|PubMed:32047033""	D	123	D362A	Q9BXM7/D362A	D	-5.01524	-5.7523	-7.10011	-5.53207	-5.01733	-5.7655	-7.10149	-5.53027	NA	-3.68878	-3.68878	-3.7968	NA	NA	NA	-3.68878	-4.73303	-5.47454	-6.70595	-5.27904	-4.73303	-5.47454	-6.70595	-5.27904
PINK1_HUMAN	Q9BXM7	D	384	A	 Abolishes MFN2 phosphorylation and interaction;with PRKN; when associated with A-219 and A-362. Loss of;enzyme activity and impaired localization of PRKN to;mitochondria; when associated with M-219 and A-362."";/evidence=""ECO:0000269|PubMed:18957282,;ECO:0000269|PubMed:23620051, ECO:0000269|PubMed:32047033""	D	141	D384A	Q9BXM7/D384A	D	-5.18995	-5.88675	-7.13585	-7.43933	-5.18877	-5.89978	-7.13715	-7.44341	NA	-3.68878	-3.68878	-3.7968	NA	NA	NA	-3.68878	-4.91188	-5.61234	-6.75383	-7.44115	-4.91188	-5.61234	-6.75383	-7.44115
PINK1_HUMAN	Q9BXM7	G	386	 A	 (in PARK6; abolishes kinase activity)"";/evidence=""ECO:0000269|PubMed:16401616,;ECO:0000269|PubMed:24784582"";/id=""VAR_062776""	G	143	G386A	Q9BXM7/G386A	D	-4.81478	-5.59203	-6.98719	-6.71191	-4.81767	-5.60269	-6.98637	-6.71318	NA	-2.73436	-2.73436	-2.89559	NA	NA	NA	-2.73436	-4.53709	-5.28574	-6.60858	-6.80197	-4.53709	-5.28574	-6.60858	-6.80197
PKN1_HUMAN	Q16512	K	644	E	 Abolishes Serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:18066052,;ECO:0000269|PubMed:8135837""	K	30	K644E	Q16512/K644E	D	-4.98885	-5.44771	-5.7292	-9.42879	-4.98885	-5.44771	-5.7292	-9.42879	NA	NA	NA	-2.37632	-7.71757	-10.39587	-11.40283	-5.96461	-7.61709	-11.7256	-12.51298	-9.57939	-4.65955	-5.01421	-6.58302	-6.51811
PKN2_HUMAN	Q16513	T	816	A	 Reduces catalytic activity."";/evidence=""ECO:0000269|PubMed:18835241""	s	156	T816A	Q16513/T816A	D	-3.74997	-4.66451	-6.11982	-5.77348	-3.74997	-4.66451	-6.11982	-5.77348	NA	NA	NA	-1.97371	-3.41278	-4.70088	-3.96337	-2.53045	-5.72471	-3.79777	-1.56678	-1.80921	-3.03703	-3.76873	-5.70413	-4.10331
PKN3_HUMAN	Q6P5Z2	K	588	E	 Abolishes autophosphorylation and catalytic;activity."";/evidence=""ECO:0000269|PubMed:10441506,;ECO:0000269|PubMed:15282551""	K	30	K588E	Q6P5Z2/K588E	D	-4.58194	-4.79197	-5.77833	-9.42879	-4.58194	-4.79197	-5.77833	-9.42879	NA	NA	NA	-2.30561	-7.71757	-10.40874	-10.71008	-5.96461	-7.10893	-10.5433	-8.29881	-8.46526	-4.11589	-4.63166	-5.65075	-8.37411
PKN3_HUMAN	Q6P5Z2	K	588	R	 Abolishes catalytic activity."";/evidence=""ECO:0000269|PubMed:10441506,;ECO:0000269|PubMed:15282551""	K	30	K588R	Q6P5Z2/K588R	D	-3.0835	-3.25325	-4.1143	-7.65193	-3.0835	-3.25325	-4.1143	-7.65193	NA	NA	NA	-1.75707	-5.79625	-8.579	-8.88741	-3.99689	-5.23426	-8.82713	-6.20497	-6.23143	-2.79258	-3.12009	-3.95612	-6.54521
PLK1_HUMAN	P53350	D	176	N	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:18615013""	D	123	D176N	P53350/D176N	D	-3.46499	-4.36916	-6.24827	-5.7213	-3.46499	-4.36916	-6.24827	-5.7213	NA	NA	NA	-2.29778	-7.49103	-5.77347	-5.45921	-4.8709	-5.29726	-6.05232	-9.46174	-5.52392	-3.27672	-4.12411	-5.25464	-5.65341
PLK1_HUMAN	P53350	T	210	A	 Abolishes activity. Abolishes checkpoint;recovery."";/evidence=""ECO:0000269|PubMed:12207013,;ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:17461553,;ECO:0000269|PubMed:18615013, ECO:0000269|PubMed:19160488""	s	156	T210A	P53350/T210A	D	-2.90271	-3.7077	-4.26049	-5.52735	-2.90271	-3.7077	-4.26049	-5.52735	NA	NA	NA	-2.02778	-3.98391	-4.53645	-3.03904	-2.53045	-4.34699	-3.86548	-4.16819	-2.6187	-2.78163	-3.5051	-4.42594	-5.41364
PLK3_HUMAN	Q9H4B4	K	91	R	 Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:11447225,;ECO:0000269|PubMed:14980500, ECO:0000269|PubMed:17804415,;ECO:0000269|PubMed:19103756, ECO:0000269|PubMed:19490146,;ECO:0000269|PubMed:20889502, ECO:0000269|PubMed:20940307""	K	30	K91R	Q9H4B4/K91R	D	-2.4327	-2.98813	-3.91209	-4.67047	-2.4327	-2.98813	-3.91209	-4.67047	NA	NA	NA	-1.74635	-6.30429	-7.66535	-4.8399	-3.99689	-3.64206	-7.15549	-4.0542299999999996	-4.53496	-2.08665	-2.45082	-3.0235	-4.05836
PLK3_HUMAN	Q9H4B4	D	203	A	 Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:11156373""	D	141	D203A	Q9H4B4/D203A	D	-4.84667	-5.64507	-5.91626	-6.31285	-4.84667	-5.64507	-5.91626	-6.31285	NA	NA	NA	-3.44543	-9.05162	-10.18052	-7.56822	-6.30247	-5.67839	-10.29357	-12.55467	-9.7925	-4.15093	-4.95395	-4.90946	-5.81491
PLK4_HUMAN	O00444	D	154	A	 Catalytically inactive mutant that causes some;centrosome amplification above background levels when;overexpressed."";/evidence=""ECO:0000269|PubMed:16244668""	D	141	D154A	O00444/D154A	D	-5.06705	-5.94616	-6.73969	-7.40653	-5.06705	-5.94616	-6.73969	-7.40653	NA	NA	NA	-3.23556	-7.83913	-10.70848	-8.46637	-6.30247	-8.31811	-10.85345	-7.03732	-6.39706	-4.99729	-5.76207	-6.56961	-7.10963
PTK6_HUMAN	Q13882	K	219	M	 Abolishes kinase activity and cell;transformation, and phosphorylation of STAP2."";/evidence=""ECO:0000269|PubMed:10980601,;ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:8940083""	K	30	K219M	Q13882/K219M	D	-2.4124	-3.07736	-3.88147	-6.08801	-10.79983	-9.90425	-12.23944	-11.65522	-12.66152	-9.90689	-12.22904	-11.66609	-4.68235	-6.19021	-6.91192	-7.48896	-3.93205	-4.63349	-7.61489	-8.87687	-2.40356	-2.94182	-3.2495	-6.053
PTK6_HUMAN	Q13882	K	219	R	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:27480927""	K	30	K219R	Q13882/K219R	D	-1.56712	-2.01761	-2.64483	-4.06058	-8.75494	-7.10408	-7.66644	-7.54898	-11.23507	-7.08183	-7.66192	-7.54391	-2.58128	-3.93317	-4.59087	-5.13188	-2.64013	-3.10657	-5.19292	-8.31284	-1.55957	-1.91075	-2.12326	-4.03821
PTK6_HUMAN	Q13882	Y	342	A	 3-fold lower specific kinase activity.;Decreased, but still significant, autophosphorylation.;Decreased, but still significant, autophosphorylation; when;associated with A-447."";/evidence=""ECO:0000269|PubMed:12121988""	k	153	Y342A	Q13882/Y342A	D	-3.11347	-2.37855	-3.62009	-3.26334	NA	-5.41631	-3.20412	-3.18709	NA	-5.41922	-3.16312	-3.15941	NA	NA	-3.34263	-3.29699	-3.30807	-2.36	-2.89459	-2.69819	-3.0951	-2.38037	-2.80263	-3.53896
RAF1_HUMAN	P04049	K	375	W	 Catalytically inactive."";/evidence=""ECO:0000269|PubMed:20956560""	K	30	K375W	P04049/K375W	D	-3.99967	-4.21249	-4.63319	-7.27391	-10.16022	-12.61103	-12.69887	-12.34331	-10.77908	-12.98338	-12.72043	-12.28724	-5.06773	-7.12039	-8.20364	-7.30699	-4.16625	-4.85453	-7.69801	-8.88036	-3.67782	-3.9522	-4.36878	-5.13807
RAF1_HUMAN	P04049	D	486	 N	 (in NS5; has reduced or absent kinase;activity; dbSNP:rs80338798)"";/evidence=""ECO:0000269|PubMed:17603483"";/id=""VAR_037817""	D	141	D486N	P04049/D486N	D	-3.70078	-4.00413	-3.43816	-5.66264	-7.65743	-6.80875	-6.68875	-6.47001	-8.72913	-6.8205	-6.66037	-6.44005	-4.40269	-6.64401	-8.1321	-5.59298	-3.43335	-5.01992	-8.99348	-9.61034	-2.83389	-3.63	-4.31464	-5.34211
RAF1_HUMAN	P04049	T	491	 I	 (in NS5; has reduced or absent kinase;activity; dbSNP:rs80338799)"";/evidence=""ECO:0000269|PubMed:17603483"";/id=""VAR_037818""	k	146	T491I	P04049/T491I	D	-3.73906	-4.106	-3.99571	-1.25206	-1.5495	-1.25781	-1.09938	-1.36625	-0.64901	-0.77976	-0.70343	-1.15498	-3.12035	-3.75719	-3.7527	-1.5483	-3.43231	-4.74665	-5.6394	-2.22168	-2.85361	-3.65224	-4.38445	-1.12669
RAF1_HUMAN	P04049	L	603	 P	 (in CMD1NN; shows impaired kinase activity;and reduced MAPK3 activation with this mutation;;dbSNP:rs587777586)"";/evidence=""ECO:0000269|PubMed:24777450"";/id=""VAR_071847""	l	259	L603P	P04049/L603P	D	-4.74404	-5.14856	-4.7586	-4.69156	-6.73093	-8.48348	-8.80282	-9.09713	-6.55632	-8.41446	-8.73367	-9.01643	NA	-7.00314	-4.91476	-4.17556	-4.6185600000000004	-4.85801	-5.66322	-5.82285	-4.10572	-4.68974	-4.68748	-3.27898
RIPK1_HUMAN	Q13546	K	45	A	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:30988283,;ECO:0000269|PubMed:8612133""	K	30	K45A	Q13546/K45A	D	-3.81031	-4.8988	-6.32746	-6.79885	-10.64654	-9.82481	-9.79159	-9.44788	-10.83155	-9.76795	-9.62128	-9.44079	-5.33909	-7.03684	-8.92552	-7.31299	-9.45087	-11.72082	-12.17809	-4.81353	-3.47039	-4.11885	-5.69564	-6.50767
RIPK1_HUMAN	Q13546	S	161	A	 Decreases RIPK1 kinase activity."";/evidence=""ECO:0000269|PubMed:18408713""	k	146	S161A	Q13546/S161A	D	-2.6836700000000002	-0.81817	-0.72481	-0.98872	-0.45135	-1.01031	-1.11253	-0.30433	-0.20352	-0.82241	-0.87361	-0.13	-1.81937	-1.66125	-1.54393	-0.40612	-1.31149	-0.23844	-0.11327	-0.36934	-2.36913	-1.40375	-1.05135	-0.8262
RIPK2_HUMAN	O43353	K	47	A	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:9575181,;ECO:0000269|PubMed:9642260""	K	30	K47A	O43353/K47A	D	-3.34452	-3.77845	-7.20417	-6.51882	-14.57666	-11.50193	-9.57079	-9.44788	-14.51716	-11.43621	-9.54051	-9.41497	-6.76357	-8.51347	-9.17245	-7.31299	-3.63982	-8.03229	-11.43271	-5.44104	-3.29432	-3.50908	-6.87158	-6.46388
RIPK2_HUMAN	O43353	D	146	N	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:9705938""	D	123	D146N	O43353/D146N	D	-3.38787	-4.07971	-6.85701	-4.32278	-6.779	-6.2992	-5.91182	-5.36252	-6.72342	-6.26483	-5.95314	-5.33844	-6.36263	-7.99273	-5.73376	-4.66389	-3.90214	-8.10576	-9.44684	-5.63734	-3.12628	-3.81374	-6.38185	-4.22057
RIPK3_HUMAN	Q9Y572	K	50	D	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:10339433,;ECO:0000269|PubMed:10358032, ECO:0000269|PubMed:22265414""	K	30	K50D	Q9Y572/K50D	D	-3.28716	-5.40671	-6.7362	-6.91432	-3.28716	-5.40671	-6.7362	-6.91432	NA	NA	NA	-2.41575	NA	NA	NA	-2.41575	-2.41575	-3.57003	-4.6041	-5.81535	-2.41575	-3.57003	-4.6041	-5.81535
RIPK3_HUMAN	Q9Y572	D	142	N	 Abolishes kinase activity and ability to;mediate necroptosis."";/evidence=""ECO:0000269|PubMed:22265413""	D	123	D142N	Q9Y572/D142N	D	-3.31974	-5.43788	-6.51834	-6.86439	-3.31974	-5.43788	-6.51834	-6.86439	NA	NA	NA	-2.50228	NA	NA	NA	-2.50228	-2.50228	-3.62665	-4.72155	-5.71453	-2.50228	-3.62665	-4.72155	-5.71453
RIPK3_HUMAN	Q9Y572	T	182	A	 Abolishes kinase activity. Loss of interaction;with PELI1 and PELI1-mediated ubiquitination. No loss of;interaction with STUB1 and STUB1-mediated ubiquitination.;No loss of interaction with RIPK1. Loss of ability to;mediate TNF-induced necroptosis. Loss of;autophosphorylation at Ser-227."";/evidence=""ECO:0000269|PubMed:29883609""	t	160	T182A	Q9Y572/T182A	D	-2.77559	-4.81477	-5.71959	-5.95305	-2.77559	-4.81477	-5.71959	-5.95305	NA	NA	NA	-1.96043	NA	NA	NA	-1.96043	-1.96043	-3.02463	-4.23174	-5.10402	-1.96043	-3.02463	-4.23174	-5.10402
RIPK3_HUMAN	Q9Y572	S	227	A	 Abolishes ability to mediate necroptosis.;Partial loss of kinase activity. No loss of PELI1-mediated;degradation."";/evidence=""ECO:0000269|PubMed:22265413,;ECO:0000269|PubMed:29883609""	e	204	S227A	Q9Y572/S227A	D	-0.92396	-1.61944	-2.06486	-1.98432	-0.92396	-1.61944	-2.06486	-1.98432	NA	NA	NA	-1.54464	NA	NA	NA	-1.54464	-1.54464	-1.14029	-1.28635	-1.73482	-1.54464	-1.14029	-1.28635	-1.73482
RN5A_HUMAN	Q05823	R	462	 Q	 (risk factor for prostate cancer; reduced;enzymatic activity; dbSNP:rs486907)"";/evidence=""ECO:0000269|PubMed:11799394,;ECO:0000269|PubMed:11941539, ECO:0000269|PubMed:12415269,;ECO:0000269|PubMed:17344846"";/id=""VAR_012056""	k	101	R462Q	Q05823/R462Q	D	-2.58597	-1.68783	-1.72333	-1.43883	-1.30856	-0.98589	-1.77765	-0.96641	0.18869	0.36438	0.54773	0.14015	NA	-2.33291	-1.34266	-1.16497	-1.89619	-1.42184	-1.04306	-0.93933	-2.60374	-1.83401	-1.00913	-1.08708
ROR1_HUMAN	Q01973	R	736	 T	 (in DFNB108; impairs plasma membrane;location; abolishes downstream NFkB activation;;dbSNP:rs1553163562)"";/evidence=""ECO:0000269|PubMed:27162350"";/id=""VAR_079530""	R	252	R736T	Q01973/R736T	D	-4.38478	-5.30665	-6.48509	-7.79919	-5.23397	-6.58463	-8.11766	-9.18831	-6.70399	-6.6931	-6.82746	-8.2624	NA	-3.08857	-3.08857	-3.91198	-3.64695	-4.86337	-6.71216	-8.16066	-3.64695	-4.85791	-6.44688	-7.83504
SGK1_HUMAN	O00141	K	127	M	 Abolishes enzymatic activity."";/evidence=""ECO:0000269|PubMed:11696533,;ECO:0000269|PubMed:12911626, ECO:0000269|PubMed:15040001""	K	30	K127M	O00141/K127M	D	-3.57252	-3.87723	-4.27394	-4.53397	-3.57252	-3.87723	-4.27394	-4.53397	NA	NA	NA	-2.94067	-6.72876	-10.59946	-10.62148	-6.03829	-4.67937	-9.84766	-12.7619	-9.85426	-3.25498	-3.49853	-3.90065	-4.48128
SGK1_HUMAN	O00141	T	256	A	 Low activity."";/evidence=""ECO:0000269|PubMed:10191262""	s	156	T256A	O00141/T256A	D	-2.71264	-2.96989	-3.32197	-3.68611	-2.71264	-2.96989	-3.32197	-3.68611	NA	NA	NA	-2.0443	-3.54303	-4.01933	-4.08534	-2.53045	-2.87355	-4.24337	-3.44452	-1.88727	-2.42072	-2.66192	-3.00117	-3.50694
SGK1_HUMAN	O00141	T	256	D	 Low activity."";/evidence=""ECO:0000269|PubMed:10191262""	s	156	T256D	O00141/T256D	D	-3.64096	-4.06597	-5.32513	-5.89629	-3.64096	-4.06597	-5.32513	-5.89629	NA	NA	NA	-2.85896	-5.63462	-6.59134	-4.28586	-2.11839	-4.28887	-5.74875	-3.40138	-2.74887	-3.26501	-3.55977	-4.09874	-4.7782
SGK1_HUMAN	O00141	T	256	E	 Low activity."";/evidence=""ECO:0000269|PubMed:10191262""	s	156	T256E	O00141/T256E	D	-3.75754	-4.20994	-5.29473	-5.9334	-3.75754	-4.20994	-5.29473	-5.9334	NA	NA	NA	-2.79677	-5.69988	-6.50935	-4.34981	-2.03403	-4.46546	-5.33516	-4.45983	-2.84919	-3.30357	-3.65549	-4.25112	-4.99305
SGK3_HUMAN	Q96BR1	K	191	M	 Abolishes activity."";/evidence=""ECO:0000269|PubMed:16790420""	K	30	K191M	Q96BR1/K191M	D	-3.73396	-3.41758	-3.72577	-4.53397	-3.73396	-3.41758	-3.72577	-4.53397	NA	NA	NA	-2.8255	-6.78739	-10.60307	-11.26905	-6.03829	-3.93107	-6.36546	-8.70523	-9.03314	-2.99589	-3.70957	-3.2819	-3.80211
SIK1_HUMAN	P57059	S	135	A	 Decreased kinase activity without affecting;much autophosphorylation status."";/evidence=""ECO:0000269|PubMed:18348280""	e	109	S135A	P57059/S135A	D	-2.17029	-2.1409	-2.14813	-3.15752	-2.17029	-2.1409	-2.14813	-3.15752	NA	NA	NA	-1.697	-2.08282	-1.96038	-1.26146	-0.91407	-2.85777	-3.09383	-3.02486	-1.23768	-2.7002	-1.88207	-2.50371	-3.07251
SIK1_HUMAN	P57059	T	182	A	 Prevents phosphorylation and activation by;STK11/LKB1 complex. Reduced inhibition of CRTC3-mediated;transcriptional activity."";/evidence=""ECO:0000269|PubMed:14976552,;ECO:0000269|PubMed:29211348""	s	156	T182A	P57059/T182A	D	-3.42894	-3.70623	-4.25343	-5.0395200000000004	-3.42894	-3.70623	-4.25343	-5.0395200000000004	NA	NA	NA	-2.08401	-3.9767	-3.51425	-2.53119	-2.53045	-6.37113	-7.17311	-4.39623	-2.7957	-3.22753	-3.51285	-5.42002	-5.28235
SIK1_HUMAN	P57059	S	186	A,	D,C,G: Impaired autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:18348280""	t	160	S186A	P57059/S186A	D	-2.87968	-3.12696	-3.59595	-4.31552	-2.87968	-3.12696	-3.59595	-4.31552	NA	NA	NA	-1.697	-3.2947	-2.66015	-1.87832	-1.82287	-5.30871	-5.5198	-6.66676	-3.77415	-2.7002	-2.9536	-4.52599	-4.53479
SIK1_HUMAN	P57059	S	209	A	 Decreased kinase activity without affecting;much autophosphorylation status."";/evidence=""ECO:0000269|PubMed:18348280""	s	182	S209A	P57059/S209A	D	-2.44074	-2.69959	-3.14712	-3.99165	-2.44074	-2.69959	-3.14712	-3.99165	NA	NA	NA	-1.697	-0.74835	-1.38845	-0.76705	-1.27192	-4.32558	-4.43597	-2.44303	-1.68659	-2.7002	-2.52947	-3.87703	-4.52239
SIK1_HUMAN	P57059	S	248	A	 Decreased kinase activity without affecting;much autophosphorylation status."";/evidence=""ECO:0000269|PubMed:18348280""	s	234	S248A	P57059/S248A	D	-2.87968	-2.59499	-2.65305	-4.07584	-2.87968	-2.59499	-2.65305	-4.07584	NA	NA	NA	-1.697	-3.66047	-2.83233	-2.66466	-2.832	-4.53709	-4.756	-5.25343	-5.61549	-2.7002	-2.9536	-3.88479	-4.44483
SIK2_HUMAN	Q9H0K1	T	175	A	 Prevents phosphorylation and activation by;STK11/LKB1 complex."";/evidence=""ECO:0000269|PubMed:14976552""	s	156	T175A	Q9H0K1/T175A	D	-3.23598	-3.98727	-4.1507	-5.0395200000000004	-3.23598	-3.98727	-4.1507	-5.0395200000000004	NA	NA	NA	-2.09873	-3.90924	-3.49849	-3.21047	-2.53045	-5.52669	-6.0173	-4.54228	-2.5775	-2.6025	-3.67585	-4.15085	-4.44354
SIK3_HUMAN	Q9Y2K2	T	221	A	 Prevents phosphorylation and activation by;STK11/LKB1 complex."";/evidence=""ECO:0000269|PubMed:14976552""	s	156	T221A	Q9Y2K2/T221A	D	-3.31648	-3.96384	-5.08417	-5.63014	-3.31648	-3.96384	-5.08417	-5.63014	NA	NA	NA	-2.14699	-4.83359	-3.61577	-3.21039	-2.53045	-6.45714	-5.75866	-4.10186	-2.92998	-3.31648	-3.96021	-5.07827	-5.62441
SNRK_HUMAN	Q9NRH2	T	173	A,	E: Prevents phosphorylation and activation by;STK11/LKB1 complex."";/evidence=""ECO:0000269|PubMed:15733851""	s	156	T173A	Q9NRH2/T173A	D	-2.69414	-3.70355	-4.42382	-4.52895	-2.69414	-3.70355	-4.42382	-4.52895	NA	NA	NA	-1.9931	-4.46086	-3.4968	-4.02102	-2.53045	-4.85793	-3.24051	-2.63334	-2.46181	-2.60897	-3.66307	-4.40143	-4.44176
SRC_HUMAN	P12931	K	298	M	 Kinase inactive. Abolishes ubiquitination;promoted by CBLC."";/evidence=""ECO:0000269|PubMed:14661060""	K	30	K298M	P12931/K298M	D	-3.13	-3.84611	-4.94856	-6.38899	-8.76573	-10.56955	-12.30074	-11.65522	-9.45461	-10.42455	-12.31351	-11.63857	-4.59966	-6.19021	-6.91192	-7.48896	-3.64634	-4.9277	-10.09462	-8.94262	-3.10371	-3.13165	-3.75239	-6.00247
ST38L_HUMAN	Q9Y2H1	K	119	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:15037617""	K	30	K119A	Q9Y2H1/K119A	D	-2.84743	-3.07369	-4.4887	-6.11638	-2.84743	-3.07369	-4.4887	-6.11638	NA	NA	NA	-2.53255	-9.335	-10.37276	-11.2518	-6.35451	-4.35406	-8.8228	-11.4249	-9.72541	-2.70431	-3.15076	-4.38985	-5.93665
ST38L_HUMAN	Q9Y2H1	S	282	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:15037617""	s	156	S282A	Q9Y2H1/S282A	D	-1.98376	-2.2283	-2.95488	-3.45123	-1.98376	-2.2283	-2.95488	-3.45123	NA	NA	NA	-1.67981	-2.19656	-1.89653	-1.51222	-0.64995	-3.29744	-3.50859	-2.63011	-1.87364	-1.81125	-2.26586	-3.32365	-3.52833
STK11_HUMAN	Q15831	L	67	 P	 (in PJS; abolishes kinase activity, leading;to loss of autophosphorylation; dbSNP:rs137853077)"";/evidence=""ECO:0000269|PubMed:9428765,;ECO:0000269|PubMed:9837816"";/id=""VAR_006202""	v	19	L67P	Q15831/L67P	D	-3.97092	-4.17486	-4.85737	-6.25917	-3.97092	-4.17486	-4.85737	-6.25917	NA	NA	NA	-3.7308	-2.07907	-1.53194	-1.01836	-1.05001	-3.24725	-2.72865	-2.48577	-2.5168	-3.968	-4.06364	-4.83618	-6.23135
STK11_HUMAN	Q15831	K	78	I	 Loss of kinase activity, leading to greatly;reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:11430832,;ECO:0000269|PubMed:9837816""	K	30	K78I	Q15831/K78I	D	-3.59903	-3.70642	-4.54348	-7.3067	-3.59903	-3.70642	-4.54348	-7.3067	NA	NA	NA	-3.34959	-9.05515	-7.32226	-5.99143	-6.52557	-5.94144	-6.57492	-7.25294	-6.92068	-3.59749	-3.57171	-4.50102	-7.29474
STK11_HUMAN	Q15831	K	78	M	 Loss of kinase activity, leading to reduced;autophosphorylation and acting as a dominant-negative;mutant."";/evidence=""ECO:0000269|PubMed:11430832,;ECO:0000269|PubMed:9837816""	K	30	K78M	Q15831/K78M	D	-3.20825	-3.26964	-4.09398	-6.62924	-3.20825	-3.26964	-4.09398	-6.62924	NA	NA	NA	-2.93098	-8.6264	-6.76331	-5.5362	-6.03829	-5.18802	-5.86868	-6.50782	-6.06795	-3.2031	-3.15392	-4.05268	-6.61595
STK11_HUMAN	Q15831	G	163	 D	 (in TGCT; a tumor with seminoma and teratoma;components; associated with severely impaired but;detectable kinase activity; somatic mutation; impairs;heterotrimeric complex assembly with STRADA and CAB39;;predominantly nuclear localization; dbSNP:rs137853078)"";/evidence=""ECO:0000269|PubMed:19892943,;ECO:0000269|PubMed:9605748, ECO:0000269|PubMed:9887330"";/id=""VAR_033140""	g	110	G163D	Q15831/G163D	D	-3.61318	-4.23706	-5.15885	-6.49196	-3.61318	-4.23706	-5.15885	-6.49196	NA	NA	NA	-3.12601	-6.11944	-5.48327	-5.33201	-5.71704	-4.98276	-5.9242	-6.24839	-5.88523	-3.59713	-4.065	-5.09765	-6.48285
STK11_HUMAN	Q15831	D	176	 N	 (in PJS; loss of kinase activity, leading to;greatly reduced autophosphorylation; fails to phosphorylate;PTEN in vitro; no significant effect on nucleocytoplasmic;localization; dbSNP:rs730881979)"";/evidence=""ECO:0000269|PubMed:15987703,;ECO:0000269|PubMed:9837816"";/id=""VAR_071058""	D	123	D176N	Q15831/D176N	D	-2.44039	-2.84046	-3.66013	-4.79469	-2.44039	-2.84046	-3.66013	-4.79469	NA	NA	NA	-2.11065	-7.6654	-4.65973	-4.83838	-4.8709	-4.61347	-5.96574	-6.53359	-4.84838	-2.43075	-2.74488	-3.63004	-4.79256
STK11_HUMAN	Q15831	E	199	 K	 (in colorectal cancer; somatic mutation;;impaired kinase activity; dbSNP:rs121913317)"";/evidence=""ECO:0000269|PubMed:9731485"";/id=""VAR_065641""	k	146	E199K	Q15831/E199K	D	-2.50602	-2.9124	-3.68036	-2.32209	-2.50602	-2.9124	-3.68036	-2.32209	NA	NA	NA	-2.20871	0.85835	1.06975	1.53494	1.58073	-3.30357	-1.57919	-0.6483	-0.15209	-2.48788	-2.81679	-3.62865	-2.31034
STK11_HUMAN	Q15831	W	308	 C	 (in PJS; abolishes kinase activity, leading;to loss of autophosphorylation; dbSNP:rs1057520042)"";/evidence=""ECO:0000269|PubMed:9837816"";/id=""VAR_071059""	y	263	W308C	Q15831/W308C	D	-6.37506	-6.75438	-7.53077	-9.80936	-6.37506	-6.75438	-7.53077	-9.80936	NA	NA	NA	-6.09901	-10.35501	-8.68713	-8.37421	-8.48017	-8.19383	-7.18758	-7.1889	NA	-6.37025	-6.63257	-7.50475	-9.81271
STK26_HUMAN	Q9P289	K	53	E	 Abolished serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:29232556""	K	30	K53E	Q9P289/K53E	D	-2.44705	-3.95275	-5.25364	-6.51326	-9.46946	-15.16836	-9.62451	-7.71221	-9.63841	-9.22287	-9.60883	-7.69668	-5.16423	-7.7318	-6.7328	-7.36268	-2.6775	-5.86428	-6.70265	-6.91246	-2.36837	-2.94363	-5.18801	-6.03908
STK38_HUMAN	Q15208	K	118	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:12493777,;ECO:0000269|PubMed:7761441""	K	30	K118A	Q15208/K118A	D	-2.83546	-3.10445	-4.49186	-6.11638	-2.83546	-3.10445	-4.49186	-6.11638	NA	NA	NA	-2.53932	-9.34706	-10.35007	-10.62073	-6.35451	-4.39269	-9.50364	-10.32697	-9.44484	-2.77146	-3.11596	-4.40536	-5.94637
STK38_HUMAN	Q15208	S	281	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:12493777""	s	156	S281A	Q15208/S281A	D	-1.98927	-2.22564	-2.96289	-3.45123	-1.98927	-2.22564	-2.96289	-3.45123	NA	NA	NA	-1.66255	-2.19779	-1.6683	-1.20074	-0.64995	-3.31657	-4.01224	-2.53173	-1.6626	-1.92211	-2.23465	-3.33327	-3.54132
STRAA_HUMAN	Q7RTN6	Y	185	F	 Suppresses STK11/LKB1 activation without;affecting complex assembly."";/evidence=""ECO:0000269|PubMed:19892943""	y	113	Y185F	Q7RTN6/Y185F	D	-2.31185	-3.00712	-3.29644	-5.21901	-2.22448	-3.05205	-3.32867	-2.44284	-2.44257	-3.0049	-3.26306	-2.36811	-4.22186	-2.13901	-2.29944	-3.08879	-2.52298	-5.22007	-4.71262	-2.70687	-2.25483	-2.43126	-3.34331	-4.73342
TAOK1_HUMAN	Q7L7X3	K	57	A	 Abolishes kinase activity, ability to activate;the MAPK8/JNK cascade and cleavage by caspase-3 (CASP3)."";/evidence=""ECO:0000269|PubMed:16407310""	K	30	K57A	Q7L7X3/K57A	D	-4.11062	-4.50765	-5.33491	-6.10049	-7.69643	-15.05366	-9.48934	-8.42019	-8.94944	-10.66226	-9.50736	-8.42465	-5.95906	-7.73802	-8.64278	-7.61408	-4.07156	-6.34963	-9.5726	-7.26518	-2.95148	-3.97918	-4.67226	-4.69672
TBK1_HUMAN	Q9UHD2	K	30	R	 Decreases ubiquitination. Abolishes;ubiquitination, phosphorylation and kinase activity; when;associated with R-401."";/evidence=""ECO:0000269|PubMed:23453971""	e	22	K30R	Q9UHD2/K30R	D	-2.53386	-1.72775	-1.43762	-1.70983	-2.53734	-1.64119	-1.42021	-1.20627	-1.6957	-1.43063	-1.71476	0.04579	NA	-1.4244	-1.4244	-2.01217	-2.36116	-2.56775	-1.58499	-1.61451	-2.36116	-2.56775	-1.58499	-1.6136
TBK1_HUMAN	Q9UHD2	D	33	A	 Decreases phosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:23453971""	k	25	D33A	Q9UHD2/D33A	D	-5.02476	-3.90451	-3.69173	-1.60471	-5.02048	-3.86033	-3.64197	-1.54683	-3.57519	-2.48027	-2.05347	-2.24922	NA	-3.1549	-3.1549	-2.838	-4.77373	-5.05485	-4.01613	-1.89801	-4.77373	-5.05485	-4.01613	-1.91395
TBK1_HUMAN	Q9UHD2	S	172	E	 Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:11839743,;ECO:0000269|PubMed:23453972""	s	156	S172E	Q9UHD2/S172E	D	-4.53173	-5.04092	-5.83213	-3.21749	-4.53651	-5.10613	-5.93017	-3.42783	-2.94146	-4.85011	-5.45217	-5.94388	NA	-2.53676	-2.53676	-3.36844	-4.21359	-4.58147	-5.37051	-2.923	-4.21359	-4.58147	-5.37051	-2.91638
TGFR2_HUMAN	P37173	K	277	R	 Abolishes kinase activity, TGF-beta signaling;and interaction with DAXX."";/evidence=""ECO:0000269|PubMed:11483955""	K	30	K277R	P37173/K277R	D	-1.7246	-1.99657	-2.26127	-1.71613	-2.561	-3.49072	-4.44394	-4.64009	-2.80887	-3.91217	-5.70423	-4.65577	-2.07207	-2.58076	-2.99442	-3.20346	-1.70591	-2.20289	-2.82334	-2.07327	-1.67685	-1.85349	-2.18258	-1.53555
TITIN_HUMAN	Q8WZ42	K	32207	A	 Disrupts catalytic activity."";/evidence=""ECO:0000269|PubMed:9804419""	K	30	K32207A	Q8WZ42/K32207A	D	-3.01511	-5.21642	-6.84027	-7.44711	-10.00113	NA	NA	NA	-7.24886	NA	NA	NA	NA	NA	NA	-2.66314	-9.20819	-9.6989	NA	NA	-3.01511	-5.21642	-6.84027	-7.44711
TLK2_HUMAN	Q86UE8	H	493	 R	 (in MRD57; reduced kinase activity;;dbSNP:rs1567974030)"";/evidence=""ECO:0000269|PubMed:29861108,;ECO:0000269|PubMed:29955062"";/id=""VAR_081028""	i	32	H493R	Q86UE8/H493R	D	-4.7689	-5.14597	-7.98372	-6.61302	-4.78528	-5.94976	-8.18223	-7.42369	-4.97638	-3.22635	-3.89433	-4.20921	NA	-3.50529	-3.50529	-4.04212	-4.46218	-5.78151	-7.86548	-5.25571	-4.46165	-5.78199	-7.86583	-5.2503
TLK2_HUMAN	Q86UE8	H	518	N	 Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	l	52	H518N	Q86UE8/H518N	D	-5.06919	-5.42443	-8.33335	-5.10401	-5.08196	-6.31264	-8.52334	-6.4811	-5.1504200000000004	-3.90713	-4.88287	-5.13363	NA	-3.60589	-3.60589	-4.18963	-4.82149	-6.16551	-8.23722	-4.08703	-4.82156	-6.16509	-8.237	-4.08388
TLK2_HUMAN	Q86UE8	H	518	 R	 (in MRD57; severely reduced kinase activity;;dbSNP:rs1567995650)"";/evidence=""ECO:0000269|PubMed:29861108,;ECO:0000269|PubMed:29955062"";/id=""VAR_081029""	l	52	H518R	Q86UE8/H518R	D	-4.8472	-5.18888	-8.00199	-5.71751	-4.86015	-5.98706	-8.19919	-7.26748	-4.97638	-3.51628	-4.34204	-4.60391	NA	-3.50529	-3.50529	-4.04212	-4.60497	-5.8308	-7.89124	-4.55341	-4.60458	-5.83099	-7.89138	-4.54873
TLK2_HUMAN	Q86UE8	S	617	 L	 (in MRD57; exhibits abnormal perinuclear;localization instead of diffuse nuclear localization;;impairs kinase activity; reduced phosphorylation of ASF1A)"";/evidence=""ECO:0000269|PubMed:21572417,;ECO:0000269|PubMed:33323470"";/id=""VAR_087042""	a	145	S617L	Q86UE8/S617L	D	-4.22184	-4.45262	-6.56282	-5.90328	-4.23286	-5.04229	-6.71939	-8.20974	-4.27237	-5.60664	-6.02251	-6.23025	NA	-3.097	-3.097	-3.51331	-4.00837	-4.90246	-6.45055	-4.73371	-4.00975	-4.90135	-6.45019	-4.72852
TLK2_HUMAN	Q86UE8	S	659	A	 Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	s	175	S659A	Q86UE8/S659A	D	-2.49753	-2.67814	-3.63393	-2.9374	-2.50755	-3.14464	-3.73157	-3.84816	-2.22059	-3.20115	-3.2203	-3.08963	NA	-1.59461	-1.59461	-1.92902	-2.35083	-3.06489	-3.55735	-2.1728	-2.35181	-3.06437	-3.55728	-2.16993
TLK2_HUMAN	Q86UE8	S	686	A	 Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	g	202	S686A	Q86UE8/S686A	D	-2.35683	-2.29546	-2.19988	-0.45164	-2.37173	-2.20063	-2.28397	0.01227	-2.22059	-0.72271	-1.07934	-0.72025	NA	-1.59461	-1.59461	-1.92902	-2.20839	-1.67083	-1.80563	-0.67723	-2.20961	-1.67382	-1.81102	-0.67917
TLK2_HUMAN	Q86UE8	S	686	D	 Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	g	202	S686D	Q86UE8/S686D	D	-3.37061	-2.6647	-2.20601	-1.71627	-3.38993	-2.29112	-2.28692	-2.69276	-3.1733	-1.66474	-2.13852	-1.72989	NA	-2.34084	-2.34084	-2.78224	-3.15259	-1.71673	-1.78856	-0.85985	-3.15444	-1.72004	-1.79421	-0.8608
TLK2_HUMAN	Q86UE8	T	695	A	 Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	k	218	T695A	Q86UE8/T695A	D	-2.86882	-2.82884	-4.10603	-2.96011	-2.88115	-3.16475	-4.14938	-3.63563	-1.79089	-1.96499	-1.88843	-1.75901	NA	-2.0141	-2.0141	-2.45318	-2.64939	-3.57164	-4.11013	-2.19329	-2.64914	-3.57158	-4.11039	-2.19088
TNI3K_HUMAN	Q59H18	K	490	R	 Loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:12721663""	K	30	K490R	Q59H18/K490R	D	-4.45631	-5.6839	-4.74671	-5.25573	-8.03102	-9.24495	-7.98612	-7.54898	-8.52016	-9.26134	-7.8595	-7.48531	-4.86693	-6.21031	-7.02245	-5.13188	-2.41904	-6.6817	-6.70925	-8.64538	-2.29569	-2.49328	-4.71931	-6.10597
TRIO_HUMAN	O75962	K	2917	A	 Expected to disrupt kinase activity. Causes;reorganization of the actin cytoskeleton in the absence of;NGF."";/evidence=""ECO:0000269|PubMed:22155786""	K	125	K2917A	O75962/K2917A	D	-6.41547	-8.14879	-10.37353	NA	-8.13305	NA	NA	NA	NA	NA	NA	NA	NA	-2.75985	-3.81063	-3.82774	-6.41547	-6.94588	-9.23975	NA	-6.02197	-7.63392	-9.12495	NA
TTBK2_HUMAN	Q6IQ55	K	50	E,	A: Leads to inactivation/destabilization of the;protein."";/evidence=""ECO:0000269|PubMed:21548880""	K	30	K50E	Q6IQ55/K50E	D	-4.96008	-5.60679	-6.56944	-6.91893	-6.14113	-6.21223	-6.74719	-7.17391	-7.00855	-6.01885	-6.62952	-6.94476	-3.25103	-4.12654	-4.36154	-4.66816	-4.85729	-7.46064	-8.63867	-7.37438	-4.11717	-5.40761	-6.37688	-6.50862
TTBK2_HUMAN	Q6IQ55	K	143	E,	A: Leads to inactivation/destabilization of the;protein."";/evidence=""ECO:0000269|PubMed:21548880""	K	125	K143E	Q6IQ55/K143E	D	-5.57677	-6.04143	-6.90684	-8.75857	-7.52203	-5.3060600000000004	-6.06558	-6.49334	-9.62234	-5.24661	-5.96807	-6.25602	-3.25103	-4.12654	-4.36154	-4.66816	-5.59584	-6.8503	-7.98655	-9.20118	-4.78493	-5.98596	-6.67235	-8.48491
TTBK2_HUMAN	Q6IQ55	D	163	A	 Abolishes serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:21548880""	D	141	D163A	Q6IQ55/D163A	D	-6.3379200000000004	-6.75771	-7.43373	-10.20618	-7.11799	-8.67648	-9.18059	-9.33018	-7.68878	-9.22141	-8.98674	-9.22889	-4.2545	-5.20714	-5.45157	-5.74461	-6.41805	-8.64001	-9.64437	-10.67736	-5.74416	-6.76761	-7.44503	-10.03715
TTBK2_HUMAN	Q6IQ55	A	184	E,	G: Impaired serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:21548880""	t	155	A184E	Q6IQ55/A184E	D	-6.21766	-6.68962	-6.59612	-8.8669	-3.74798	-3.90732	-4.35038	-4.44452	-3.6139	-3.66362	-3.27272	-3.20154	-3.82724	-2.07944	-2.06177	-2.13425	-6.23283	-7.76424	-6.17373	-4.13407	-5.90538	-6.64016	-6.85358	-9.07665
TXK_HUMAN	P42681	K	299	A	 Impairs kinase activity."";/evidence=""ECO:0000269|PubMed:9813138""	K	30	K299A	P42681/K299A	D	-4.0806	-4.3543	-4.29084	-6.99302	-7.0055	-9.09702	-9.05675	-9.44788	-6.72027	-8.758	-9.04	-9.41044	-4.2431	-6.12991	-6.84842	-7.31299	-4.05211	-5.26275	-6.89694	-5.51487	-3.33473	-4.15759	-4.64209	-7.68971
UFO_HUMAN	P30530	K	567	M	 Catalytically inactive mutant."";/evidence=""ECO:0000269|PubMed:28076778""	K	30	K567M	P30530/K567M	D	-3.43495	-4.47601	-5.24087	-6.25359	-5.24531	-5.89534	-6.06979	-6.79187	-5.15798	-5.46546	-5.6728	-6.04416	NA	-3.12229	-3.91432	-4.46743	-3.47285	-4.73508	-5.24317	-6.57781	-3.34385	-4.19584	-5.21049	-6.19132
ULK1_HUMAN	O75385	K	46	I	 Abolished serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:20921139,;ECO:0000269|PubMed:28821708""	K	30	K46I	O75385/K46I	D	-6.43318	-8.19335	-7.07364	-5.47533	-6.43318	-8.19335	-7.07364	-5.47533	-8.44898	-8.86112	-10.05727	-10.24798	-9.4445	-7.57891	-8.41896	-6.52557	-7.64349	-9.41952	-5.34796	-6.11679	-5.29064	-7.81935	-6.87938	-5.24292
ULK2_HUMAN	Q8IYT8	K	39	R	 Decreased kinase activity and decreased;autophosphorylation."";/evidence=""ECO:0000269|PubMed:18936157""	K	30	K39R	Q8IYT8/K39R	D	-3.61726	-4.91999	-4.68492	-2.97071	-3.61726	-4.91999	-4.68492	-2.97071	NA	NA	NA	-1.59547	-6.5534	-7.22459	-5.37799	-3.99689	-4.26752	-8.39522	-4.13902	-3.5079	-3.08784	-3.70557	-4.04551	-3.33492
ULK3_HUMAN	Q6PHR2	K	44	R	 Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:19878745""	K	30	K44R	Q6PHR2/K44R	D	-2.04766	-2.32101	-2.58745	-1.84008	-2.04766	-2.32101	-2.58745	-1.84008	NA	NA	NA	-1.69671	-6.82387	-3.18016	-3.76274	-3.99689	-4.24605	-8.89585	-10.85253	-5.75955	-1.99718	-2.15702	-2.56766	-1.70008
VGFR1_HUMAN	P17948	K	861	M	 Abolishes enzyme activity. Abolishes;interaction with PLCG."";/evidence=""ECO:0000269|PubMed:9299537""	K	30	K861M	P17948/K861M	D	-5.01167	-5.15408	-8.0108	-7.51486	-7.89144	-9.31479	-8.97765	-10.05669	-6.69663	-7.83105	-8.96808	-9.88832	-5.062	-5.87174	-6.25641	-7.18049	-4.45586	-5.04883	-6.22639	-7.44453	-3.75698	-4.91711	-5.8248	-6.41744
VGFR2_HUMAN	P35968	V	848	 E	 (strongly reduced autophosphorylation and;kinase activity; dbSNP:rs1139776)"";/evidence=""ECO:0000269|PubMed:10037737,;ECO:0000269|PubMed:1656371"";/id=""VAR_046679""	V	15	V848E	P35968/V848E	D	-6.82826	-7.59483	-8.88194	-9.92273	-9.23371	-9.61037	-11.26397	-12.09961	-8.30989	-10.0264	-11.18973	-11.93788	-5.97269	-6.83236	-7.33553	-7.97255	-4.74271	-6.68212	-9.55062	-9.72696	-4.6027	-6.20334	-8.54873	-9.85495
VGFR3_HUMAN	P35916	K	879	G	 Abolishes enzyme activity."";/evidence=""ECO:0000269|PubMed:12881528""	K	30	K879G	P35916/K879G	D	-5.41021	-5.70606	-6.31013	-7.36748	-7.37549	-8.1671	-9.76775	-11.01666	-6.3112	-9.28107	-9.7672	-10.86032	-4.59417	-5.42116	-5.71209	-6.6516	-4.42331	-5.31499	-7.96487	-7.23599	-4.36527	-5.09956	-7.01714	-6.95035
WEE1_HUMAN	P30291	K	328	R	 Abolishes activity."";/evidence=""ECO:0000269|PubMed:8428596""	K	30	K328R	P30291/K328R	D	-2.39886	-2.88627	-3.7954	-7.01581	-2.89684	-4.81514	-7.05071	-6.66762	-3.5267	-5.71302	-6.7603	-5.52199	NA	-1.71472	-1.96443	-2.43041	-2.37281	-3.77164	-8.45903	-10.6324	-2.20239	-2.7917	-3.77861	-6.83999
WNK3_HUMAN	Q9BYP7	D	294	A	 Catalytically inactive form. Inhibits sodium-;coupled chloride cotransporters and activates potassium-;coupled chloride cotransporters."";/evidence=""ECO:0000269|PubMed:16275913,;ECO:0000269|PubMed:21613606""	D	141	D294A	Q9BYP7/D294A	D	-7.64503	-8.48355	-10.81016	-11.90258	-9.72257	-13.698	-10.62325	-6.74484	-8.06967	-9.03716	-6.83406	-4.25765	-3.31839	-5.23722	-5.74479	-4.56499	-5.93824	-10.03279	-11.78907	-9.74729	-5.48965	-7.66932	-10.24389	-10.25082
ZAP70_HUMAN	P43403	D	461	N	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:17512407""	D	123	D461N	P43403/D461N	D	-4.01696	-4.42527	-5.46973	-9.00408	-11.48426	-7.32511	-6.68972	-5.36252	-8.29928	-7.47059	-6.5959	-5.33197	-4.94639	-5.71038	-7.91407	-4.66389	-4.0873	-6.35636	-8.94864	-6.0115	-3.48054	-4.10911	-5.49112	-8.1306
ZAP70_HUMAN	P43403	D	479	N	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:15292186""	D	141	D479N	P43403/D479N	D	-4.01696	-4.42527	-5.46973	-9.01426	-8.47113	-6.40655	-6.87536	-6.47001	-7.94915	-6.42443	-6.85235	-6.43804	-4.94639	-5.71038	-7.91407	-5.59298	-4.0873	-6.35636	-8.94864	-11.73698	-3.48054	-4.10911	-5.49112	-8.15045
